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Introduction and outline of this thesis 
 
Historical overview on the circulatory system 
Already during the Golden Age of Greece, people realized that all organisms, including 
humans, require nutrition and that in more complex organisms, nutrients somehow need to 
be distributed from the intestines throughout the body. With the discovery of the differences 
between arteries and veins, Praxagoras (340 BC) shaped this idea of nutrients distribution in 
a more conceivable concept.1 He theorized that arteries originated in the heart and carried 
pneuma from the lungs to the left side of the heart, from which the breath of life was 
transported to the rest of the body. Veins on the other hand were supposed to begin in the 
liver where they carried digested food in the form of blood to the rest of the body. Building on 
the ideas of Praxagoras, Galen (129-216AD) experimentally demonstrated that arteries were 
not solely filled with pneuma, but like veins actually contained blood.2 He postulated that 
blood passed from the venous side of the heart via pores in the intraventricular septum into 
the arteries. Via the arteries, blood was transported to all parts of the body for consumption 
and remaining waste was removed by the kidneys in the form of urine.3 This refined theory 
lasted for fifteen centuries until William Harvey demonstrated that arteries and veins are 
connected in the lung- and peripheral tissues, and that blood circulates rather than that it is 
consumed.1 We now know that this circulatory system is not a static entity. In fact, it is highly 
dynamic, capable of adapting in response to both mechanical and biochemical stimuli. 
Not only has our anatomical view of the cardiovascular system evolved over time, but also 
our appreciation of its role in health and disease has shifted. According to the Ancient 
Greeks and Roman philosophers, veins contained three additional humors beside blood; 
yellow bile, black bile and phlegm, and until deep into the eighteenth century practically all 
diseases were thought to be either caused by imbalanced ratios of these four humors, or by 
a dysregulated blood flow pattern.4 Nowadays however, we know that health or disease is 
the net result of the complex interplay between an individual’s genetic background and 
environmental factors, and that cardiovascular homeostasis, as well as balanced dynamics 
in adaptation, are key components in defining the thin line between health and disease. 
Therefore, a thorough understanding of the mechanisms underlying or affecting this 
homeostasis is of major importance for development of future therapeutic strategies for 
cardiovascular diseases. 
 
Vascular development 
The importance of a functional circulatory system that not only allows oxygen and nutrient 
delivery, but for instance also facilitates efficient organism-wide immune surveillance, is 
Introduction and outline of this thesis 
 
9 
 
evidenced by its appearance early in development. Already in the third week of 
development, a primary vascular plexus is formed by vasculogenesis, a process described 
as de novo formation of blood vessels from the differentiation and association of endothelial 
progenitor cells.5 In vasculogenesis, hemangioblasts differentiate from the embryonic 
mesoderm and eventually cluster in so called blood islands at sites of vascularization.5 
Although mechanistically not fully understood yet, Fibroblast Growth Factor (FGF) signaling 
has been shown to be involved in this mesodermal differentiation.6 Progenitor cells located 
on the interior side of these blood islands differentiate into hematopoietic progenitor cells, 
which eventually give rise to blood cells. The subset of cells that surround these 
hematopoietic progenitor cells however, differentiates into angioblasts that will later develop 
into endothelial cells forming the inner lining of the mature vasculature. These angioblasts 
proliferate and migrate to form cellular tubes and eventually associate in a premature 
vascular labyrinth that provides the foundation for all major blood vessels. Genetic knockout 
studies in mice demonstrated that Vascular Endothelial Growth Factor A (VEGFA) signaling 
via its receptor Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) not only 
stimulates hematopoiesis, but also induces cell migration and proliferation required for 
proper blood island formation.7, 8 
The premature vascular labyrinth thereafter rapidly expands into a complex vascular 
network by a process called angiogenesis, defined as the formation of new vessels from 
pre-existing vessels, either via sprouting of endothelial cells, or via intussusception. In 
sprouting angiogenesis, capillary endothelial cells become activated upon exposure to 
angiogenic stimuli, including FGFs and VEGFA.9 These factors are released in response to 
oxygen and nutritional stress and, amongst others, trigger enhanced transcription of several 
metalloproteinases (MMPs) and Angiopoietin 2 (ANGPT2).10, 11 MMPs provide degradation 
of the capillary basement membrane, whereas ANGPT2 signaling via TEK Receptor 
Tyrosine Kinase (TIE2) results in local detachment of capillary-stabilizing pericytes.12 To limit 
the number of outgrowing sprouts, only a minor proportion of the capillary endothelium 
transforms into angiogenic growth factor-sensitive tip cells and migrates towards the 
angiogenic stimulus. These tip cells are followed by stalk cells, a proliferating and lumen-
forming subset of endothelial cells. Stalk cells express high levels of Vascular Endothelial 
Growth Factor Receptor 1 (VEGFR1/Flt1), which has a much higher affinity for VEGFA than 
VEGFR2, but lacks the ability to transduce its pro-angiogenic signal, rendering these stalk 
cells virtually irresponsive to the proangiogenic VEGFA stimulus.13 The elongating sprouts 
eventually fuse with other sprouts in the expanding network via anastomosis, after which the 
newly formed connection gets stabilized by basement membrane deposition and pericyte 
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recruitment, of which the latter is highly dependent on endothelial secretion of the 
chemoattractant Platelet Derived Growth Factor Subunit β.13  
Where sprouting angiogenesis contributes to expansion of the vascular network by tissue 
ingrowth of new vessels, intussusceptive angiogenesis concurs through division of existing 
vessels into multiple smaller vessels. The latter form is initiated via the formation of so called 
pillar core structures by opposing endothelial cells within a capillary. Pericytes and 
myofibroblasts invade these pillar cores and stabilize them by deposition of extracellular 
matrix components.14 These tissue pillars eventually expand, resulting into splitting of the 
capillary. Mechanistically, there is a defined overlap with sprouting angiogenesis, although 
the initial stimulus for intussusceptive angiogenesis appears to come rather from 
biomechanical stimuli in the form of elevated flow, rather than from hypoxia.14 
 
Physiological and pathological dynamics in vascular growth 
The vascular system facilitates the distribution of oxygen- and nutrients throughout the body. 
During embryonic development a vascular network emerges, which ensures that all cells of 
the body are within diffusion range of oxygen and nutrients. After birth, physical growth 
continues and requires the vascular network to grow proportionally via a strictly regulated 
exposure to pro- and anti-angiogenetic stimuli. During adulthood, however, most blood 
vessels remain in a quiescent state, although physiological changes, including expanse of 
muscle mass, or cyclic development of the uterus, may still require angiogenesis-driven 
growth of the existing vasculature, whereas loss of adipose tissue for instance, results in 
vascular regression.15  
Considering that each individual cell dependents on oxygen and nutrients, it is not surprising 
that dysregulation of angiogenic stimuli is involved in a great number of diseases. In diabetic 
patients for instance, hyperglycemia-induced pericyte detachment from the retinal capillaries 
results in microvascular destabilization and leakage.16 This initial stage of capillary 
dysfunction is often asymptomatic, but the consecutive retinal hypoxia triggers a VEGF-
dependent growth of instable capillaries into the retina and vitreous humor, eventually 
causing loss of sight.16 A similar shift towards pro-angiogenic stimuli is observed in 
malignant cell growth. The distance over which oxygen can diffuse from capillaries to 
respiring tissue is typically limited from 100-200μm, and tumors rapidly grow to sizes that 
exceed this distance.17 Consequently, these tumors secrete a constant and uncontrolled 
array of pro-angiogenic stimuli, including VEGFA, FGFs, and Interleukins, leading to 
ingrowth of highly disorganized immature vessels.18 These poorly structured vessels are 
prone to provide an escape route for tumor cells19, underscoring the notion that the 
dysregulated nature of tumor vascularization is a principal feature of disease progression. 
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Conversely, an imbalance in angiogenic stimuli favoring an anti-angiogenic response is also 
directly related to disease. In preeclampsia for instance, high circulating levels of soluble 
anti-angiogenic factors VEGFR1 and Endoglin are observed.20 In addition to the VEGFA-
scavenging properties of VEGFR1, Endoglin binds TGFβ, attenuating TGFβ-mediated 
vascular stabilization by perivascular cells, causing vascular abnormalities and 
hypoperfusion of the placenta, as well as glomerular endothelial dysfunction.21  
Among the many pathways coordinating vascular growth, endothelial signaling via Frizzled 
(FZD) receptors has previously been shown to be of crucial importance.22-24 The FZD 
receptors belong to a family of 10 transmembrane receptors (FZD1-10), which can initiate 
FZD/WNT canonical and non-canonical signaling upon binding with one of the 19 soluble 
WNT ligands. Canonical WNT signaling depends on FZD receptor and low-density 
lipoprotein receptor-related protein 5 or 6 co-activation, initiating Disheveled (DVL) to 
stabilize β-catenin, followed by β-catenin-mediated transcription.25, 26 In contrast, non-
canonical WNT signaling also involves DVL, but proceeds via WNT/Ca2+-mediated activation 
of Nuclear factor of activated T-cells (NFAT), or Wnt/planar cell polarity-mediated activation 
of c-JUN N-terminal Kinase.25 Several studies illustrated that FZD4 signaling is essential for 
proper retinal angiogenesis and that its inhibition causes impaired β-catenin-mediated 
transcription, leading to familial exudative vitreoretinopathy.23 Murine knockout models 
furthermore illustrated the importance of FZD5 en FZD7 in vascular growth.22, 24 FZD7 was 
shown to facilitate canonical WNT signaling, and like FZD4, to be essential for post-natal 
angiogenesis.24 FZD5 silencing also induced vascular defects, but in contrast to FZD4 and 
FZD7, these defects appeared in the placenta and yolk sac and resulted in embryonic 
lethality.22 In this thesis, we describe mechanistically how endothelial loss of FZD5 led to 
Protein Kinase C- (PKC) mediated upregulation of VEGFR1 and ANGPT2, which attenuated 
angiogenesis (chapter 2).  
Over the last decades, studies on the mechanisms involved in angiogenesis have 
predominantly been focused on endothelium. Although endothelial cells play a central role in 
angiogenesis, capillary homeostasis relies on well-orchestrated and bidirectional cross talk 
between endothelium and the relatively understudied pericytes. Considering their role in 
maintaining vascular stability, pericytes are inseparable from neovascularization and in our 
attempts to get a better appreciation of this process, it is thus essential that we do not limit 
our scope to the endothelium. In chapter 3 we aimed to improve our understanding of these 
perivascular cells, focusing particularly on how they are affected by direct microvascular 
endothelial interaction.  
 
  
Chapter 1 
12 
 
Vascular involvement in (pathological) immune regulation 
Beside oxygen and nutrient delivery, the vascular network also has a profound role in 
immune regulation. The unique location of endothelial cells, forming the interface between 
tissue and inflammatory cells, enables the endothelium not only to facilitate transport of 
inflammatory cells, but also to specify an inflammatory response to sites of injury or 
infection, while protecting adjacent healthy tissue. In response to inflamed tissue-derived 
cytokines, such as Interleukin 1 (IL1), Tumor Necrosis Factor α (TNFα), and Interferon γ 
(IFNγ), vessels dilate and endothelial Nuclear Factor κB (NFκB) becomes activated.27 This 
triggers the transcriptional upregulation of endothelial-leukocyte adhesion molecules, 
including Endothelial-Leukocyte Adhesion Molecule 1 (SELE) and Vascular Cell Adhesion 
Molecule 1 (VCAM1), favoring localized extravasation of leukocytes to contain and 
neutralize the inflammatory source.28 The well-functioning of this inflammatory response is of 
major importance to maintain homeostasis in complex organisms. However, when 
dysregulated or chronically activated, this immune response can result in pathological 
events. In atherosclerosis for instance, circulating lipoprotein particles penetrate the 
endothelial barrier at sites of low shear stress and deposit in the subendothelial space, 
where they trigger the recruitment macrophages.29 These macrophages internalize the 
lipoproteins and differentiate into chemokine-secreting foam cells, not only inducing 
proliferation and synthesis of extracellular matrix by neighboring smooth muscle cell, but 
also further enhancing the endothelial proinflammatory phenotype.29 This leads to a 
progressive inflammatory response in the vessel wall which can eventually result in the 
formation of a fibrous cap, overlying a lipid-rich, highly thrombogenic necrotic core. 
Depending on structure and stability, these lesion can either progressively narrow the vessel 
lumen causing local ischemia, or rupture which could result in atherothrombotic occlusion. 
 
Cardiac development 
In line with the appearance of a vascular network, embryonic heart development occurs in 
an early fetal stage. In fact, the heart is the first functional organ in vertebrates, showing 
peristaltic contraction already at week 3 of embryonic development.30 During subsequent 
development, rapid myocardial proliferation ensures appropriate cardiac growth. This 
process is regulated by various signaling pathways, including Neuregulin-, Insulin-Like 
Growth Factor- (IGF), and Bone Morphogenic Protein- (BMP) induced activation of the 
transcription factors GATA4, MEF2, and TBX.31, 32 The initiation of contractility, as well as 
the continuous growth of the fetal heart result in the requirement of considerable amounts of 
energy. The low availability of lipids, in combination with a relative low fetal oxygen tension, 
favors the use of carbohydrates as energy substrate by cardiomyocytes, predominantly in 
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the form of lactate and glucose.33 Eight weeks post conception, the heart is fully formed, 
after which the proliferative capacity of the myocytes slowly tapers off until birth, essentially 
followed by a permanent cell cycle arrest. Immediately after birth, plasma levels of fatty 
acids rise and the establishment of pulmonary gas exchange, providing a higher oxygen 
availability, enables a metabolic switch to the less oxygen efficient, but higher energy-
yielding oxidative phosphorylation of fatty acids.33 This switch in energy substrate usage is 
accompanied by enhanced nuclear receptor peroxisome proliferator–activated receptor 
alpha- (PPAR-α) and Kruppel-like factor 15- (KLF15) dependent transcription.34 Recent 
evidence indicates that the metabolic substrate usage in the fetal- and neonatal heart might 
extend beyond energetics. It has been demonstrated that proliferating cardiomyocytes from 
injured zebrafish hearts show elevated expression of genes involved in glycolysis, and that 
inhibition of glycolysis significantly lowered cardiomyocyte proliferation35, suggesting that the 
metabolic switch observed in fetal- and neonatal cardiomyocytes might serve an additional 
purpose in cardiomyocyte cell-cycle progression. 
 
Physiological and pathological dynamics in cardiac adaptation 
The heart needs to maintain a cardiac output commensurate with the body’s demands in 
both normal and stressed conditions. Upon reaching adulthood, the ability of the heart to 
adapt to stressed conditions is limited by the low capacity of cardiomyocytes to proliferate. 
However, individual cardiomyocytes can undergo enlargement, a process called 
hypertrophy. Cardiomyocyte hypertrophy leads to increased synthesis, as well as structural 
reorganization of the sarcomeres, contributing to enhanced contractile mass and lower wall 
stress, and as a result, it enables the heart to overcome an increased workload. Depending 
on the initial hypertrophic stimulus, cardiac hypertrophy can either be physiological or 
pathological. Although both forms initially develop as an adaptive response, important 
phenotypical, molecular, and prognostic differences have been identified.  
Physiological hypertrophy is often the result of postnatal growth, pregnancy, and exercise 
training, and is mainly initiated by IGF-induced activation of Phosphoinositide 3-kinase 
(PI3K) and Protein Kinase B (AKT).36 It is characterized by cardiomyocyte growth in both 
length and width, leading to increased wall thickness and eccentric remodeling with a mild 
increase in ventricular volume, and preserved, or even increased contractile function.37 In 
addition, physiological hypertrophy is fully reversible, develops in absence of fibrosis, cell 
death, and re-activation of the fetal gene program.37 Most important, physiological 
hypertrophy does not progress to heart failure.  
Pathological hypertrophy on the other hand leads to adverse cardiac events and often 
results from genetic predisposition or other cardiovascular complications, including 
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hypertension and myocardial infarction.37 It mainly develops through mechanical forces and 
circulating factors, such as Angiotensin II (ANG II) and Endothelin 1 (ET1).38 Stimulation of 
cardiomyocytes by ANG II and ET1 induces Ca2+-dependent activation of NFAT, which can 
interact with transcriptional cofactors MEF2 and GATA4 to stimulate hypertrophy-related 
transcription of fetal genes, such as Skeletal Muscle α-Actin (ACTA1).39 In addition, ANG II 
and ET1 induce the activation of PKC, which in cardiomyocytes is known to activate 
serine/threonine-protein phosphatase 1 (PP1A).40 PP1A lowers phosphorylation of 
Phospholamban (PLN), leading to impaired Ca2+ handling caused by PLN-induced inhibition 
of SR Ca(2+)-ATPase 2 (SERCA2).40 Disturbed Ca2+ handling, resulting in elevated 
cytoplasmic Ca2+ levels during diastole, not only lowers systolic Ca2+ elevations and thus 
contractile function41, it also impairs actin blockade by tropomyosin during diastole, lowering 
the dissociation of myosin-actin cross bridges, thereby attenuating active relaxation and 
contributing to diastolic dysfunction.41-43 Pathological hypertrophy is furthermore associated 
with elevated cell death as well as both interstitial and perivascular fibrosis. Cardiac fibrosis 
elevates passive stiffness of the myocardium, and consequently contributes to diastolic 
dysfunction. Moreover, pathological cardiac remodeling is associated with mitochondrial 
dysfunction, and insufficient capillary support leading to hypoxia.44 This hypoxic state, in 
concert with mitochondrial dysfunction, causes a reduction of fatty acid oxidation and an 
increase in glycolysis and lactate metabolism.45 These more oxygen-efficient metabolic 
pathways however, only produce a fraction of the ATP produced in mitochondria and cannot 
compensate for the loss of energy production resulting from decreased fatty acid oxidation.37 
Since both attachment of myosin heads to actin, leading to contraction, as well as 
detachment causing relaxation, requires ATP, a low energy availability both affects systolic 
and diastolic function and could contribute to development of heart failure. 
Depending on the stimulus, pathological hypertrophy may either be concentric or eccentric.  
Concentric remodeling generally occurs in response to systolic pressure overload, whereas 
eccentric remodeling develops in response to volume overload-induced elevation of diastolic 
wall stress. These distinct compensatory responses can be explained by the Laplace law, 
T=P*r/2h, in which left ventricular wall stress (T) is directly related to left ventricular pressure  
(P) and radius (r), and inversely related to left ventricular wall thickness.46 Pressure overload 
(↑P), for instance during chronic hypertension or aortic stenosis, causes an elevation of wall 
stress (↑T), which can be normalized by lowering the radius and increasing the wall 
thickness by the addition of new sarcomeres in parallel. This concentric remodeling initially 
lowers the wall stress, but in later stages progressively impairs diastolic function and 
contributes to the development of heart failure with preserved ejection fraction (HFpEF).47 
Volume overload (↑r) on the other hand, as observed for instance in response to mitral 
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regurgitation, also causes an elevation of wall stress (↑T), which can only be restored by 
hypertrophic remodeling of the cardiomyocytes. In contrast to concentric remodeling, volume 
overload causes an in-series addition of sarcomeres, thereby lengthening the 
cardiomyocytes.48 This initially lowers the wall stress and enhances the stroke volume to 
compensate for the lost volume due to regurgitation, but proceeding elevation of the left 
ventricular chamber volume progressively compromises both systolic and diastolic function, 
eventually causing heart failure with reduced ejection fraction (HFrEF).  
 
Vascular dynamics in cardiac remodeling 
Cardiomyocyte hypertrophy, either physiological or pathological, initially serves to adapt to 
an increased workload. The increase in muscle mass, generated to overcome this elevated 
workload, results in an overall higher energy demand and an augmented supply of nutrients 
and oxygen is thus required. In physiologically hypertrophied hearts, local hypoxia-induced 
activation of Hypoxia Inducible Factor 1α (HIF1α), as well as the hypertrophic stimuli-
induced activation of the transcriptional regulator GATA4, results in cardiomyocyte 
transcription and secretion of VEGFA49, 50, ensuring a proportionate growth of muscle mass 
and microvessels. In pathological hypertrophy however, the increase in muscle mass is 
associated with a relative reduction in the number of capillaries, resulting in myocardial 
hypoxia.51 This paradoxical reduction in capillary density might result from a Transformation-
related Protein 53- (TP53) dependent inhibition of the transcriptional activity of HIF1α.50  
A mismatch in oxygen and nutrient delivery to pathologically hypertrophied cardiomyocytes 
is not always the result of insufficient capillary growth. For instance, endothelial dysfunction 
and capillary rarefaction, as are often observed in HFpEF, also contribute to myocardial 
ischemia.52 In addition to the resulting hypoxia, coronary microvascular insufficiency also 
results in a lower bioavailability of endothelium-derived nitric oxide (NO), leading to reduced 
Protein Kinase G-induced phosphorylation of the muscular spring Titin (TTN), and thus to 
impaired cardiac relaxation during diastole.52 The events causing coronary microvascular 
dysfunction and rarefaction are still incompletely understood, though a better appreciation 
hereof might shed new light on the complex etiology of HFpEF.  
In chapter 4 we describe the results from an observational study in ZSF1 rats, a model for 
early HFpEF, in which we found that the functional cardiac impairments were associated 
with subendocardial development of highly proliferating endothelial clusters, showing a 
distinct lack of vascular morphology. These results led us to hypothesize that the 
hyperproliferative vascular reaction in ZSF1 heart could be part of a destructive response, 
that leads to replacement of functional vascular structures by fibrotic tissue with semi- and 
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nonfunctional microvascular clusters, which may ultimately deteriorate into large fibrotic 
areas that are devoid of vascular support. 
 
Renal function and role in cardiovascular homeostasis 
The primary function of the kidneys is to remove dissolved (metabolic) waste products 
generated by cells throughout the body. In order to do so, the kidney is composed of 
complex units of intertwining capillaries and renal tubules, called nephrons. These nephrons 
contain highly specialized structures, including the glomerulus, in which blood pressure 
forces fluids and dissolved solutes from the capillaries into the renal tubule. In the different 
segments of the renal tubule, most of the water and useful organic molecules are reclaimed, 
leaving a concentrated solution of waste products that enters the calyx as urine. Normal 
kidney function relies on adequate glomerular filtration rate (GFR), which in turn depends on 
glomerular blood pressure. A low GFR in response to hypovolemia results in accumulation 
of circulating waste products, and after prolonged presence could induce ischemic damage 
to the kidney.53 Vice versa, a high GFR from the perspective of an individual nephron, for 
instance as an adaptive response to nephron loss, leads to glomerular hypertension and 
subsequent glomerulosclerosis with progressive decline in renal function.54 Glomerular 
blood pressure can be regulated in multiple ways; local short-term regulation of glomerular 
blood pressure can be accomplished by adjusting the diameter of the pre- and post-
glomerular arterioles, whereas long-term adaptation, involving adjustments of blood 
pressure and blood volume, is under neurohormonal control. In response to low GFR, the 
kidney releases renin in the circulation.55 Renin and angiotensin converting enzyme (ACE) 
induces the conversion of angiotensinogen into ANG II, which stimulates vasoconstriction 
and secretion of antidiuretic hormone and aldosterone55. ANG II-induced secretion of these 
hormones leads to water and sodium retention, and in combination with vasoconstriction 
these events induce an elevation of blood pressure and GFR. When blood volume and 
blood pressure are too high, Natriuretic Peptide A is secreted by atrial cardiomyocytes, 
which opposes the effects of the renin-angiotensin system (RAS).56 
Since kidneys for their well-functioning not only depend on normal blood pressure and blood 
volume, but also have a profound role in the regulation thereof, it is not surprising to find that 
cardiovascular and renal homeostasis are directly connected. Renal dysfunction in response 
to an acute or chronic decline in cardiac output (cardiorenal syndrome type I and II, 
respectively57) predominantly results from renal hypoperfusion-mediated activation of RAS.58 
Sodium and water retention induced by RAS activation causes macro- and microvascular 
disease, affecting both renal and cardiac homeostasis.58 In addition to the above-described 
functions, ANG II also elevates renal ET1 levels, which activates NFκB- and TGFβ-induced 
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renal inflammation and fibrosis.57 Moreover, low perfusion of the kidneys also causes 
hypoxia-induced oxidative stress, which impairs endothelial NO activity and may promote 
inflammation.59 The subsequent secretion of inflammatory factors, including IL1 and TNFα, 
contributes to the ET1-induced renal inflammation leading to progression of renal injury and 
loss of kidney function. Conversely, cardiac dysfunction in response to an acute or chronic 
decline in renal function (renocardiac syndrome type III and IV, respectively57) is also highly 
dependent on RAS activation. As described previously, ANG II and ET1 can directly induce 
NFAT-dependent cardiomyocyte hypertrophy, but in addition also contribute to concentric or 
eccentric cardiac remodeling via the induction of hypertension and hypervolemia, 
respectively.60 In addition, the secretion of proinflammatory factors in response to renal 
ischemia, as well as the gradual accumulation of renal toxins, also affects cardiac function 
by promoting endothelial dysfunction and cardiomyocyte apoptosis, and by decreasing 
cardiac contractility.61 
 
Comorbidities in development of diastolic dysfunction 
Diastolic dysfunction, often leading to HFpEF, is associated with hypertension-induced 
concentric cardiac remodeling. However, it has recently been shown that treatment of 
HFpEF with antihypertensive drugs alone does not reduce morbidity and mortality62, 
implicating that the etiology of HFpEF embodies more than a relatively simple maladaptive 
hypertrophic response. In addition to hypertrophic remodeling, LV material from HFpEF 
patients also revealed presence of increased myocardial passive stiffness and incomplete 
relaxation, as well as oxidative stress, interstitial fibrosis and inflammation63, 64. Based on 
these findings, a new paradigm has been proposed52, stating that HFpEF results from a 
comorbidity-induced systemic inflammatory state, leading to coronary microvascular 
dysfunction and lower NO production. The consecutive limitation in NO bioavailability 
impairs myocardial PKG activity, leading to cardiomyocyte hypertrophy and reduced PKG-
induced phosphorylation of TTN. The prominent role of comorbidities in disease onset and 
progression is shared by both types of HF, however, many of these comorbidities, including 
obesity, diabetes, hypertension and anemia, are more prevalent in HFpEF than in HFrEF.65 
As approximately half of the HFpEF patients have five or more major comorbidities, it is hard 
to interpret the individual or synergistic contribution to disease development. It is for instance 
estimated that at least 75% of the incidence of hypertension in the human population is 
related to obesity, and both comorbidities thus often present together.66 The current 
consensus is that metabolic- and hypertensive disease contribute to the systemic state of 
inflammation, and as such, potentially act synergistically in development and progression of 
diastolic dysfunction. However, direct evidence for such a synergistic relation is lacking. 
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More insight in the putative synergistic effects might provide a better understanding of the 
pathogenesis of HFpEF.  
In chapter 5 we tested the hypothesis that metabolic- and hypertensive disease act 
synergistically in development and/or progression of HFpEF. Our findings in ZSF1 rats 
treated with placebo or deoxycorticosterone acetate- and dietary salt-induced severe 
hypertension did not support this hypothesis. Instead, we found important phenotypical 
differences in comorbidity-induced cardiac adaptation, thus emphasizing the need for 
thorough and individualized phenotypical characterization of HFpEF patients. 
 
Genetics in renal- and cardiovascular homeostasis 
Health or disease appears to be the net result of the complex interplay between 
environmental factors and an individual’s genetic background. In addition to the described 
comorbidities, genetic studies have also provided valuable insights in the etiology of renal- 
and cardiovascular disease. In vitro and in vivo verification of these genetic studies indicated 
that rare mutations found in genes encoding Low-Density Lipoprotein Receptor and Nephrin 
for instance, can initiate atherosclerotic- or renal disease, respectively.67, 68 Besides these 
rare variants, genome wide association studies (GWASs) have identified multiple common 
variants or single nucleotide polymorphisms (SNPs) as genetic risk factors for onset and 
progression of renal- and cardiovascular disease.69-72 Although strong correlations were 
found between these common variants and disease development, functional annotation of 
these loci remains an issue, as a disease-associated SNP only marks the genetic variation 
of its linkage disequilibrium (LD) region and does not necessarily represent the disease 
causing allele itself. Currently, functional annotation of GWAS data is mainly conducted by 
linking susceptibility loci by spatial proximity to the nearest gene coding region. However, 
recent epigenetic studies have also revealed that DNA is packed with regulatory elements 
(DREs), such as enhancers and repressors, located in both coding- and non-protein-coding 
DNA regions.73 These DREs play a crucial role in transcriptional regulation in a cell type- 
and circumstance-specific manner. In response to a particular stimulus, activation of specific 
transcription factors and cofactors, in addition to increased DNA region accessibility, DREs 
can stimulate or repress the transcription of their targets by interacting with a target gene’s 
transcriptional start site via the formation of 3D chromatin loops. Genetic variation co-
localizing with these DREs can affect the function of these elements, potentially leading to 
transcriptional dysregulation. It has been reported that DREs can regulate expression levels 
of targets located up to thousands of kilo base pairs up- or downstream74, which far exceeds 
the current standard distance for GWAS annotation. SNPs located in DRE regions could 
hypothetically interfere with transcriptional regulation of gene targets. If the affected DREs 
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regulate the expression of specific factors involved in a certain critical protective mechanism, 
this could contribute to onset or progression of disease.  
In chapter 6 and chapter 7 we describe how we used circular chromosome conformation 
capture-sequencing (4C-seq) to identify putative candidate genes for atherosclerosis and 
chronic kidney disease, respectively, by examining 3D chromatin interactions of DREs 
colocalizing with disease-associated susceptibility loci. Cross-linking the folded and 
interacting DRE segments, followed by two DNA restriction-ligation steps and DNA 
sequencing, allowed us to identify DRE-interacting target genes that could be considered as 
new gene candidates for hypothesis-driven future studies.  
 
Outline of this thesis 
This thesis describes novel insights in the molecular regulation of renal and cardiovascular 
homeostasis in health and disease. First, in chapter 2 we describe the mechanism by which 
loss of WNT receptor FZD5 attenuates the angiogenic process. Knockdown of endothelial 
FZD5 induced the combined transcriptional upregulation of the vascular destabilizing factor 
ANGPT2 and pro-angiogenic VEGFA scavenging VEGFR1. In chapter 3 we describe a 
transcriptome-based analysis of the immense effect of endothelial interaction on pericyte 
behavior, providing us with a better appreciation of the mechanisms that contribute to 
pericyte-induced vascular stabilization. Moving to metabolic disease models, we present in 
chapter 4 the results from a study in ZSF1 rats, in which we found that diastolic dysfunction 
was associated with subendocardial development of highly proliferating endothelial clusters, 
showing a distinct lack of vascular morphology. These results led us to hypothesize that the 
hyperproliferative vascular reaction in ZSF1 heart could be part of a destructive response, 
that induces replacement of functional vascular structures by fibrotic tissue with semi- and 
nonfunctional microvascular clusters, which may ultimately deteriorate into large fibrotic 
areas that are devoid of vascular support. In chapter 5 we used the same ZSF1 model to 
test the hypothesis that metabolic- and hypertensive disease act synergistically in 
development of diastolic dysfunction. Our findings in ZSF1 with or without severe 
hypertension did not support our hypothesis and clearly indicated that obesity and 
hypertension induce important phenotypical differences in cardiac adaptation. Moreover, 
these observations emphasize the need for thorough and individualized phenotypical 
characterization of HFpEF patients. In chapter 6 and chapter 7 we describe how we used 
4C-seq to identify putative candidate genes for future hypothesis-driven studies on 
atherosclerosis and chronic kidney disease, respectively. Examining 3D chromatin 
interactions of DREs that colocalize with disease-associated susceptibility loci enabled us to 
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identify genes that might be transcriptionally dysregulated in carriers of these variants. 
Finally, we interpret and discuss the results of chapters 2-7 in chapter 8. 
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Abstract 
Formation of a functional vascular system is essential and its formation is a highly regulated 
process initiated during embryogenesis, which continues to play important roles throughout 
life in both health and disease. In previous studies, FZD5 was shown to be critically involved 
in this process and here we investigated the molecular mechanism by which endothelial loss 
of this receptor attenuates angiogenesis. 
Using short interference RNA mediated loss of function assays, the function and mechanism 
of signaling via FZD5 was studied in human endothelial cells (ECs). Our findings indicate 
that FZD5 signaling promotes neovessel formation in vitro in a collagen matrix based 3D co-
culture of primary vascular cells. Silencing of FZD5 reduced EC proliferation, as a result of 
G0/G1 cell cycle arrest, and decreased cell migration. Furthermore, FZD5 knockdown 
resulted in enhanced expression of the factors ANGPT2 and VEGFR1, which are mainly 
known for their destabilizing effects on the vasculature. In FZD5 silenced ECs, ANGPT2 and 
VEGFR1 upregulation was induced by enhanced PKC signaling, without the involvement of 
canonical WNT signaling, non-canonical WNT/Ca2+ mediated activation of NFAT, and non-
canonical WNT/PCP mediated activation of JNK. We demonstrated that PKC induced 
transcription of ANGPT2 and VEGFR1 involved the transcription factor Ets1. 
The current study demonstrates a pro-angiogenic role of FZD5, which was shown to be 
involved in endothelial tubule formation, cell cycle progression and migration, and partly 
does so by repression of PKC/Ets1 mediated transcription of VEGFR1 and ANGPT2. 
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Introduction 
New formation of blood vessels from pre-existing vessels, a process called angiogenesis, is 
a critical step in embryogenesis and continues to play important roles throughout life in both 
health and disease.1 It is a dynamic process that is tightly regulated by a diverse range of 
signal transduction cascades and imbalances in these pathways can be a causative or a 
progressive factor in many diseases.2  
Multiple studies suggest an important role for endothelial signal transduction via Frizzled 
(FZD) receptors in angiogenesis.3-5 The FZD receptors belong to a family of 10 
transmembrane receptors (FZD1-10), which can initiate FZD/WNT canonical and non-
canonical signaling upon binding with one of the 19 soluble WNT ligands. Canonical WNT 
signaling depends on FZD receptor and LRP 5/6 co-activation, initiating Disheveled (DVL) to 
stabilize β-catenin, followed by β-catenin-mediated transcriptional regulation.6-8 In contrast, 
non-canonical WNT signaling also involves DVL, but proceeds via WNT/Ca2+ mediated-
activation of Nuclear factor of activated T-cells (NFAT) or WNT/Planar Cell Polarity (PCP) 
mediated activation of c-JUN N-terminal Kinase (JNK).6 A potential link between FZD5 and 
angiogenesis was previously demonstrated in FZD5 full knockout mice.5 FZD5 silencing 
induced in utero death at approximately E10.5, which was associated with vascular defects 
in the placenta and yolk sac. Furthermore, isolated endothelial cells (ECs) from FZD5 
deficient mice showed a reduction in cell proliferation, which is crucial for neo vessel 
formation. These findings suggest that FZD5 can be an important regulator of angiogenesis. 
However, the exact type of endothelial FZD5/WNT signaling and the downstream molecular 
mechanism causal to the poor vascular phenotype in absence of this receptor requires 
further in depth evaluation. 
Here we studied the angiogenic potential of FZD5 and investigated the signaling pathways 
that are mediated by FZD5/WNT signaling in human ECs. Our findings indicate that WNT5a, 
which is endogenously expressed in ECs, binds and signals via FZD5, but in absence of this 
receptor triggers a poor angiogenic phenotype via an alternative signaling route. We 
demonstrated that FZD5 is essential for neovessel formation in vitro in a collagen matrix 
based 3D co-culture of primary human vascular cells. Silencing of FZD5 reduced EC 
proliferation as a result of G0/G1 cell cycle arrest and decreased cell migration capacity. 
Furthermore, FZD5 knockdown resulted in enhanced expression of the factors Angiopoietin 
2 (ANGPT2) and Fms Related Tyrosine Kinase 1 (VEGFR1), which are mainly known for 
their destabilizing effects on the vasculature.9-11 In FZD5 silenced ECs, ANGPT2 and 
VEGFR1 upregulation was induced by enhanced Protein Kinase C (PKC) signaling, without 
the involvement of canonical WNT signaling, non-canonical WNT/Ca2+ mediated activation 
of NFAT, and non-canonical WNT/PCP mediated activation of JNK. Further downstream, 
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PKC induced transcription of ANGPT2 and VEGFR1 involved the transcription factor Protein 
C-Ets-1 (Ets1), as knockdown of both FZD5 and Ets1 resulted in a marked repression of 
ANGPT2 and VEGFR1 expression levels. In addition, silencing of Ets1 partially restored the 
impaired endothelial tubule formation capacity of FZD5 silenced ECs. 
 
 
Methods 
Cell culture 
Human Umbilical Vein Endothelial Cells (HUVECs; Lonza) and Human Brain Vascular 
Pericytes (Sciencell) were cultured on gelatin coated plates in EGM2 medium (EBM2 
medium supplemented with EGM2 bullet kit; Lonza, and 100U/ml penicillin/streptomycin; 
Lonza) and DMEM (supplemented with 100U/ml penicillin/streptomycin; Lonza, and 10% 
FCS; Lonza) respectively, in 5% CO2 at 37 ˚C. The experiments were performed with cells at 
passage 3-5. Lentivirus green fluorescent protein (GFP) transduced HUVECs and lentivirus 
discosoma sp. red fluorescent protein (dsRED) transduced pericytes were used at passage 
5-7. HUVECs and GFP-labeled HUVECs were used from 6 different batches derived from 
pooled donors. Pericytes and dsRED-labeled pericytes were used from 8 different batches 
derived from single donors. FZD5, Ets1, and WNT5a knockdown in HUVECs was achieved 
by cell transfection of a pool containing 4 targeting short interference RNA (siRNA) 
sequences, whereas PKC isoforms where knocked down with individual siRNA strands 
(Dharmacon), all in a final concentration of 100nM. Control cells were either untreated or 
transfected with a pool of 4 non-targeting siRNA sequences (Dharmacon) in a final 
concentration of 100nM. Target sequences are listed in table 1. Inhibition of GSK3β, NFAT, 
JNK, and PKC activation was achieved with 20µM LiCl (Sigma), 1µM Cyclosporine A (CsA; 
Sigma), 20µM SP600125 (Sigma), and 5, 10 and 20nM staurosporine (CST) respectively. 
Phosphatase activity was inhibited with 50nM Calyculin A. Free Ca2+ induced activation of 
NFAT-mediated transcription was achieved with 10µM A23187. In experiments involving a 
serum starvation step, the cells were cultured for 24 hours in EBM2. 
 
Quantitative PCR and Western blot analysis 
Total RNA was isolated using RNA mini kit (Bioline) and reversed transcribed into cDNA 
using iScript cDNA synthesis kit (Bioline). Gene expression was assessed by qPCR using 
SensiFast SYBR & Fluorecein kit (Bioline) and primers as listed in table 2. Expression levels 
are relative to the housekeeping gene β-actin. For assessment of protein levels, cells were 
lysed in cold NP-40 lysis buffer (150mM NaCl, 1.0% NP-40, 50 mM Tris, pH 8.0)  
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Table 1: siRNA sequences used in cell culture. 
Target gene Target sequence 
Non-targeting UGGUUUACAUGUCGACUAA 
 UGGUUUACAUGUUGUGUGA 
 UGGUUUACAUGUUUUCUGA 
 UGGUUUACAUGUUUUCCUA 
FZD5 GCAUUGUGGUGGCCUGCUA 
 GCACAUGCCCAACCAGUUC 
 AAAUCACGGUGCCCAUGUG 
 GAUCCGCAUCGGCAUCUUC 
Ets1 AUAGAGAGCUACGAUAGUU 
 GAAAUGAUGUCUCAAGCAU 
 GUGAAACCAUAUCAAGUUA 
 CAGAAUGACUACUUUGCUA 
WNT5a GCCAAGGGCUCCUACGAGA 
 GUUCAGAUGUCAGAAGUAU 
 CAUCAAAGAAUGCCAGUAU 
 GAAACUGUGCCACUUGUAU 
PKCα UAAGGAACCACAAGCAGUA 
PKCδ CCAUGUAUCCUGAGUGGAA 
PKCε GUGGAGACCUCAUGUUUCA 
PKCη GCACCUGUGUCGUCCAUAA 
 
 
supplemented with 1mM β-glycerolphosphate, 1mM PMSF, 10mM NaF, 1mM NaOV, and 
protease inhibitor cocktail (Roche). Total protein concentration was quantified by Pierce® 
BCA Protein Assay Kit (Thermo Scientific) as a loading control. Lysates were denaturated in 
Laemmli buffer (60mM Tris pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% 
bromophenol blue) at 90°C for 5 min followed by electrophoresis on a 10% SDS-page gel 
(Biorad). Subsequently, proteins were transferred to a nitrocellulose membrane (Pierce) and 
incubated for 1 hour in PBS with 5% non-fat milk, followed by incubation with rabbit anti-
FZD5 (Milipore), goat anti-β-actin (Abcam), rabbit anti-β-catenin, anti-non-phospho β-catenin 
and phospho-β-catenin (CST, validated in Supplemental Figure 3A), rabbit anti-ANGPT2 
(Abcam), rabbit anti-JNK and phospho-JNK (CST, validated in Supplemental Figure 4C), 
rabbit anti-JUN and phospho-JUN (CST, validated in Supplemental Figure 4C), rabbit anti-
WNT5a (CST) rabbit anti-DVL2 (CST) according to manufacturer’s description. Protein 
bands were visualized with the Li-Cor detection system (Westburg). Levels of secreted 
VEGFR1 in cultured medium were assessed 72 hours post transfection using a VEGFR1 
ELISA kit (R&D systems). 
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Table 2: Primer sequences used for (q)PCR. 
Gene Sense primer sequence Antisense primer sequence 
FZD1 GCCCTCCTACCTCAACTACCA ACTGACCAAATGCCAATCCA 
FZD2 GCTTCCACCTTCTTCACTGTC GCAGCCCTCCTTCTTGGT 
FZD3 CTTCCCTGTCGTAGGCTGTGT GGGCTCCTTCAGTTGGTTCT 
FZD4 ATGAACTGACTGGCTTGTGCT TGTCTTTGTCCCATCCTTTTG 
FZD5 TACCCAGCCTGTCGCTAAAC AAAACCGTCCAAAGATAAACTGC 
FZD6 GCGGAGTGAAGGAAGGATTAG TGAACAAGCAGAGATGTGGAA 
FZD7 CGCCTCTGTTCGTCTACCTCT CTTGGTGCCGTCGTGTTT 
FZD8 GCCTATGGTGAGCGTGTCC CTGGCTGAAAAAGGGGTTGT 
FZD9 CTGGTGCTGGGCAGTAGTTT GCCAGAAGTCCATGTTGAGG 
FZD10 CCTTCATCCTCTCGGGCTTC AGGCGTTCGTAAAAGTAGCAG 
WNT1 CAACAGCAGTGGCCGATGGTGG CGGCCTGCCTCGTTGTTGTGAAG 
WNT2 GTCATGAACCAGGATGGCACA TGTGTGCACATCCAGAGCTTC 
WNT2b AAGATGGTGCCAACTTCACCG CTGCCTTCTTGGGGGCTTTGC 
WNT3 GAGAGCCTCCCCGTCCACAG CTGCCAGGAGTGTATTCGCATC 
WNT3a CAGGAACTACGTGGAGATCATG CCATCCCACCAAACTCGATGTC 
WNT4 GCTCTGACAACATCGCCTAC CTTCTCTCCCGCACATCC 
WNT5a GACCTGGTCTACATCGACCCC GCAGCACCAGTGGAACTTGCA 
WNT5b TGAAGGAGAAGTACGACAGC CTCTTGAACTGGTTGTAGCC 
WNT6 TTATGGACCCTACCAGCAT ATGTCCTGTTGCAGGATG 
WNT7a GCCGTTCACGTGGAGCCTGTGCGTGC AGCATCCTGCCAGGGAGCCCGCAGCT 
WNT7b GATTCGGCCGCTGGAACTGCTC TGGCCCACCTCGCGGAACTTAG 
WNT8a CTGGTCAGTGAACAATTTCC GTAGCACTTCTCAGCCTGTT 
WNT8b GTCTTTTCACCTGTGTCCTC AGGCTGCAGTTTCTAGTCAG 
WNT10a CTGTTCTTCCTACTGCTGCT ACACACACCTCCATCTGC 
WNT10b GCACCACAGCGCCATCCTCAAG GGGGTCTCGCTCACAGAAGTCAGGA 
WNT11 CACTGAACCAGACGCAACAC CCTCTCTCCAGGTCAAGCAAA 
WNT14 ACAAGTATGAGACGGCACTC AGAAGCTAGGCGAGTCATC 
WNT15 TGAAACTGCGCTATGACTC GTGAGTCCTCCATGTACACC 
WNT16 GAGAGATGGAACTGCATGAT GATGGGGAAATCTAGGAACT 
AXIN2 TTGAATGAAGAAGAGGAGTGGA TCGGGAAATGAGGTAGAGACA 
CCND1 GTCCATGCGGAAGATCGTCG TCTCCTTCATCTTAGAGGCCACG 
C-MYC CACAGCAAACCTCCTCACAG CGCCTCTTGACATTCTCCTC 
ANGPT1 GCTGAACGGTCACACAGAGA CTTTCCCCCTCAAAGAAAGC 
ANGPT2 TTATCACAGCACCAGCAAGC TTCGCGAGAACAAATGTGAG 
VEGFA AAGGAGGAGGGCAGAATCAT ATCTGCATGGTGATGTTGGA 
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3D analysis of endothelial tubule formation 
Twenty-four hours post siRNA transfection, GFP-labeled HUVECs were harvested and 
suspended with non-transfected dsRED labeled pericytes in collagen as previously 
described by Stratman.12 In summary, HUVECs and pericytes were mixed in a 5:1 ratio in 
EBM2 supplemented with Ascorbic Acid, Fibroblast Growth Factor, and 2% FCS from the 
EGM2 bullet kit. Additionally, C-X-C motif chemokine 12, Interleukin 3, and Stem Cell Factor 
were added in a concentration of 800ng/ml (R&D systems). The cell mixture was suspended 
in bovine collagen (Gibco) with a final concentration of 2mg/ml and pipetted in a 96 wells 
plate. One hour of incubation in 5% CO2 at 37 ˚C was followed by the addition of 100µl of 
the adjusted EBM2 medium on the collagen gels. The addition of recombinant human 
ANGPT2 and VEGFR1 (R&D systems) was done 24 hours post seeding in the collagen 
matrix, both in a final concentration of 1000ng/ml. Forty-eight hours and 120 hours post 
seeding, these co-cultures were imaged by fluorescence microscopy, followed by analysis of 
the number of junctions, the number of tubules, and the tubule length using AngioSys. At 
least 3 technical replicates were averaged per condition per independent replicate. 
 
Migration assay 
Twenty-four hours post siRNA transfection, HUVECs were plated at a density of 0.5 x 105 
cells/well in an OrisTM Universal Cell migration Assembly Kit (Platypus Technologies) 
derived 96 well plate with cell seeding stoppers. Twenty-four hours post sub culturing, the 
cell stoppers were removed and cells were allowed to migrate into the cell free region for 16 
hours in 5% CO2 at 37 ˚C. Subsequently, the cells were washed in PBS and stained by 
Calcein-AM followed by visualization using fluorescence microscopy. Wells in which cell 
seeding stoppers were not removed were used as a negative control. Results were analyzed 
VEGFR2 AGCGATGGCCTCTTCTGTAA ACACGACTCCATGTTGGTCA 
VEGFR1 TGTCAATGTGAAACCCCAGA GTCACACCTTGCTCCGGAAT 
DSCR1 GAGGACGCATTCCAAATCAT AGTCCCAAATGTCCTTGTGC 
TF TACTTGGCACGGGTCTTCTC TGTCCGAGGTTTGTCTCCA 
Ets1 GGAGCAGCCAGTCATCTTTC GGTCCCGCACATAGTCCTT 
PKCα CGACTGGGAAAAACTGGAGA ACTGGGGGTTGACATACGAG 
PKCδ ATTGCCGACTTTGGGATGT TGAAGAAGGGGTGGATTTTG 
PKCε AAGCCACCCTTCAAACCAC GGCATCAGGTCTTCACCAAA 
PKCη TCCCACACAAGTTCAGCATC CCCAATCCCATTTCCTTCTT 
MMP1 GATTCGGGGAGAAGTGATGTT CGGGTAGAAGGGATTTGTG 
Β-actin TCCCTGGAGAAGAGCTACGA AGCACTGTGTTGGCGTACAG 
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by Clemex. At least 3 technical replicates were averaged per condition per independent 
replicate. 
 
Intracellular immunofluorescent staining 
Forty-eight hours post siRNA transfection, HUVECs were seeded on gelatin coated glass 
coverslips in 12 wells plates at a density of 0.5 x 105 cells/well (sub-confluent) and 3.5 x 105 
cells/well (confluent). Subsequently, cells adhered for 24 hours followed by fixation for 15 
min in 4% paraformaldehyde and blocking for 60 min in PBS with 5% bovine serum albumin 
(Sigma) and 0.3% Triton X-100 (Sigma). After blocking, coverslips were placed on droplets 
PBS with 1% BSA and 0.3% Triton X-100 containing rabbit anti-β-catenin antibody (CST) for 
16 hours in a humidified environment at 4°C. Thereafter, coverslips were incubated on PBS 
with 1% BSA and 0.3% Triton X-100 containing an Alexa Fluor 594-labeled secondary 
antibody (Invitrogen) and phalloidin-rhodamin (Invitrogen) for 1 hour at room temperature, 
finally followed by mounting the stained coverslips on vectashield with DAPI (Brunschwig). 
Coverslips were imaged by confocal microscopy. 
 
Proliferation, cell cycle assay and apoptosis 
Twenty-four hours post siRNA transfection, HUVECs were seeded in 6 wells plates at a 
density of 0.5 x 105 cells/well. To study the effect of FZD5 knockdown on proliferation, 
HUVECs were harvested 24 hours, 48 hours, and 72 hours post sub culturing and counted 
by flow cytometry. For analysis of cell cycle progression, cells were harvested 48h post sub 
culturing and fixated in 70% ethanol for 60 minutes on ice. Subsequently, cells were stained 
with PI and treated with RNAse (Sigma) for 30 minutes at 37 ˚C and analyzed by flow 
cytometry. Apoptosis was studied 72 hours after transfection using an in situ cell death 
detection kit (Roche) as described by manufacturer on 4% PFA fixated cells. 
 
WNT5a adenovirus preparation, transduction and stimulation 
Recombinant adenoviruses were produced using the Gateway pAd/CMV/V5DEST vector 
and ViraPowerTM Adenoviral Expression System (Invitrogen), according to manufacturer’s 
instructions. Briefly, the WNT5a expression cassette was cloned from the pENTRTM 221 
WNT5a entry vector (Invitrogen) into pAd/CMV/V5-DEST expression vector (Invitrogen) via 
the LR-reaction II (invitrogen). After verification by DNA sequencing, the pAd/CMV plasmids 
were linearized by Pac1 restriction and subsequently transfected with Lipofectamine 2000 
(Invitrogen) in 293A cells. Infected cells were harvested by the time 80% of the cells 
detached from plates followed by isolation of viral particles from crude viral lysate. HeLa 
cells were used to produce WNT5a (or dsRED, referred to as adSHAM) by transduction with 
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a calculated 5 viral particles per cell. Forty-eight hours post transduction, HeLa cells were 
cultured for 24 hours on EBM2, which eventually was used to stimulate serum-starved 
endothelium for 3 hours. 
 
Statistical analysis 
For each experiment, N represents the number of independent replicates. Statistical 
analysis was performed by GraphPad Prism using one-way ANOVA followed by post hoc 
Tukey’s test, unless stated otherwise. Results are expressed as mean ± SEM. Significance 
was assigned when P<0.05 (two-tailed).  
 
 
Results 
FZD5 siRNA induces a specific knockdown of endothelial FZD5  
The function of FZD5 was studied in vitro using siRNA mediated silencing in HUVECs, 
which were shown to express all FZD receptors other than FZD10 (Supplemental Figure 
1A), and WNT2b, 3, 4, 5a, and 11 (Supplemental Figure 1B). Both qPCR and Western blot 
analysis confirmed a significant loss of FZD5 expression in cells treated with an siRNA pool 
specific for FZD5, compared to untreated control cells and cells treated with a pool of non-
targeting siRNA, referred to as siSHAM (Supplemental Figure 1C-D). Although FZD 
receptors share highly similar domains, knockdown of FZD5 was specific. None of the other 
FZD receptors were differentially expressed after treatment with FZD5 siRNA, other than 
FZD5 (Supplemental Figure 1C).  
 
WNT5a signals via endothelial FZD5 
Previous studies listed WNT5a and Secreted Frizzled-Related Protein 2 (SFRP2) as most 
likely candidates to activate FZD5-mediated signaling in ECs.13-15 In contrast to SFRP216, 
WNT5a is endogenously expressed by HUVECs (Supplemental Figure 1B). To address the 
potential signal capacities of this endogenously expressed WNT5a as ligand for FZD5, HeLa 
cells were transduced with an adenoviral overexpression plasmid for WNT5a to produce 
cultured medium containing high levels of this WNT ligand. HeLa cells were selected for this 
purpose over HUVECs as these cells were shown to have a more refined machinery to 
produce and secrete functional WNT5a than HUVECs, as illustrated by enhanced mRNA 
expression of WNTless (WLS) and Porcupine (PORCN) (data not shown). Transduction with 
this overexpression vector (adWNT5a) led to a significant upregulation of WNT5a compared 
to dsRED control transduced cells (adSHAM) (Figure 1A). To assess whether FZD5 was 
involved in transducing the signal of WNT5a, cultured medium from transduced HeLa cells 
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Figure 1: WNT5a induced FZD5-mediated DVL activation in HUVECs. (A) Representative 
Westernblot of adenoviral-based WNT5a overexpression in HeLa cells, 72 hours post transduction. 
N=4. (B) Representative Western blot of DVL and phosphorylated DVL in HUVECs after 3 hours 
stimulation with cultured medium (CM) from HeLa cells overexpressing dsRED or WNT5a, 72 hours 
post siRNA transfection in HUVECs. N=6 
 
was applied to serum starved HUVECs after which DVL activation was monitored. Western 
blot analysis showed that WNT5a strongly induced DVL phosphorylation in untreated or 
non-targeting siRNA treated HUVECs, however this effect was blocked in absence of FZD5 
(Figure 1B), confirming the importance of endothelial FZD5 in transducing WNT5a signaling. 
 
FZD5 expression is essential for endothelial proliferation, migration, and tubule formation 
The angiogenic capacities of these FZD5 silenced HUVECs were evaluated in a well-
validated in vitro 3D angiogenesis assay developed for studying formation of micro-capillary 
structures.12 In this assay, HUVECs with Green Fluorescent Protein (GFP) marker 
expression and dsRED labelled pericytes directly interact in a collagen type I matrix 
environment, resulting in EC sprouting, tubule formation, and neovessel stabilization as a 
result of perivascular recruitment of pericytes. At day 5 post-seeding, well-defined, micro-
capillaries with pericyte coverage can be observed. Imaging and quantification of the 
vascular structures was conducted at day 2 and 5. Endothelial knockdown of FZD5 strongly 
impaired endothelial tubule formation (Figure 2A). Quantification revealed a significant 
reduction in the total tubule length, the number of endothelial junctions, and the number of 
endothelial tubules, both after 2 and 5 days (Figure 2B).  
To get a better insight in the causative factor for this poor vascular phenotype, the migration 
and proliferation capacities of FZD5 silenced ECs were studied. A plug-in migration assay 
was performed to analyze the effects of FZD5 knockdown on endothelial mobility. 
Knockdown of FZD5 significantly inhibited the migration of ECs towards the open cell-devoid 
area compared to untreated and non-targeting siRNA treated ECs (Figure 3A-B). In addition, 
knockdown of FZD5 significantly reduced cell numbers compared to control and siSHAM 
condition (Figure 3C). To clarify whether this was a result of impaired cell proliferation or 
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Figure 2: FZD5 expression is crucial for vascular formation in vitro. (A) Representative fluorescent 
microscope images of GFP labelled HUVECs (green) in coculture with dsRED labelled pericytes (red) in 
a 3D collagen matrix during vascular formation. Shown are the results at day 2 and 5 of non-transfected 
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◄control, siSHAM, and siFZD5 conditions. Scale bar in the left columns represents 1mm. Scale bar in 
the right columns represents 350µm. (B) Bar graphs show the quantified results of the coculture assay. 
Shown are the total tubule length, and the number of endothelial junctions and tubules relative to the 
control conditions, both after 2 days and 5 days. N=4, *P<0.05 compared to control and siSHAM 
condition. 
 
increased apoptosis, cell cycle progression was analyzed in a cell-cycle assay in which total 
DNA was stained with PI, followed by flow cytometry. A strong increase of cells in the G0/G1 
phase of the cell-cycle was observed after knockdown of FZD5, indicative of a cell cycle 
arrest (Figure 3D-E). For apoptosis analysis, a terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) based detection staining was used. Although seeded in similar 
densities, FZD5 knockdown led to a significant reduction of nuclei per image field. 
 
 
Figure 3: Endothelial knockdown of FZD5 significantly inhibited EC migration and proliferation, 
but had no effect on apoptosis. (A) Representative fluorescent microscope images of Calcein-AM 
labelled HUVECs (green) in a plug-stopper based migration assay. Shown are the results of 16 hours of 
migration of non-transfected control, siSHAM, and siFZD5 conditions. Scale bar represents 500µm. 
Open migration areas produced by the plug-stopper before initiation of the assay are indicated by dotted 
lines. (B) Bar graph shows the quantified results of migration assay. Shown are the percentages of 
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◄surface area within the dotted circle covered by HUVECs after 16 hours of migration. N=4, *P<0.05 
compared to control and siSHAM condition. (C) ECs expansion at 24 hours, 48 hours, and 72 hours 
post seeding in similar densities, as quantified by flow cytometry. N=3, *P<0.05 compared to control and 
siSHAM condition (two-way ANOVA followed by Bonferroni post hoc test). (D) Representative histogram 
of flow cytometric analysis of PI based DNA staining showing the distribution of cells over the cell-cycle 
in the different groups at 48 hours post transfection. (E) Quantified results of cell-cycle analysis. 
Percentage of cells in G0/G1 phase is shown. N=3, *P<0.05 compared to control and siSHAM condition. 
(F) Quantified results of TUNEL staining. Percentage TUNEL positive cells of total number of cell is 
shown, 72 hours post-transfection of control, siSHAM, and siFZD5 conditions. N=3, no significance. (G) 
Representative fluorescent microscope images of DAPI bases nuclei staining in HUVECs (blue, upper 
row) and TUNEL staining of the same cells (red, lower row). Positive control was treated with DNAse 
solution. Scale bar represents 200µm. 
 
However, the relative number of TUNEL positive nuclei in the FZD5 knockdown condition 
was similar when compared to control and siSHAM condition, showing that the reduction of 
ECs in the FZD5 knockdown condition is not related to increased apoptosis (Figure 3F-G). 
 
Loss of FZD5 does not interfere with endogenous canonical WNT signaling 
To further dissect the molecular mechanism of endothelial FZD5 signaling in angiogenesis, 
known FZD/WNT signaling pathways were studied. Downstream FZD signaling occurs via 
the canonical WNT signaling pathway, also known as the WNT/β-catenin pathway, or by the 
less well described non-canonical WNT signaling pathways. Activation of canonical WNT 
signaling is characterized by an accumulation of cytoplasmic β-catenin, eventually resulting 
in nuclear translocation and subsequent expression of β-catenin dependent target genes. To 
evaluate the effect of FZD5 knockdown on the canonical WNT signaling pathway, total 
levels of β-catenin, as well as phospho-β-catenin (ser33/37/thr41) and non phospho-β-
catenin (active) were examined 24h, 48h and 72h post transfection by Western blot. 
Ser33/37/thr41 phosphorylation is induced by GSK3β and primes β-catenin for subsequent 
degradation, and could be indicative for a reduced activity of canonical WNT signaling. Total 
β-catenin, as well as non phospho-β-catenin (active) levels were unaffected by FZD5 
silencing, and no phospho-β-catenin (ser33/37/thr41) was observed in all conditions (Figure 
4A-B), even though the antibody was capable of detecting GSK3β-induced β-catenin 
phosphorylation (Figure 4C). Furthermore, expression levels of previously described 
endothelial target genes of β-catenin were studied using qPCR, but no differences were 
observed in the expression of AXIN2, CCND1 and C-MYC after knockdown of FZD5 (Figure 
4D). An immunofluorescent staining, validated to detect cellular distribution of β-catenin 
(Supplemental Figure 3B), was also performed on transfected ECs, as stable total levels of 
β-catenin found by Western blot did not deviate between cytoplasmic- or nuclear localized β- 
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Figure 4: FZD5 knockdown did not affect the canonical WNT signaling pathway in ECs. (A) 
Representative Western blot result of total levels of β-catenin, non phospho-β-catenin, phospho-β-
catenin (ser33/37/thr41), and β-actin loading control, at different time points post-transfection. (B) 
Quantified results of β-catenin Western blot. Shown are β-catenin levels relative to β-actin loading 
control. N=3, no significance. (C) Western blot result of total levels of β-catenin and phospho-β-catenin 
in response to treatment with the phosphatase inhibitor Calyculin A (50nM) with and without a 30 minute 
pretreatment of the GSK3β inhibitor LiCl (20mM). (D) QPCR analysis of the mRNA expression levels of 
β-catenin target genes AXIN2, Cyclin D1 (CCND1) and C-MYC in the different conditions 72 hours post 
transfection. N=4, no significance. (E) Immunofluorescent staining β-catenin (green), F-actin (red), and 
DAPI (blue) in confluent and sub-confluent (F) HUVECs after knockdown of FZD5. N=3. 
 
catenin. In line with the other experiments focusing on β-catenin-mediated signaling, no 
differences in β-catenin localization were observed after knockdown of FZD5, both in 
confluent and sub confluent cells (Figure 4E and 4F, respectively). 
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FZD5 knockdown induces the expression of several (anti-) angiogenic factors 
To further elucidate the anti-angiogenic phenotype observed after FZD5 knockdown, 
expression levels of several important regulators of angiogenesis were analyzed. In contrast 
to what was previously reported17, our findings in HUVECs indicate that expression of  
 
 
Figure 5: FZD5 knockdown led to increased expression of vascular regression associated genes 
VEGFR1 and ANGPT2. (A) QPCR results of expression levels of ANGPT2 and VEGFR1 in the different 
conditions 72 hours post transfection. N=11, *P<0.05 compared to control and siSHAM condition. (B) 
Representative Western blot results of ANGPT2 expression levels in the different conditions 72 hours 
post transfection. N=3. (C) Enzyme-linked immuno sorbent assay based quantification of secreted 
VEGFR1 levels in cultured endothelial medium 72h post transfection. N=8, *P<0.05 compared to control 
and siSHAM condition. (D) Representative fluorescent microscope images of GFP labelled HUVECs 
(green) in coculture with dsRED labelled pericytes (red) in a 3D collagen matrix during vascular 
formation. Shown are the results at day 5 of an untreated control, and after stimulation with PBS, 
ANGPT2 (1000ng/ml), VEGFR1 (1000ng/ml), and ANGPT2 + VEGFR1 (1000ng/ml both). Scale bar in 
the upper row represent 1mm, in the bottom row 350µm. (E) Bar graphs show the quantified results of 
the coculture assay. Shown are the total tubule length, and the number of endothelial junctions and 
tubules after 5 days. N=4, *P<0.05 compared to control and siSHAM condition.  
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Tissue Factor (TF) is not positively regulated by FZD5 signaling, as FZD5 knockdown did 
not attenuate TF expression. In fact, TF was slightly upregulated in FZD5 silenced HUVECs 
compared to untreated control cells, yet was statistically equal to non-targeting siRNA 
treated HUVECs (Supplemental Figure 2). Interestingly, Vascular Endothelial Growth Factor 
A (VEGFA) decoy receptor VEGFR1, and the vascular destabilizing factor ANGPT2 were 
significantly upregulated at both mRNA and protein level in HUVECs treated with FZD5 
siRNA when compared to untreated or non-targeting siRNA treated HUVECs (Figure 5A-C). 
Expression levels of VEGF receptor 2, VEGFA, as well as ANGPT1 remained unaffected in 
absence of FZD5 (Supplemental Figure 2). In line with previous findings of Lobov et al., 
combined addition of VEGFR1 and ANGPT2 in the 3D coculture system completely 
attenuated endothelial tubule formation (Figure 5D-E).9 
Knockdown of a FZD receptor could not only attenuate signal transduction, but due to 
impaired inhibitory crosstalk between the individual pathways, or via alternative receptor 
binding by the WNT ligand could also have a stimulatory effect.18, 19 Since FZD5 knockdown 
had no effect on the canonical WNT signaling pathway, the described non-canonical 
WNT/Ca2+ and PCP pathways were studied for their potential role in the upregulation of 
ANGPT2 and VEGFR1. Activation of the WNT/Ca2+ pathway could induce VEGFR1 and 
ANGPT2 transcription, as stimulation of the WNT/Ca2+ pathway leads to free Ca2+-induced 
activation of Calcineurin, which in turn could promote NFAT-mediated transcription by 
dephosphorylating NFAT.6 The mRNA expression level of Down Syndrome Critical Region 1 
(DSCR1) was evaluated to assess the potential link between FZD5 knockdown and NFAT 
activation, as DSCR1 is a profound target gene of NFAT, involved in a feedback loop to fine-
tune NFAT-mediated transcription.20, 21 However, no correlation between endothelial 
knockdown of FZD5 and DSCR1 upregulation was observed (Figure 6A). The involvement 
of NFAT-mediated transcription was also evaluated by pharmacological inhibition of the 
WNT/Ca2+ signaling cascade using the Calcineurin inhibitor Cyclosporine A (CsA). The 
effectiveness of CsA (1µM) was confirmed by its ability to inhibit calcium ionophore 
(A23187) induced transcription of DSCR1 as a result of free Ca2+-mediated NFAT activation 
in ECs (Figure 6A). In line with the absence of DSCR1 upregulation in the FZD5 knockdown 
condition, the upregulation of VEGFR1 and ANGPT2 could not be linked to an increase of 
NFAT-mediated transcription in the FZD5 knockdown condition, as CsA stimulation failed to 
reduce ANGPT2 and VEGFR1 upregulation in FZD5 silenced cells (Figure 6B). 
Besides activation of the WNT/Ca2+ pathway, the PCP pathway could also stimulate the 
expression of VEGFR1 and ANGPT2 via activation of the WNT/PCP signaling cascade 
linked to downstream JNK-induced transcriptional activation of c-JUN.22, 23 Activation of 
JNK/c-JUN-mediated transcription involves phosphorylation of JNK, which was slightly 
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Figure 6: FZD5 knockdown led to increased expression of vascular regression associated genes 
VEGFR1 and ANGPT2, independent of the non-canonical WNT/Ca2+ and PCP pathways. (A) 
QPCR results of NFAT target gene Dscr1 in the different conditions 72 hours post transfection and in 
response to ionophore A23187 (10µM) induced Ca2+ flux, with and without NFAT inhibitor Cyclosporin A 
(CsA) (1µM). N=5, *P<0.05 compared to control and siSHAM condition, and DMSO treated and CsA + 
A23187 treated ECs respectively. (B) ANGPT2 and VEGFR1 mRNA expression levels in HUVECs in 
response to CsA, supplemented 48 hours post transfection. N=4, *P<0.05 compared to control and 
siSHAM condition (two-way ANOVA followed by Bonferroni post hoc test). (C) Representative Western 
blot of total JNK, phospho-JNK, and β-actin levels at different time points post-transfection. (D) 
Quantified results of JNK and phospho-JNK Western blot. Shown are individual (phospho) JNK isoform 
(p46 and p54) levels relative to β-actin loading control. N=6, *P<0.05 compared to control and siSHAM 
condition within 1 time comparison (24, 48 or 72 hours). (E) Western blot of total JNK, phospho-JNK, 
and β-actin levels in response to different concentrations of JNK inhibitor SP600125 after 1 hour. (F) 
QPCR analysis showing the effect of SP600125, supplemented 48 hours post transfection, on VEGFR1 
and ANGPT2 mRNA levels in the different conditions. N=4, *P<0.05 compared to control and siSHAM 
condition, #P<0.05 as indicated in graph (two-way ANOVA followed by Bonferroni post hoc test). 
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increased both 48h and 72h post transfection (Figure 6C-D). JNK-mediated phosphorylation 
of c-JUN however was not observed (supplemental Figure 4A-B). Since JNK is a kinase with 
a broad spectrum of downstream substrates24, the JNK inhibitor SP600125 was used to 
block activation of JNK to define whether the enhanced phosphorylation of JNK played a 
role in the upregulation of VEGFR1 and ANGPT2. The effectiveness of SP600125 (20µM) 
was confirmed by its ability to inhibit JNK phosphorylation in ECs (Figure 6E). Treatment of 
HUVECs with SP600125 did not diminish FZD5 silencing-induced upregulation of VEGFR1 
and ANGPT2 (Figure 6F). In contrast, SP600125 treatment rather induced a general 
upregulation of ANGPT2, indicating that activation of JNK was not causally related to the 
FZD5 knockdown-mediated upregulation of both genes.  
 
ANGPT2 and VEGFR1 upregulation is mediated via PKC and Ets1 
Previously it was demonstrated that WNT signal transduction could also involve PKC.25-27 
PKCs are part of a kinase family with a diverse range of potential downstream targets. To 
verify whether FZD5 knockdown-induced upregulation of VEGFR1 and ANGPT2 depended 
on activation of PKC, HUVECs were treated with the PKC inhibitor Staurosporine in the 
concentration range of 5nM to 20nM, as not all different PKC family members are equally 
inhibited at similar concentrations. Interestingly, both ANGPT2 and VEGFR1 overexpression 
induced by FZD5 knockdown was dose dependently reduced by PKC inhibition compared to 
control and siSHAM condition (Supplemental Figure 5A). Since HUVECs express multiple 
PKC isoforms28, 29, PKC expression was knocked down by siRNA to interrogate which 
isoform mediated the observed upregulation of ANGPT2 and VEGFR1. Individual PKC 
isoform knockdown only had a minor effect on the FZD5 knockdown-induced 
overexpression of the anti-angiogenic factors, whereas combined knockdown of the novel 
PKCs (nPKCs) completely attenuated the upregulation of ANGPT2 and VEGFR1 (Figure 
7A, Supplemental Figure 5B).  
PKC signaling can induce elevated synthesis of the transcription factor Ets130, 31, which has 
binding sites in the promoter regions of both ANGPT2 and VEGFR1.32, 33 Ets1 was 
significantly upregulated in absence of FZD5, which was orchestrated by PKC 
(Supplemental Figure 5C). Involvement of Ets1 in transcriptional regulation of ANGPT2 and 
VEGFR1 was evaluated in the FZD5 knockdown condition using a double knockdown of 
both FZD5 and Ets1. Knockdown of Ets1 alone had no effect on the expression of VEGFR1 
and ANGPT2 compared to control and siSHAM condition, indicating no active transcription 
regulation of these two genes by Ets1 in control conditions. However, knockdown of Ets1 in 
FZD5-silenced HUVECs fully inhibited upregulation of ANGPT2 and partially inhibited the 
upregulation of VEGFR1 when compared to FZD5-silenced controls (Figure 7B). The 
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Figure 7: FZD5 knockdown induced upregulation of ANGPT2 and VEGFR1 expression is 
mediated via enhanced PKC and Ets1 signaling. (A) QPCR results showing expression levels of 
ANGPT2 and VEGFR1 in HUVECs after knockdown of FZD5 alone, in combination with different PKC 
isoforms, and in combination with all novel PKC isoforms (PKCδ,ε,η), 48 hours post transfection. N=4, 
*P<0.05 compared to control and siSHAM condition, #P<0.05 as indicated in graph. (B) QPCR results of 
ANGPT2 and VEGFR1 expression in HUVECs, 72 hours post transfection, with and without knockdown 
of transcription factor Ets1, a downstream target of PKC. N=4, *P<0.05 compared to control and 
siSHAM condition, #P<0.05 as indicated in graph. (C) Representative fluorescent microscope images of 
GFP labelled HUVECs (green) in coculture with dsRED labelled pericytes (red) in a 3D collagen matrix 
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◄ during vascular formation. Shown are the results at day 5 of non-transfected control, siSHAM, 
siFZD5, siEts1 and the combined knockdown of FZD5 and Ets1. Scale bar in the upper row represent 
1mm, in the bottom row 350µm. (D) Bar graphs show the quantified results of the coculture assay. 
Shown are the total tubule length, and the number of endothelial junctions and tubules after 5 days. 
N=6, *P<0.05 compared to control and siSHAM condition, #P<0.05 as indicated in graph. 
 
involvement of Ets1-induced transcription was further substantiated by a similar Ets1 
dependent upregulation of Matrix metalloproteinase 1 (MMP1), a verified endothelial target 
gene of Ets1 (Supplemental Figure 6A-B).34 To evaluate if the anti-angiogenic phenotype of 
FZD5 silencing observed in the 3D angiogenesis coculture assay was mediated via this 
pathway, Ets1 was silenced in GFP-labeled HUVECs. Analysis of the 3D coculture results 
demonstrated that inhibition of Ets1 in the FZD5 knockdown condition partly rescued the 
FZD5 knockdown mediated reduction of endothelial tubule formation (Figure 7C-D).  
 
 
Discussion 
The main findings of the current study are: (1) Endothelial FZD5 expression is essential for 
vascular formation, as shown in a 3D coculture assay. (2) FZD5 silencing inhibits EC 
proliferation and migration. (3) Endothelial loss of FZD5 expression does not interfere with 
endogenous canonical WNT signaling. (4) FZD5 knockdown leads to increased expression 
of vascular regression associated factors VEGFR1 and ANGPT2, independent of both the 
non-canonical WNT/Ca2+-mediated activation of NFAT and PCP-mediated activation JNK. 
(5) Inhibition of  nPKC signaling, as well as knockdown of the PKC target Ets1 suppressed 
the upregulation of VEGFR1 and ANGPT2 in absence of FZD5. The Ets1 knockdown 
intervention also partially rescued the FZD5 knockdown-induced inhibitory effect on new 
vessel formation. 
 
Previously it was reported that FZD5 is indispensable for murine embryogenesis.5 FZD5 
knockout embryos died in utero from severe defects in yolk sac and placenta 
vascularization. Using trophoblast specific FZD5 knockout mice, Lu and co-workers reported 
that the observed phenotype in the FZD5 full knockout placenta was partly initiated by a 
defect in chorionic branching morphogenesis.35 As defective branching morphogenesis of 
the chorion of these mice resulted in a smaller placental labyrinth layer compared to wild-
type littermates, it remained difficult to distinguish whether the placental defects observed in 
the FZD5 full knockout mice were indeed vascular related, or the outcome of proportional 
growth limitations resulting from the reduced villous volume. In our study, we demonstrated 
that endothelial knockdown of FZD5 in vitro leads to a severe reduction in vascular tubule 
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formation in a 3D coculture model, thereby providing evidence for the direct role of FZD5 in 
new vessel growth. 
 
The most detailed described FZD/WNT signaling cascade is the canonical or ß-catenin 
dependent pathway. Without stimulation of the canonical pathway, ß-catenin is degraded by 
a destruction complex consisting of Axin, Glycogen Synthase Kinase 3ß, Adenomatous 
Polyposis Coli, and Casein Kinase 1α. Upon binding of WNT ligands to a FZD receptor in 
the presence of the co-receptor Lrp5 or Lrp6, a conformation change in Lrp extracts Axin 
away from the destruction complex, leading to an increase in intracellular ß-catenin levels. 
When translocated into the nucleus, ß-catenin binds to the TCF/Lef complex and promotes 
the expression of ß-catenin target genes.6-8 Knockdown of a FZD receptor could both have 
an inhibiting effect on this pathway, due to a reduction in receptors capable of transducing a 
signal for downstream signaling cascade activation, and an activating effect, either due to 
impaired inhibitory crosstalk between the individual pathways or via alternative receptor 
binding by the WNT ligand.18, 19 Involvement of FZD5 in this canonical pathway appears to 
be tissue dependent. Steinhart et al. recently demonstrated that canonical WNT signaling 
via FZD5 was involved in pancreatic tumor growth and Caricasole et al. reported enhanced 
ß-catenin mediated signaling upon WNT7a interaction with both FZD5 and Lrp6 in the rat 
pheochromocytoma cell line PC12.36, 37 In the mouse optic vesicle however, no evidence 
suggest that FZD5 activates or suppresses canonical WNT signaling.38, 39 Our analysis of 
endogenous canonical FZD/WNT signaling suggests that FZD5 is not involved in WNT ß-
catenin signaling in ECs. 
 
In contrast to the ß-catenin target genes, expression levels of ANGPT2 and VEGFR1 were 
significantly upregulated in HUVECs with suppressed FZD5 expression. ANGPT2 on itself is 
known to have a positive effect on neovessel formation, as it is involved in pericyte 
detachment and destabilization of the endothelium to potentiate the actions of pro-
angiogenic factors.40, 41 However, in absence of VEGFA, or in the presence of an increased 
expression of VEGFR1, a decoy receptor for VEGFA, ANGPT2 is known to induce vascular 
regression.9-11 Both ANGPT2 and VEGFR1 are potential downstream target genes of the 
non-canonical FZD/WNT signaling pathways. Upon stimulation of the FZD/WNT/Ca2+ 
pathway, activation of phospholipase C leads to cleavage of the membrane component PIP2 
into DAG and IP3. When IP3 binds its receptor on the endoplasmic reticulum, Ca2+ is 
released in the cytosol, activating the transcription factor NFAT via Calcineurin.6 In recent 
studies, VEGFR1 and ANGPT2 were shown to be transcriptional targets of NFAT.42, 43 Like 
ANGPT2 and VEGFR1, the endogenous NFAT inhibitor DSCR1 is also a verified target of 
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the transcription factor NFAT20, 21, yet our data showed that the expression level of DSCR1 
remained stable after knockdown of FZD5. More important, our experiments demonstrated 
that inhibition of NFAT activation with CsA after endothelial knockdown of FZD5 did not 
inhibit the upregulation of ANGPT2 and VEGFR1, suggesting that it was unlikely that the 
enhanced transcription of these anti-angiogenic factors was mediated by enhanced activity 
of NFAT. Alternatively, stimulation of the FZD/WNT/PCP pathway could also induce the 
transcription of VEGFR1 and ANGPT2 via GTPase mediated activation of JNK, which 
eventually activates c-JUN based transcription.6 Multiple studies provided evidence for 
transcriptional regulation of VEGFR1 and ANGPT2 either by c-JUN alone, or by the 
transcription complex AP-1 involving c-JUN.22, 23 Our data indicated that FZD5 knockdown 
led to an increase in JNK phosphorylation, but no increase in c-JUN phosphorylation was 
observed. In addition, inhibition of JNK activity with SP600125 ruled out the involvement of 
the PCP-JNK signal transduction axis as causal factor for the enhanced expression of 
vascular regression associated factors ANGPT2 and VEGFR1 in ECs with FZD5 
knockdown, as upregulation of these factors remained evident. In future studies however, it 
remains of interest to further dissect the relevance of this altered JNK signaling in absence 
of FZD5. 
 
Multiple reports have previously suggested a role for PKC involvement in FZD/WNT 
signaling.25-27 Staurosporine, as well as siRNA-mediated knockdown of nPKCs inhibited the 
upregulation of ANGPT2 and VEGFR1 in HUVECs with suppressed expression of FZD5, 
indicating the involvement of PKC signaling in the transcriptional regulation of these genes 
in FZD5 silenced ECs. The promoter regions of both ANGPT2 and VEGFR1 contain binding 
sites of the transcription factor Ets132, 33, which was shown by our data to be PKC 
dependently upregulated in absence of FZD5. Our results demonstrate the involvement of 
enhanced Ets1 mediated transcription of these two genes in FZD5 silenced ECs, as Ets1 
knockdown resulted in a marked repression of ANGPT2 and VEGFR1 expression levels. 
Another validated endothelial target of PKC/Ets1-mediated transcription MMP1, which like 
ANGPT2 and VEGFR1 was previously shown to be involved in vascular regression34, was 
also upregulated via Ets1 in absence of FZD5. The involvement of Ets1 was further 
validated using the 3D coculture model, in which Ets1 knockdown in FZD5 silenced ECs 
partially rescued the inhibitory effect on new vessel formation that was observed in FZD5 
silenced conditions. These results indicate a repressing function on PKC/Ets1 signaling by 
FZD5 in ECs, leading to reduced expression of vascular regression associated factors 
ANGPT2 and VEGFR1.  
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In this study the effect of FZD5 knockdown on the different FZD/WNT signaling routes was 
studied without the addition of exogenous WNT factors. HUVECs secrete WNT factors 
themselves, amongst which the typical canonical factor WNT3 and non-canonical factor 
WNT5a. Knockdown of endothelial FZD5 led to functional defects, as well as differential 
expression of important genes in the angiogenic process, indicating that lack of FZD5 
interferes with endogenous FZD/WNT signaling. The nature of this endogenous signaling in 
absence of FZD5 was shaped by the finding that combined knockdown of FZD5 and 
endogenous WNT5a significantly suppressed ANGPT2 and VEGFR1 upregulation 
(Supplemental Figure 7). It was previously demonstrated that WNT factors induce signaling  
 
 
Figure 8: Schematic representation 
of the proposed model of signaling 
via FZD5 in ECs. Our data provide 
evidence for a new proposed model 
of signaling in ECs in absence of 
FZD5 in which knockdown of this 
receptor provokes its ligand WNT5a 
to signal via an alternative receptor, 
thereby triggering the activation of 
nPKC/Ets1-mediated transcription of 
vascular regression associated 
factors, amongst which VEGFR1 and 
ANGPT2. 
 
 
 
 
 
 
via a variety of FZD and non-FZD receptors, and that binding selectivity is receptor context 
dependent.13, 44 As suppression of endogenous WNT5a signaling partially rescued the FZD5 
knockdown induced upregulation of ANGPT2 and VEGFR1, our data suggest that 
endothelial knockdown of FZD5 provokes its ligand WNT5a to signal via an alternative 
receptor, thereby triggering the activation of the observed PKC/Ets1-mediated transcription 
(Figure 8). Although our experiments demonstrate that this alternative signaling route via 
PKC and Ets1 plays an important role in the poor angiogenic phenotype in absence of 
FZD5, the relative contribution of suppressed FZD5 signaling itself to this phenomenon is 
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yet to be determined. Future studies should also aim to identify the unknown alternative 
WNT5a receptor. 
 
The aim of this study was to explore the involvement of FZD5 in vascular and perivascular 
biology, which might eventually serve as a foundation for future therapeutic strategies, e.g. 
in modulating tumor vasculature. A recent genome-wide CRISPR-Cas9 study demonstrated 
that FZD5 is a potential druggable target in specific subtypes of pancreatic tumors.36 
Signaling via FZD5 in these tumor cells was shown to be crucial in β-catenin mediated 
proliferation and treatment of these pancreatic adenocarcinoma cells with FZD5 antibodies 
led to inhibited cell growth, both in vitro and in xenograft models in vivo. Although these 
pancreatic adenocarcinoma tumors are not excessively vascularized, they were previously 
shown to depend on angiogenesis for growth.45, 46 Our data demonstrate the importance of 
FZD5 in ECs during angiogenesis and might imply that targeting the FZD5 in these types of 
tumors not only affects the pancreatic adenocarcinoma cells, but could in addition potentially 
result in beneficial suppression of tumor vascularization. 
 
In summary, the current study provides evidence for an important role of endothelial FZD5 in 
angiogenesis, thereby providing novel insights in the molecular mechanism causal to the 
poor angiogenic phenotype in absence of this receptor.  
Endothelial loss of FZD5 stimulates PKC/Ets1-mediated transcription of ANGPT2 and VEGFR1                                                                                                                                                                                                    
51 
 
References 
1. Potente, M, Gerhardt, H, Carmeliet, P: Basic and therapeutic aspects of angiogenesis. Cell, 146: 
873-887, 2011. 
2. Carmeliet, P: Angiogenesis in health and disease. Nat Med, 9: 653-660, 2003. 
3. Paes, KT, Wang, E, Henze, K, Vogel, P, Read, R, Suwanichkul, A, Kirkpatrick, LL, Potter, D, 
Newhouse, MM, Rice, DS: Frizzled 4 is required for retinal angiogenesis and maintenance of 
the blood-retina barrier. Invest Ophthalmol Vis Sci, 52: 6452-6461, 2011. 
4. Peghaire, C, Bats, ML, Sewduth, R, Jeanningros, S, Jaspard, B, Couffinhal, T, Duplaa, C, Dufourcq, 
P: FZD7 (Frizzled-7) Expressed by Endothelial Cells Controls Blood Vessel Formation 
Through WNT/beta-Catenin Canonical Signaling. Arterioscler Thromb Vasc Biol, 36: 2369-
2380, 2016. 
5. Ishikawa, T, Tamai, Y, Zorn, AM, Yoshida, H, Seldin, MF, Nishikawa, S, Taketo, MM: Mouse WNT 
receptor gene FZD5 is essential for yolk sac and placental angiogenesis. Development, 128: 
25-33, 2001. 
6. Niehrs, C: The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol, 13: 767-779, 2012. 
7. MacDonald, BT, Tamai, K, He, X: WNT/beta-catenin signaling: components, mechanisms, and 
diseases. Dev Cell, 17: 9-26, 2009. 
8. Clevers, H: WNT/beta-catenin signaling in development and disease. Cell, 127: 469-480, 2006. 
9. Lobov, IB, Brooks, PC, Lang, RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary 
structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A, 99: 11205-11210, 
2002. 
10. Zygmunt, T, Gay, CM, Blondelle, J, Singh, MK, Flaherty, KM, Means, PC, Herwig, L, Krudewig, A, 
Belting, HG, Affolter, M, Epstein, JA, Torres-Vazquez, J: Semaphorin-PlexinD1 signaling 
limits angiogenic potential via the VEGF decoy receptor sVEGFR1. Dev Cell, 21: 301-314, 
2011. 
11. Hanahan, D: Signaling vascular morphogenesis and maintenance. Science, 277: 48-50, 1997. 
12. Stratman, AN, Malotte, KM, Mahan, RD, Davis, MJ, Davis, GE: Pericyte recruitment during 
vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. 
Blood, 114: 5091-5101, 2009. 
13. Dijksterhuis, JP, Baljinnyam, B, Stanger, K, Sercan, HO, Ji, Y, Andres, O, Rubin, JS, Hannoush, 
RN, Schulte, G: Systematic mapping of WNT-FZD protein interactions reveals functional 
selectivity by distinct WNT-FZD pairs. J Biol Chem, 290: 6789-6798, 2015. 
14. He, X, Saint-Jeannet, JP, Wang, Y, Nathans, J, Dawid, I, Varmus, H: A member of the Frizzled 
protein family mediating axis induction by WNT-5A. Science, 275: 1652-1654, 1997. 
15. Peterson, YK, Nasarre, P, Bonilla, IV, Hilliard, E, Samples, J, Morinelli, TA, Hill, EG, Klauber-
DeMore, N: Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation 
of nuclear factor of activated T-cells c3 signaling to promote angiogenesis. Angiogenesis, 20: 
615-628, 2017. 
16. Goodwin, AM, Sullivan, KM, D'Amore, PA: Cultured endothelial cells display endogenous activation 
of the canonical WNT signaling pathway and express multiple ligands, receptors, and 
secreted modulators of WNT signaling. Dev Dyn, 235: 3110-3120, 2006. 
17. Arderiu, G, Espinosa, S, Pena, E, Aledo, R, Badimon, L: Monocyte-secreted WNT5a interacts with 
FZD5 in microvascular endothelial cells and induces angiogenesis through tissue factor 
signaling. J Mol Cell Biol, 6: 380-393, 2014. 
18. Topol, L, Jiang, X, Choi, H, Garrett-Beal, L, Carolan, PJ, Yang, Y: WNT-5a inhibits the canonical 
WNT pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol, 162: 
899-908, 2003. 
19. Flentke, GR, Garic, A, Hernandez, M, Smith, SM: CaMKII represses transcriptionally active beta-
catenin to mediate acute ethanol neurodegeneration and can phosphorylate beta-catenin. J 
Neurochem, 128: 523-535, 2014. 
20. Minami, T, Horiuchi, K, Miura, M, Abid, MR, Takabe, W, Noguchi, N, Kohro, T, Ge, X, Aburatani, H, 
Hamakubo, T, Kodama, T, Aird, WC: Vascular endothelial growth factor- and thrombin-
induced termination factor, Down syndrome critical region-1, attenuates endothelial cell 
proliferation and angiogenesis. J Biol Chem, 279: 50537-50554, 2004. 
21. Lange, AW, Molkentin, JD, Yutzey, KE: DSCR1 gene expression is dependent on NFATc1 during 
cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 
mice. Dev Biol, 266: 346-360, 2004. 
22. Ye, FC, Blackbourn, DJ, Mengel, M, Xie, JP, Qian, LW, Greene, W, Yeh, IT, Graham, D, Gao, SJ: 
Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 
expression via AP-1 and Ets1. J Virol, 81: 3980-3991, 2007. 
Chapter 2 
52 
 
23. Salomonsson, L, Svensson, L, Pettersson, S, Wiklund, O, Ohlsson, BG: Oxidised LDL decreases 
VEGFR-1 expression in human monocyte-derived macrophages. Atherosclerosis, 169: 259-
267, 2003. 
24. Bogoyevitch, MA, Kobe, B: Uses for JNK: the many and varied substrates of the c-Jun N-terminal 
kinases. Microbiol Mol Biol Rev, 70: 1061-1095, 2006. 
25. Liu, A, Chen, S, Cai, S, Dong, L, Liu, L, Yang, Y, Guo, F, Lu, X, He, H, Chen, Q, Hu, S, Qiu, H: 
WNT5a through noncanonical WNT/JNK or WNT/PKC signaling contributes to the 
differentiation of mesenchymal stem cells into type II alveolar epithelial cells in vitro. PLoS 
One, 9: e90229, 2014. 
26. Sheldahl, LC, Park, M, Malbon, CC, Moon, RT: Protein kinase C is differentially stimulated by WNT 
and Frizzled homologs in a G-protein-dependent manner. Curr Biol, 9: 695-698, 1999. 
27. Kinoshita, N, Iioka, H, Miyakoshi, A, Ueno, N: PKC delta is essential for Dishevelled function in a 
noncanonical WNT pathway that regulates Xenopus convergent extension movements. 
Genes Dev, 17: 1663-1676, 2003. 
28. Lorenzi, O, Frieden, M, Villemin, P, Fournier, M, Foti, M, Vischer, UM: Protein kinase C-delta 
mediates von Willebrand factor secretion from endothelial cells in response to vascular 
endothelial growth factor (VEGF) but not histamine. J Thromb Haemost, 6: 1962-1969, 2008. 
29. Gliki, G, Abu-Ghazaleh, R, Jezequel, S, Wheeler-Jones, C, Zachary, I: Vascular endothelial growth 
factor-induced prostacyclin production is mediated by a protein kinase C (PKC)-dependent 
activation of extracellular signal-regulated protein kinases 1 and 2 involving PKC-delta and by 
mobilization of intracellular Ca2+. Biochem J, 353: 503-512, 2001. 
30. Naito, S, Shimizu, S, Maeda, S, Wang, J, Paul, R, Fagin, JA: Ets-1 is an early response gene 
activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol, 274: C472-
480, 1998. 
31. Lindemann, RK, Ballschmieter, P, Nordheim, A, Dittmer, J: Transforming growth factor beta 
regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells 
through a novel Smad/Ets synergism. J Biol Chem, 276: 46661-46670, 2001. 
32. Wakiya, K, Begue, A, Stehelin, D, Shibuya, M: A cAMP response element and an Ets motif are 
involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth 
factor receptor 1) gene. J Biol Chem, 271: 30823-30828, 1996. 
33. Hegen, A, Koidl, S, Weindel, K, Marme, D, Augustin, HG, Fiedler, U: Expression of angiopoietin-2 in 
endothelial cells is controlled by positive and negative regulatory promoter elements. 
Arterioscler Thromb Vasc Biol, 24: 1803-1809, 2004. 
34. Naito, S, Shimizu, S, Matsuu, M, Nakashima, M, Nakayama, T, Yamashita, S, Sekine, I: Ets-1 
upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in 
vascular endothelial cells. Biochem Biophys Res Commun, 291: 130-138, 2002. 
35. Lu, J, Zhang, S, Nakano, H, Simmons, DG, Wang, S, Kong, S, Wang, Q, Shen, L, Tu, Z, Wang, W, 
Wang, B, Wang, H, Wang, Y, van Es, JH, Clevers, H, Leone, G, Cross, JC, Wang, H: A 
positive feedback loop involving Gcm1 and FZD5 directs chorionic branching morphogenesis 
in the placenta. PLoS Biol, 11: e1001536, 2013. 
36. Steinhart, Z, Pavlovic, Z, Chandrashekhar, M, Hart, T, Wang, X, Zhang, X, Robitaille, M, Brown, KR, 
Jaksani, S, Overmeer, R, Boj, SF, Adams, J, Pan, J, Clevers, H, Sidhu, S, Moffat, J, Angers, 
S: Genome-wide CRISPR screens reveal a WNT-FZD5 signaling circuit as a druggable 
vulnerability of RNF43-mutant pancreatic tumors. Nat Med, 2016. 
37. Caricasole, A, Ferraro, T, Iacovelli, L, Barletta, E, Caruso, A, Melchiorri, D, Terstappen, GC, 
Nicoletti, F: Functional characterization of WNT7A signaling in PC12 cells: interaction with A 
FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem, 278: 
37024-37031, 2003. 
38. Burns, CJ, Zhang, J, Brown, EC, Van Bibber, AM, Van Es, J, Clevers, H, Ishikawa, TO, Taketo, MM, 
Vetter, ML, Fuhrmann, S: Investigation of Frizzled-5 during embryonic neural development in 
mouse. Dev Dyn, 237: 1614-1626, 2008. 
39. Maretto, S, Cordenonsi, M, Dupont, S, Braghetta, P, Broccoli, V, Hassan, AB, Volpin, D, Bressan, 
GM, Piccolo, S: Mapping WNT/beta-catenin signaling during mouse development and in 
colorectal tumors. Proc Natl Acad Sci U S A, 100: 3299-3304, 2003. 
40. Rennel, ES, Regula, JT, Harper, SJ, Thomas, M, Klein, C, Bates, DO: A human neutralizing 
antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation, 18: 598-607, 2011. 
41. White, RR, Shan, S, Rusconi, CP, Shetty, G, Dewhirst, MW, Kontos, CD, Sullenger, BA: Inhibition of 
rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. 
Proc Natl Acad Sci U S A, 100: 5028-5033, 2003. 
42. Stefater, JA, 3rd, Lewkowich, I, Rao, S, Mariggi, G, Carpenter, AC, Burr, AR, Fan, J, Ajima, R, 
Molkentin, JD, Williams, BO, Wills-Karp, M, Pollard, JW, Yamaguchi, T, Ferrara, N, Gerhardt, 
Endothelial loss of FZD5 stimulates PKC/Ets1-mediated transcription of ANGPT2 and VEGFR1                                                                                                                                                                                                    
53 
 
H, Lang, RA: Regulation of angiogenesis by a non-canonical WNT-VEGFR1 pathway in 
myeloid cells. Nature, 474: 511-515, 2011. 
43. Minami, T, Jiang, S, Schadler, K, Suehiro, J, Osawa, T, Oike, Y, Miura, M, Naito, M, Kodama, T, 
Ryeom, S: The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical 
for the establishment of lung metastases. Cell Rep, 4: 709-723, 2013. 
44. van Amerongen, R, Mikels, A, Nusse, R: Alternative WNT signaling is initiated by distinct receptors. 
Sci Signal, 1: re9, 2008. 
45. Hotz, HG, Gill, PS, Masood, R, Hotz, B, Buhr, HJ, Foitzik, T, Hines, OJ, Reber, HA: Specific 
targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion 
protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg, 6: 159-
166; discussion 166, 2002. 
46. Hotz, HG, Reber, HA, Hotz, B, Sanghavi, PC, Yu, T, Foitzik, T, Buhr, HJ, Hines, OJ: Angiogenesis 
inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg, 5: 131-138, 
2001. 
 
  
Chapter 2 
54 
 
Supplemental data 
 
 
 
Supplemental Figure 1: FZD5 siRNA induced a significant and specific knockdown of FZD5. (A) 
PCR results showing expression levels of FZD receptors in HUVECs. N=3 (#1-3 indicate these 
replicates). (B) PCR results showing expression levels of WNT ligands in HUVECs. N=3 (#1-3 indicate 
these replicates). (C) QPCR results of expression levels of all FZD receptors expressed in HUVECs 
(FZD1-9) in the different conditions 20 hours post transfection. N=7, *P<0.05 compared to control and 
siSHAM condition. (D) Representative Western blot of FZD5 and β-actin levels 72 hours post 
transfection. N=5. 
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Supplemental Figure 3: Positive control experiments for β-catenin Western blot and 
immunofluorescent staining. (A) Representative Western blot of total β-catenin, non-phospho β-
catenin, and β-actin levels in HUVECs after 30 min stimulation with DMSO or different concentrations of 
the phosphatase inhibitor Calyculin A (positive control for verification of phosphorylation status). (B) 
Representative immunofluorescent staining of β-catenin (green) in HUVECs after stimulation with PBS 
or recombinant WNT3a. Scale bars represent 100µm and 25µm. 
Supplemental Figure 2: 
Effect of FZD5 knockdown 
on important angiogenic 
regulators.  qPCR results 
showing expression levels of 
VEGFR2, VEGFA, ANGPT1 
and TF in the different 
conditions 72 hours post 
transfection. N=5, #P<0.05 
compared to untreated control 
condition. 
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Supplemental Figure 4: FZD5 knockdown did not affect c-JUN phosphorylation. (A) 
Representative Western blot of total c-JUN, phospho c-JUN and β-actin levels at different time points 
post-transfection. (B) Quantified results of c-JUN and phospho c-JUN Western blot. Shown are 
(phospho) c-JUN levels relative to β-actin loading control. N=3, no significance. (C) Representative 
Western blot of total JNK, phospho JNK, total c-JUN, phospho c-JUN and β-actin levels in HUVECs 
after 30 min stimulation with DMSO or different concentrations of the phosphatase inhibitor Calyculin A 
(positive control for verification of phosphorylation status). 
 
Endothelial loss of FZD5 stimulates PKC/Ets1-mediated transcription of ANGPT2 and VEGFR1                                                                                                                                                                                                    
57 
 
 
Supplemental Figure 5: Upregulation of ANGPT2 and VEGFR1 in HUVECs with suppressed FZD5 
expression via novel PKC signaling. (A) QPCR results of ANGPT2 and VEGFR1 in response to 
treatment to PKC inhibitor staurosporine (0-20nM), supplemented 48 hours post transfection to the 
different conditions. N=4, *P<0.05 compared to control and siSHAM condition within comparable 
conditions (two-way ANOVA followed by Bonferroni post hoc test). (B) QPCR results showing 
expression levels of conventional PKC isoform PKCα, novel PKC isoforms PKCδ, PKCε, and PKCη, 
FZD5, and transcription factor Ets1 (C) in HUVECs after knockdown of FZD5 alone, in combination with 
different PKC isoforms, and in combination with all novel PKC isoforms (PKCδ,ε,η), 48 hours post 
transfection. N=4, *P<0.05 compared to control and siSHAM condition, #P<0.05 as indicated in graph. 
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Supplemental Figure 6: FZD5 and Ets1 knockdown validation and Ets1 dependent MMP1 
expression in absence of FZD5.  qPCR results showing expression levels of FZD5 and Ets1 (A), and 
Ets1 target gene MMP1 (B) in HUVECs after knockdown of FZD5, Ets1, and in a combined knockdown 
of FZD5 and Ets1, 72 hours post transfection. N=4, *P<0.05 compared to control and siSHAM condition, 
#P<0.05 as indicated in graph. 
 
 
 
 
  
Supplemental Figure 7: 
Endogenous endothelial 
WNT5a expression triggers 
ANGPT2 and VEGFR1 
upregulation in absence of 
FZD5. qPCR results showing 
expression levels of 
ANGPT2, VEGFR1, FZD5 
and WNT5a in HUVECs after 
knockdown of FZD5 alone or 
in combination with Wnt5a, 
72 hours post transfection. 
N=11, *P<0.05 compared to 
control and siSHAM 
condition, #P<0.05 as 
indicated in graph. 
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Abstract 
Microvascular homeostasis is strictly regulated, requiring close interaction between 
endothelial cells and pericytes. Here, we aimed to improve our understanding of how 
microvascular crosstalk affects pericytes. Human-derived pericytes, cultured in absence, or 
presence of human endothelial cells, were studied by RNA sequencing. Compared with 
mono-cultured pericytes, a total of 6704 genes were differentially expressed in co-cultured 
pericytes. Direct endothelial contact induced transcriptome profiles associated with pericyte 
maturation, suppression of extracellular matrix production, proliferation, and morphological 
adaptation. In vitro studies confirmed enhanced pericyte proliferation mediated by 
endothelial-derived PDGFβ and pericyte-derived HB-EGF and FGF2. Endothelial-induced 
PLXNA2 and ACTR3 upregulation also triggered pericyte morphological adaptation. 
Pathway analysis predicted a key role for TGFβ signaling in endothelial-induced pericyte 
differentiation, whereas the effect of signaling via gap- and adherens junctions was limited. 
We demonstrate that endothelial cells have a major impact on the transcriptional profile of 
pericytes, regulating endothelial-induced maturation, proliferation, and suppression of ECM 
production.  
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Introduction 
Complex organisms such as vertebrates rely on a well-functioning circulatory system to 
meet the body’s oxygen and nutrient demand, and to remove waste products. The 
circulatory system is composed of blood vessels, lined by a single layer of endothelial cells 
(ECs) on the luminal side. These ECs are surrounded by a basement membrane which they 
share with mural cells. In the microvasculature, these mural cells consist of pericytes.1  
Maintaining microvascular homeostasis is a strictly regulated process, which requires close 
interplay between ECs and pericytes. Dysregulation of this comprehensive interaction is 
associated with the onset and progression of a variety of diseases.2 Lack of pericytes 
compromises vascular integrity and causes leaky unstable vessels (e.g. in rapidly growing 
tumors)3, as well as highly proliferative endothelium (e.g. in diabetic retinopathy).4 Moreover, 
pericytes have previously been linked to pathological organ fibrosis5, though whether injury-
induced stimulation, or loss of endothelial interaction drives this differentiation is poorly 
understood. Former studies on microvascular cross-talk provided valuable insights into the 
mechanisms involved in regulating vascular homeostasis. For instance, Platelet Derived 
Growth Factor β (PDGFβ) secretion by ECs was shown to modulate pericyte proliferation 
and migration towards the endothelium4, whereas pericyte-derived Vascular Endothelial 
Growth Factor A (VEGFA) and Angiopoietin 1 (ANGPT1) secretion were reported to 
promote endothelial survival and maturation.6, 7 In addition to these paracrine interactions, 
ECs and pericytes also connect physically. At distinct places, the basement membrane 
separating the two cell types is interrupted, allowing the formation of direct connection sites 
called peg and socket contacts.8 These contacts are highly enriched in gap- and adherens 
junctions, which provide a direct signaling route for ions, nutrients, metabolites, and 
secondary messengers.9 Over the years, numerous studies have focused on the different 
aspects of signaling between these closely associated microvascular cells. However, since 
most emphasis was put on how pericytes affect endothelial behavior, only little is known 
about the consequence of this cross-talk for pericytes.  
To gain a deeper understanding of the impact of vascular crosstalk on these critical, yet 
relatively underexposed, contributors of microvascular homeostasis, an RNA sequence- 
(RNAseq) based analysis was performed to compare the mRNA expression profiles of 
single cultured pericytes, with those of pericytes cultured in direct contact with endothelial 
cells. The results demonstrate that ECs have a major impact on the transcriptional profile of 
pericytes and provide functional evidence for endothelium-induced pericyte maturation, 
proliferation, and suppression of ECM expression.  
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Methods 
Cell culture 
HMVECs (Lonza) and human brain-derived pericytes (Sciencell) were cultured on 0.1% 
gelatin coated plates in EGM-2MV medium (EBM2 medium supplemented with EGM-2MV 
bullet kit; Lonza) and DMEM (supplemented with 10% fetal calf serum (FCS); Lonza), 
respectively, in 5% CO2 at 37 ˚C. HMVECs were transduced with a lentiviral GFP construct 
and pericytes with a lentiviral dsRED construct. Experiments were performed with cells at 
passage 4-6. CDH2, CX43, HB-EGF, FGF2 and VEGFA, PLXN2A, ACTR3 knockdown in 
pericytes, and PDGFβ knockdown in HMVECs was achieved by cell transfection with a pool 
containing 4 targeting siRNA sequences (Dharmacon) in a final concentration of 100nM. 
Control cells were transfected with a pool of 4 non-targeting siRNA sequences (Dharmacon) 
in a final concentration of 100nM. Target sequences are listed in Table 1. 
 
 
Table 1: siRNA sequences used for knockdown experiments 
Target gene Target sequence 
Non-targeting UGGUUUACAUGUCGACUAA UGGUUUACAUGUUUUCUGA 
 UGGUUUACAUGUUGUGUGA UGGUUUACAUGUUUUCCUA 
CDH2 GUGCAACAGUAUACGUUAA CAUAGUAGCUAAUCUAACU 
 GGACCCAGAUCGAUAUAUG GACAGCCUCUUCUCAAUGU 
CX43 CAGUCUGCCUUUCGUUGUA GUACAUCUAUGGAUUCAGC 
 UGACAAGGUUCAAGCCUAC GAACCUACAUCAUCAGUAU 
PDGFβ CCGAGGAGCUUUAUGAGAU GCAAGCACCGGAAAUUCAA 
 GAAGAAGGAGCCUGGGUUC GGGCCGAGUUGGACCUGAA 
HB-EGF GAAAAUCGCUUAUAUACCU GGACCCAUGUCUUCGGAAA 
 UGAAGUUGGGCAUGACUAA GGAGAAUGCAAAUAUGUGA 
FGF2 CUAAAUGUGUUACGGAUGA GCUAAGAGCUGAUUUUAAU 
 UCAAAGGAGUGUGUGCUAA GAUGGAAGAUUACUGGCUU 
VEGFA GCAGAAUCAUCACGAAGUG GGAGUACCCUGAUGAGAUC 
 CAACAAAUGUGAAUGCAGA GAUCAAACCUCACCAAGGC 
PLXNA2 GGUCAAUGAGUGAGAUCGU CCAGCCAAGUUUCGUCAUA 
  CUGGGAACCUAAUCGAUUU ACUAUGAGCUACACAGCGA 
ACTR3 GCAGUAAAGGAGCGCUAUA GGAAUUGAGUGGUGGUAGA 
  GUGAUUGGCAGCUGUAUUA GCCAAAACCUAUUGAUGUA 
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Fluorescence-activated cell sorting 
GFP-labeled HMVECs and dsRED-labeled pericytes were seeded in a confluent layer (4 
million cells) on 10cm dishes, either in co-culture at a 5:1 (HMVECs:pericytes) ratio, or in 
single culture (Figure 1A). Both single cultures and co-cultures were cultured on EBM 
supplemented with 5% FCS for 6h, followed by 20h on EBM supplemented with 0.5% FCS. 
For fluorescence activated cell sorting (FACS), cells were trypsinized, washed once in cold 
PBS and suspended in cold sterile filtered PBS containing 2% bovine serum albumin. GFP-
labeled HMVECs and dsRED-labeled pericytes were separately sorted in cold FCS based 
on their fluorescent signal. Subsequently, cells were washed once in cold PBS, lysed in 
RNA lysis buffer and stored at -80 ˚C (Figure 1B). 
 
RNA sequencing 
RNA sequencing was done as previously described.10 Briefly, sequencing libraries were 
made from poly-adenylated RNA using the Rapid Directional RNA-Seq Kit (NEXTflex) and 
sequenced on Illumina NextSeq500 to produce single-end 75 base long reads (Utrecht 
Sequencing Facility). Reads were aligned to the human reference genome GRCh37 using 
STAR version2.4.2a. Read groups were added to the BAM files with Picard’s 
AddOrReplaceReadGroups (v1.98). The BAM files were sorted with Sambamba v0.4.5, and 
transcript abundances were quantified with HTSeq-count version 0.6.1p117 using the union 
mode. Subsequently, reads per kilobase of transcript per million reads sequenced were 
calculated with edgeR’s rpkm() function. Differentially expressed genes in the transcriptome 
data were identified using the DESeq2 package with standard settings.11 
 
Quantitative PCR and Western blot analysis 
RNA was reverse transcribed into cDNA using iScript cDNA synthesis kit (Bioline). Gene 
expression was assessed by qPCR using SensiFast SYBR & Fluorecein kit (Bioline) and 
primers as listed in Table 2. Expression levels are relative to the housekeeping gene 
Ribosomal Phosphoprotein P0 (RPLP0) and RNA Polymerase II Subunit L (POLR2L). For 
assessment of protein levels, cells were lysed in cold NP-40 lysis buffer (150mM NaCl, 1.0% 
NP-40, 50 mM Tris, pH 8.0) supplemented with 1mM β-glycerolphosphate, 1mM PMSF, 
10mM NaF, 1mM NaOV, and protease inhibitor cocktail (Roche). Total protein concentration 
was quantified by Pierce® BCA Protein Assay Kit (Thermo Scientific) as a loading control. 
Lysates were denaturated in Laemmli buffer at 90°C for 5 min followed by electrophoresis 
on a 10% SDS-PAGE gel (Biorad). Subsequently, proteins were transferred to a 
nitrocellulose membrane (Pierce) and incubated for 1 hour in PBS with 5% non-fat milk,  
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followed by incubation with rabbit anti-CX43 and rabbit anti-N-cadherin (CST) according to 
manufacturer’s description. Protein bands were visualized with the Li-Cor detection system 
(Westburg). 
 
Table 2: Primer sequences used for (q)PCR 
Gene Sense primer sequence Antisense primer sequence 
RPLP0 CAGATTGGCTACCCAACTGTT GGAAGGTGTAATCCGTCTCCAC 
POLR2L TCACTTGTGGCAAGATCGTCG GGGTGCATAATTGAGCAGCTTC 
GLI1 TCCTACCAGAGTCCCAAGTTTC GCCCTATGTGAAGCCCTATTT 
NG2 ACCTTCAACTACAGGGCACAAG AGGACATTGGTGAGGACAGG 
ACTA2 ACTGAGCGTGGCTATTCCTTC CAGGCAACTCGTAACTCTTCTC 
CD146 CTGCTGAGTGAACCACAGGA CACCTGGCCTGTCTCTTCTC 
NES CCTGGGAAAGGGAGAGTACC GATTCAGCTCTGCCTCATCC 
PDGFRβ GAGGAATCCCTCACCCTCTC GGGTATATGGCCTTGCTTCA 
BBC3 GACCTCAACGCACAGTACGAG AGGAGTCCCATGATGAGATTGT 
T53INP1 TTCCTCCAACCAAGAACCAG GATGCCGGTAAACAGGAAAA 
GDF15 CTCCAGATTCCGAGAGTTGC AGAGATACGCAGGTGCAGGT 
CDK1 CTGGGGTCAGCTCGTTACTC AGGCTTCCTGGTTTCCATTT 
RBL1 ATACGACTTGGCGAATCAGG GAGCGCTTCTTGGTGTAAGG 
MYC CTCCTGGCAAAAGGTCAGAG TCGGTTGTTGCTGATCTGTC 
MCM2 ATTTCGTCCTGGGTCCTTTCT CTGGTTTCACCTCCTGGTTCT 
CCND1 GTCCATGCGGAAGATCGTCG TCTCCTTCATCTTAGAGGCCACG 
PDGFβ CCCCACACTCCACTCTGATT GCCCTGGCCTCTAGTCTTCT 
FGF2 AGAGCGACCCTCACATCAAG TCGTTTCAGTGCCACATACC 
HB-EGF GGTGGTGCTGAAGCTCTTTC GCTTGTGGCTTGGAGGATAA 
VEGFA CATCCAATCGAGACCCTGG ATGTGCTGGCCTTGGTGAG 
PLXNA2  AAAGGAAGAGGACCCCAGAA GACAGCAAGCACAGAAGCAC 
ACTR3  CTGGGTTGCGGAAGTGATAG TGTATACCCCGTGCCACAGT 
CTGF CCGTACTCCCAAAATCTCCA GTAATGGCAGGCACAGGTCT 
TAGLN AAGAATGATGGGCACTACCG ACTGATGATCTGCCGAGGTC 
SERPINE1 TCTTTGGTGAAGGGTCTGCT TTGAATCTGCTGCTGGGTTT 
CX43 TGGATTCAGCTTGAGTGCTG GGTCGCTCTTTCCCTTAACC 
CDH2 GACAATGCCCCTCAAGTGTT CCATTAAGCCGAGTGATGGT 
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Immunofluorescent staining 
Pericytes labeled with dsRED were seeded in a confluent layer (50.000 cells) on 96 wells 
plates in a 1:5 ratio, either with unlabeled HMVECs, or with unlabeled pericytes. After 
seeding, the cells were cultured on EBM supplemented with 5% FCS for 6h, followed by 20h 
on EBM supplemented with 0.5% FCS. After 20h in culture, cells were fixed for 20min in 2% 
paraformaldehyde and blocked for 60min in PBS containing 5% bovine serum albumin 
(Sigma) and 0.3% Triton X-100 (Sigma). Hereafter, 100μl PBS containing 1% BSA, 0.3% 
Triton X-100, and 1:400 rabbit anti-Ki67 antibody (CST) was added per well, followed by a 
16h incubation at 4°C. After incubation with the primary antibody, Ki67 was stained with an 
Alexa Fluor 594-labeled secondary antibody (Invitrogen), dissolved (1:200) in PBS 
containing 1% BSA and 0.3% Triton X-100 for 2h at room temperature. Vectashield with 
DAPI (Brunschwig) was applied to the fixed cell cultures, followed by imaging using 
fluorescence microscopy. Analysis of Ki67 positive pericyte nuclei was averaged per 
individual experiment from at least 5 random image fields in ImageJ using the Cell Counter 
plugin. 
 
Pathway analysis 
RNAseq results were analyzed using IPA. IPA was used to study upstream regulators 
(growth factors and transcriptional regulators) of differentially expressed genes. P-values 
were calculated based on a right-tailed Fisher Exact Test, calculated by IPA.  
 
Statistics 
Data are presented as means ± SEM. Groups were compared by students t-test (two-tailed) 
or 1-way ANOVA followed by Tukey post hoc test when appropriate. Statistical significance 
was accepted when p<0.05. 
 
 
Results 
Endothelial cells markedly affect pericyte phenotype 
To evaluate the impact of endothelial-pericyte interaction on pericyte behavior, discosoma 
sp. red- (dsRED) labeled pericytes were cultured in a confluent layer either alone, or in the 
presence of green fluorescent protein- (GFP) labeled human dermal microvascular 
endothelial cells (HMVECs), enabling direct contact between the two different cell types 
fluorescent signal, after which RNA was isolated and processed for RNA sequencing (Figure 
1B). A comparison of the transcription profile of single cultured pericytes and co-cultured 
pericytes in a principal component analysis (PCA) clearly illustrated the major effect 
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Figure 1: Expression profiles were generated from mono- and co-cultured pericytes via RNA 
sequencing. (A) Pericytes labeled with dsRED (red) were either cultured alone (I), or in direct contact 
with GFP-labeled HMVECs (green) (II). Magnified view of co-cultured cells clearly shows the elongated 
pericytes that appear to be in contact with multiple ECs (III). (B) Schematic overview of the experiments: 
Pericytes labeled with dsRED were cultured in a confluent layer, either alone, or in direct contact with 
GFP-labeled HMVECs for the duration of 20 hours (I). Hereafter, cells were trypsinized and sorted 
based on fluorescent signal (II), after which RNA was isolated from the pericytes for RNA sequencing 
(III). 
 
of endothelial-pericyte crosstalk on pericytes (Figure 2A). In total, 6704 genes were 
differentially expressed (P adjusted <0.05; Figure 2B). Of these 6704 differentially expressed 
genes, 6081 were protein coding genes (almost one third of the estimated 19000 protein 
coding genes in the human genome)12, suggesting that direct contact with ECs dramatically 
affects pericyte’s transcriptomes.  
 
Direct contact with endothelium stimulates pericyte maturation 
A newly formed endothelial network is initially unstable and requires support from recruited 
pericytes. These pericytes either migrate from adjacent vessels or differentiate from local 
mesenchymal stem cells.13 Comparing expression profiles from single cultured pericytes 
with pericytes co-cultured with ECs clearly illustrated the importance of interaction with ECs 
in this differentiation process. Expression of Glioma-associated oncogene 1 (GLI1), a zinc 
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Figure 2: Endothelial cells have a major impact on the expression profile of pericytes. (A) PCA 
plot of expression profiles in single cultured pericytes (blue) and co-cultured pericytes (red). (B) Graphic 
display of differential gene expression (MA plot) in which log2FC is plotted against the mean of 
normalized counts. Red dots represent the 6704 differentially expressed genes (P adjusted <0.05), gray 
dots represent non-differentially expressed genes. 
 
finger type transcription factor and downstream effector of the Hedgehog signaling pathway 
that has been reported to be expressed in pericyte-like progenitors14, was significantly 
reduced in co-cultured pericytes (Figure 3A). In contrast, well-validated pericyte markers, 
including Chondroitin Sulfate Proteoglycan 4 (CSPG4/NG2), Alpha Smooth Muscle Actin 2 
(ACTA2), Melanoma Cell Adhesion Molecule (CD146), and Nestin (NES), were highly 
upregulated after direct interaction with ECs (Figure 3B). Interestingly, Platelet Derived 
Growth Factor Receptor B (PDGFRβ), one of the most frequently used pericyte- and 
mesenchyme markers, was significantly downregulated in co-cultured pericytes (Figure 3B). 
 
Endothelial signaling stimulates pericyte proliferation and survival 
Prior studies showed that pericyte-endothelial interaction had a profound positive effect on 
endothelial survival and maturation.15 Interestingly, studying the upstream transcription 
factors of the differentially expressed genes using QIAGEN’s Ingenuity Pathway Analysis 
(IPA) led to the suggestion that direct interaction with ECs also stimulated pericyte 
proliferation and survival (Figure 4A), which corresponds with functional findings reported 
previously.16 Expression levels of 330 Tumor Protein 53- (TP53) dependent target genes in 
co-cultured pericytes, including BCL2 Binding Component 3 (BBC3), Tumor Protein P53 
Inducible Nuclear Protein 1 (TP53INP1), and Growth Differentiation Factor 15 (GDF15), 
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Figure 3: Direct contact with endothelium stimulates pericyte maturation. (A) QPCR results 
showing expression levels of mesenchymal transcription factor GLI1, and (B) pericyte markers NG2, 
ACTA2, CD146, NES, and PDGFRβ relative to RPLP0 and POLR2L in pericytes in monoculture (Per), 
and after 20h in co-culture with HMVECs (Per+ECs). N=3, *P<0.05 compared to pericytes in 
monoculture. 
 
suggested suppressed activity of this pro-apoptotic and cell cycle inhibiting factor (Figure 
4B). Vice versa, the activity of proliferation-stimulating transcription factors E2F1 and E2F3 
appeared to be enhanced in co-cultured pericytes. Expression of 139 E2F target genes, 
including Cyclin Dependent Kinase 1 (CDK1), Retinoblastoma Transcriptional Corepressor 
Like 1 (RBL1), Proto-Oncogene C-Myc (MYC), Minichromosome Maintenance Complex 
Component 2 (MCM2), and Cyclin D1 (CCND1), was significantly enhanced after direct 
interaction with ECs (Figure 4C). To functionally validate the impact of endothelial contact on 
pericyte proliferation, we performed immunostaining for the proliferation (G1/S/G2M) marker 
Ki67 in dsRED-labeled pericytes, cultured in a confluent layer either with unlabeled 
HMVECs, or with unlabeled pericytes (Figure 4D). In line with the observed transcriptional 
adaptations in co-cultured pericytes, quantification of the percentage of Ki67-positive nuclei 
in dsRED labeled pericytes clearly illustrated a significantly increased pericyte proliferation 
during co-culture with endothelium as compared with mono-cultured pericytes (Figure 4E). It 
was previously reported that pericyte proliferation could be stimulated by VEGFA17, 
potentially via an autocrine signaling loop resulting from endothelium-induced upregulation 
of VEGFA expression in pericytes. In the present study however, a significant 
downregulation of VEGFA was observed in co-cultured pericytes, though expression was 
still higher than in co-cultured ECs (Figure 4F). To evaluate the involvement of pericyte- 
derived VEGFA in pericyte proliferation, as well as that of potent growth factors Heparin-
binding EGF-like growth factor (HB-EGF) and fibroblast growth factor 2 (FGF2), which in 
contrast to VEGFA were upregulated in co-cultured pericytes, short interference RNA- 
(siRNA) mediated knockdown was performed in dsRED-labeled pericytes followed by 
coculture with ECs and Ki-67 immunostaining (Supplemental Figure 1A and 1C). 
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Figure 4: Endothelial signaling stimulates pericyte proliferation and survival. (A) IPA-derived 
prediction of activated or repressed transcription regulators in co-cultured pericytes compared with 
single cultured pericytes. Plotted is the –log(p-value) of overlap, in which green indicates predicted 
activation in co-culture versus predicted inhibition in red. (B) QPCR results showing expression levels of 
TP53 target genes BBC3, TP53INP1, and GDF15, as well as (C) E2F target genes CDK1, RBL1, MYC, 
MCM2 and CCND1 relative to RPLP0 and POLR2L in pericytes in monoculture (Per), and after 20h in 
co-culture with HMVECs (Per+ECs). N=3, *P<0.05 compared to pericytes in monoculture. (D) 
Immunofluorescent Ki67 (green), and DAPI (blue) staining in dsRED-labeled pericytes, either cultured 
with unlabeled HMVECs (left) or with unlabeled pericytes (right). (E) Bar graph shows the quantified 
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◄ results of the Ki67 staining. Shown are the percentages of dsRED-labeled pericyte nuclei positive for 
the proliferation marker Ki67. N=3, *P<0.05 compared to dsRED-labeled pericytes in culture with 
unlabeled pericytes. (F) QPCR results showing expression levels of VEGFA in pericytes in monoculture 
(Per), and after 20h in co-culture in both pericytes (Per+ECs) and HMVECs (ECs+Per). N=3, *P<0.05 
compared to pericytes in monoculture and ECs in co-culture, #P<0.05 compared to pericytes in mono- 
and co-culture. (G) Bar graph showing the percentage of Ki67 positive nuclei in dsRED-labeled 
pericytes after knockdown of HB-EGF, FGF2, and VEGFA in pericytes, and (H) PDGFβ in ECs. N=4, 
*P<0.05 compared to siNT-treated condition.  
 
Quantification of the percentage of Ki67-positive nuclei in dsRED labeled pericytes revealed 
that knockdown of VEGFA had no effect on pericyte proliferation, whereas knockdown of 
HB-EGF and FGF2 significantly reduced the proliferative response of pericytes in co-culture 
with pericytes (Figure 4G). Similarly, endothelial knockdown of PDGFβ, a well-known 
pericyte mitogen that was upregulated in co-cultured ECs (Supplemental Figure 1B and 1D), 
significantly reduced proliferation of pericytes in co-culture with ECs (Figure 4H). 
 
Direct endothelial contact triggers outgrowth of pericyte projections 
Mature pericytes have a highly specialized morphology that is distinctly different from other 
microvascular cells. They align their nuclei with the endothelium and extend thin processes 
along and around the capillaries. These elongated projections allow individual pericytes to 
contact and communicate with multiple ECs and were recently shown to have an active role 
in maintaining normal cerebral microvascular lumen diameter.18 These thin processes show 
morphological similarities with axons growing from neurons. Growing axons have a highly 
dynamic structure at the peripheral tip, called the growth cone, which senses the 
environment for attracting or repelling guiding cues. Following these cues, actin remodeling 
at the leading edge guides the growth cone, followed by a polymerizing and elongating 
bundle of microtubules.19 Interestingly, an exceptionally high number of genes involved in 
this process was differentially expressed in co-cultured pericytes, as identified by IPA. 
Among these differentially expressed genes was a variety of different growth cone-guiding 
molecules, including Semaphorins (SEMA), Ephrins (EFN), Netrins (NTN), and their 
respective receptors (Figure 5A). Many Alpha and Beta Tubulins (TUBA and TUBB, 
respectively), composing the core of the growing projections, were upregulated in co-
cultured pericytes (Figure 5B). Similarly, enhanced expression was observed for Cofilins 
(CFL) and all but one Actin Related Protein 2/3 Complex subunits (ARPC), which regulate 
actin polymerization required for growth cone dynamics (Figure 5B).20 To verify whether 
these transcriptional adaptations were associated with morphological changes that resemble 
outgrowth of pericyte projections, dsRED-labeled pericytes were again cultured in a 
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Figure 5: Direct endothelial contact triggers outgrowth of pericyte projections. (A) schematic 
presentation of RNAseq data for differentially expressed Semaphorins, Ephrins, Netrins, and their 
respective receptors, as well as (B) subunits of the Actin Related Protein 2/3 Complex and Tubulins, 
which were all listed by IPA in a group of 200 differentially expressed genes involved in projection 
outgrowth. Shown is a color-based representation of the log2FC in each of the 3 individual experiments 
(red is downregulated in co-culture, green is upregulated in co-culture), followed by the average log2FC 
and the adjusted p-value. (C) Representative fluorescence microscopy images of dsRED-labeled 
pericytes in co-culture with unlabeled HMVECs (left), or with unlabeled pericytes (right). (D) Bar graph 
showing the percentage of dsRED-labeled pericytes with outgrowth of projections after knockdown of 
PLXNA2 and ACTR3 in pericytes. N=4, *P<0.05 compared to siNT-treated condition. 
 
confluent layer for the duration of 20 hours, either in combination with unlabeled HMVECs, 
or with unlabeled pericytes followed by fluorescent microscopy imaging. Interestingly, 
pericytes in direct contact with ECs had a completely different morphology, indeed forming 
extensive projections (Figure 5C). To study whether the differentially expressed growth 
cone-guiding molecules could in fact be involved in the observed morphological adaptation 
in pericytes, a proof-of-principle approach was used in which Plexin A2 (PLXNA2) and Actin 
Related Protein 3 (ACTR3), both well expressed and highly upregulated in co-cultured 
pericytes (Supplemental Figure 2A), were knocked down (Supplemental Figure 2B). After 
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culturing these siRNA-transfected pericytes in a confluent layer with HMVECs for the 
duration of 20 hours, the percentage of protrusion-forming pericytes was quantified using 
fluorescence microscopy. Knockdown of both PLXNA2 and ACTR3 significantly reduced the 
relative number of pericytes with projections (Figure 5D), substantiating the idea that direct 
interaction with ECs triggered a transcriptional response in pericytes necessary for 
morphological maturation. 
 
Endothelial interaction suppresses overall ECM production in pericytes 
Recent studies showed that pericytes, detaching from the capillaries, not only leave the 
microvascular endothelium in a vulnerable position, but at the same time might undergo 
differentiation into ECM-producing cells themselves.5, 21 Whether this differentiation is a 
consequence of disrupted mutual cross-talk, or involves other extravascular signaling routes 
is not fully understood. Interestingly, expression of 24 Collagen subtypes was significantly 
suppressed in pericytes co-cultured with endothelial cells, compared with mono-cultured 
pericytes (Figure 6A). Moreover, a variety of other ECM components, including Fibronectin 1 
(FN1), and Alpha- and Beta Laminins (LAMA and LAMB, respectively) was transcriptionally 
downregulated in co-cultured pericytes (Figure 6A). This suppressed ECM expression in co-
cultured pericytes might argue that differentiation into a fibrotic phenotype is indeed inhibited 
by direct interaction with ECs. Several studies have suggested that pericyte differentiation 
towards ECM producing cells depends on enhanced Transforming Growth Factor B (TGFβ) 
signaling.22, 23 However, in line with findings from many other studies (reviewed by Gaengel 
et al.24), our findings indicated that pericytes in contact with ECs have much higher 
activation of TGFβ signaling than pericytes lacking interaction with ECs. In fact, based on 
315 differentially expressed genes, IPA considered TGFβ1 (overlap p-value 3.56E-34) as 
the most active upstream growth factor in co-cultured pericytes (Figure 6B). Other 
upregulated genes in co-cultured pericytes beside ACTA2, included Connective Tissue 
Growth Factor (CTGF), Smooth Muscle Protein 22 Alpha (TAGLN), and Plasminogen 
Activator Inhibitor 1 (SERPINE1), all of which are well-known TGFβ target genes (Figure 
6C). These findings illustrate that, even in the presence of activated TGFβ signaling, ECM 
excretion by pericytes is suppressed when in contact with endothelium. 
 
Destabilizing key gap- and adherens junctions has no effect on transcriptional adaptation 
In the mature microvasculature, pericytes and ECs are embedded in a shared basement 
membrane. At distinct places this basement membrane is interrupted, enabling pericytes 
and ECs to form direct connections called peg and socket interactions. These sites are  
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Figure 6: Endothelial interaction suppresses overall ECM production in pericytes. (A) Schematic 
presentation of RNAseq data for differentially expressed Collagens, Laminins, and Fibronectin. Shown 
is a color-based representation of the log2FC in each of the 3 individual experiments (red is 
downregulated in co-culture, green is upregulated in co-culture), followed by the average log2FC and 
the adjusted p-value. (B) IPA-derived prediction of the most activated or repressed growth factors in co-
cultured pericytes compared with single cultured pericytes. Plotted is the –log(p-value) of overlap, in 
which green indicates predicted activation in co-culture versus predicted inhibition in red. (C) QPCR 
results showing expression levels of TGFβ target genes CTGF, TAGLN, and SERPINE1 relative to 
RPLP0 and POLR2L in pericytes in monoculture (Per), and after 20h in co-culture with HMVECs 
(Per+ECs). N=3, *P<0.05 compared to pericytes in monoculture. 
 
enriched in CDH2 adherens junctions and CX43 gap junctions, which provide a direct 
signaling route for ions, nutrients, metabolites, and secondary messengers, and which is 
complementary to paracrine signaling routes (Figure 7A). This direct signaling was 
previously reported to play a key role in a particular aspect of endothelium-induced mural 
cell differentiation.25 Interestingly in the present study, both CDH2 and CX43 were 
significantly upregulated in co-cultured pericytes, as validated by qPCR, suggesting 
enhanced requirement and thus signaling via these direct contacts in co-cultured pericytes 
(Figure 7B). This raised the question to what extent this signaling was mandatory for 
pericyte differentiation. To address this questions, we took a similar approach as listed in 
Figure 1, but pericytes were now treated with non-targeting (NT) siRNA, CHD2-targeting 
siRNA, or CX43-targeting siRNA, to disrupt the main gap- and adherens junctions, followed 
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Figure 7: Destabilizing key gap- and adherens junctions does not affect transcriptional 
adaptation (A) Pericytes (red) and ECs (green) can either interact via paracrine interaction (I) or via 
direct interaction at peg and socket contacts (II). These contacts are enriched in adherens junction 
protein CDH (α) and gap junction protein CX43 (β). (B) QPCR results showing expression levels of 
CX43 and CDH2 relative to RPLP0 and POLR2L in pericytes in monoculture (Per), and after 20h in co-
culture with HMVECs (Per+ECs). N=3, *P<0.05 compared to pericytes in monoculture. (C) 
Representative Western blots of CX43, CDH2, and β-actin levels in pericyte lysates at 48h and 72h 
post-transfection. N=4. (D) Schematic presentation of RNAseq data for differentially expressed TGFβ 
target genes. Shown is a color-based representation of the log2FC (red is downregulated in co-culture, 
green is upregulated in co-culture), followed by the adjusted p-value. N=3. 
 
by RNA sequencing. Knockdown efficiency was validated by Western blot for both CDH2 
and CX43 (Figure 7C). Expression profiles of co-cultured pericytes treated with NT siRNA 
were compared with that of co-cultured pericytes with either CDH2- or CX43 knockdown. It 
was observed that, beside siRNA-mediated downregulation of CDH2 and CX43, only KRT8 
was differentially expressed in co-cultured pericytes with suppressed CX43 expression 
compared with co-cultured pericytes treated with NT siRNA (Log2FC: 0.54, adjusted p-
value: 2.43E-02). KRT8 however was also upregulated in single cultured pericytes after 
CX43 knockdown (Log2FC: -0.52, adjusted p-value: 1.28E-02), indicating this was not 
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related to destabilized interaction among ECs and pericytes. This also implicates that, in 
contrast to what has previously been reported, lack of CX43 expression thus did not block 
TGFβ-induced mural cell maturation. In co-cultured pericytes treated with CX43-targeting 
siRNA, an evident upregulation was still observed for known TGFβ target genes CTGF, 
ACTA2, TAGLN, and SERPINE1 (Figure 7D). 
 
 
Discussion 
The main findings of the current study are: (1) Interaction with ECs drives pericyte 
differentiation and maturation. (2) ECs stimulate pericyte proliferation and survival. (3) Direct 
endothelial contact stimulates the outgrowth of pericyte projections, and (4) represses 
overall ECM production in these perivascular cells. (5) Key gap- and adherens junctions 
genes CX43 and CDH2 do not appear to be involved in endothelium-induced differentiation 
of pericytes. 
 
Pericytes have previously been described to be multipotent cells.26, 27 Thus, Crisan et al. 
reported that pericytes from multiple human organs, isolated using a combination of surface 
markers (including NG2, CD146, and PDGFRβ), were myogenic, osteogenic, chondrogenic, 
and adipogenic.28 In light of these findings, it is not unexpected that direct interaction with 
ECs, resembling the physiological microvascular situation, triggers a defined adaptation in 
gene expression in these highly plastic cells when compared with single cultured pericytes. 
At the same time, these findings also align with studies showing that disease-induced loss of 
EC-pericyte interaction has a major impact on pericyte behavior. Among the differentially 
expressed genes in co-cultured pericytes there was a variety of well-known pericyte 
markers. The enhanced transcription of these markers was consistent with previous findings 
showing that endothelial contact with pericytes or mesenchymal progenitor cells plays a 
major role in their differentiation towards mature pericytes.14, 29 Remarkably, beside all 
upregulated pericyte markers, one of the most frequently used pericyte markers, PDGFRβ, 
was downregulated in pericytes after direct contact with ECs. PDGFRβ is a membrane-
bound receptor with high affinity for Platelet Derived Growth Factor β and δ (PDGFβ and δ, 
respectively).30 PDGFβ is abundantly expressed in ECs, and during vascular development 
endothelial-derived PDGFβ triggers pericyte proliferation and migration towards a newly 
formed vessel to effectuate pericyte-induced vascular stabilization.31 Noteworthy, PDGFRβ 
expression is highly dependent on cell cycle activation, in a way that actively dividing cells 
have suppressed expression of the receptor.32 The transcription factor MYC, actively 
involved in cell cycle progression, was identified as a key repressor of the PDGFRβ 
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promoter.33, 34 Co-cultured pericytes were validated by Ki67 immunostaining to be actively 
proliferating, and not only was their expression of MYC upregulated almost threefold, 
analysis using IPA also suggested active transcriptional modulation by MYC in co-cultured 
pericytes (overlap p-value 1.03E-27). It is therefore likely that, among all the upregulated 
pericyte markers, the observed proliferative response in pericytes after direct contact with 
ECs triggers the – perhaps somewhat counterintuitive – suppression of PDGFRβ.  
The enhanced proliferation in pericytes after contact with ECs supports the work of Tarallo 
et al.16 Using cell culture inserts, on which pericytes and ECs were cultured on either side, 
they found that ECs enhanced the number of pericytes, albeit after a relative long incubation 
of 8 days. Taking into consideration that TGFβ was confirmed by IPA to be the most active 
upstream growth factor inducing the observed transcriptional response, the increased 
proliferation was remarkable as TGFβ has been reported in multiple different studies to have 
an inhibiting effect on this process.35, 36 This implies that other mitogenic factors must have 
compensated for the TGFβ-induced proliferation stop. VEGFA was previously found to 
directly induce proliferation in pericytes17. However, in contrast to the findings of Darland et 
al., who demonstrated that ECs induced VEGFA expression in pericytes37, a significant 
downregulation of VEGFA was found in co-cultured pericytes in the present study. In 
combination with the significantly lower expression of VEGFA in ECs, it therefore seemed 
unlikely that the enhanced proliferation in co-cultured pericytes was VEGFA-dependent. 
Moreover, several other mitogens, that were either highly expressed in ECs or showed 
elevated transcription in pericytes after interaction with ECs, have been reported for 
pericytes, including the aforementioned PDGFβ, FGF2 and HB-EGF.38-40 Both FGF2 and 
HB-EGF were significantly upregulated in pericytes co-cultured with ECs, and based on the 
observed transcriptional response IPA also listed these factors among the most active 
upstream growth factors (overlap p-values 9.53E-11 and 1.02E-11, respectively). 
Interestingly, siRNA-mediated knockdown of HB-EGF and FGF2 in pericytes, as well as 
PDGFβ in HMVECs, significantly reduced Ki67 positivity of co-cultured pericytes, whereas 
levels of Ki67 were not affected in VEGFA siRNA-treated pericytes. These findings 
substantiate that, beside paracrine stimulation with the well-documented endothelial-derived 
PDGFβ, direct contact with ECs triggers the transcription of these particular growth factors 
that could stimulate pericyte proliferation in an autocrine fashion. 
The endothelium-induced differentiation also involved morphological adaptations. Pericytes 
cultured in the absence of ECs had a somewhat bipolar elongated shape, whereas pericytes 
cultured in the presence of ECs were characterized by long and thin projections, a 
morphology that resembles the physiological shape of mature pericytes, which project 
finger-like extension around the capillary wall. The observed morphological differences were 
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accompanied by transcriptional adaption of particular genes. Individually, these genes can 
be involved in various cellular processes. Upregulation of tubulin isoforms for instance, is 
also observed during distinct phases of the cell cycle and migration.41 The ARP2/3 complex, 
in concert with CFLs, has been shown to be involved in the dynamics of lamellipodia 
growth42, whereas many growth cone-guiding molecules have also been shown to be 
involved in vascular patterning, mostly affecting endothelial tip cell behavior. For example, 
signaling via the NRP receptor stimulates growth cone-collapse in the nervous systems in 
response to SEMAs43, yet they appear to induce endothelial tip-cell extension and vessel 
sprouting in the vascular system in response to VEGF.44 Similarly, signaling of NTNs via 
UNC-5 Netrin Receptors (UNC5), downregulated in co-cultured pericytes, was shown to 
have a repulsive effect on endothelial branching45, 46, and Eph receptors and EFNs were 
reported to be involved in segregation of ECs with distinct arterial- or venous fates.47 
However, the fact that in co-cultured pericytes developing long cellular protrusions, 200 
genes (overlap p-value 6.78E-13) associated with axonal guidance were differentially 
expressed, suggested that these signaling molecules may also have a profound effect on 
pericyte behavior. The hypothesized activation of growth cone-guiding in pericytes upon 
endothelial interaction was substantiated by the finding that siRNA-mediated downregulation 
of PLXNA2 and ACTR3, both upregulated in co-cultured pericytes, significantly reduced the 
relative number of pericytes with projections. The reduction of projection outgrowth after 
knockdown of ACTR3 was not unexpected considering its role in onset of actin filament 
formation.48 However, PLXNs generally transduce the inhibitory effect of SEMAs on axon 
outgrowth49, and consequently, loss of PLXNA2 was expected to actually stimulate 
outgrowth of pericyte projections. In ECs and U87MG glioblastoma cells, however, it was 
demonstrated that stimulation with SEMA3B and SEMA6A only in presence of PLXNA2 
induced localized disassembly of the actin cytoskeleton and focal adhesion points, followed 
by cell contraction and the appearance of thin projections that remain attached to the 
substrate around the contracted cell50, yielding a morphological resemblance with the co-
cultured pericytes. To date, little is known about the growth cone-guiding signaling pathways 
in pericytes, yet the associated morphological changes may be of great importance for 
vascular integrity, as was recently shown in the adult mouse brain, where local ablation of 
pericytes provoked resident pericytes to extend the tips of their projections to cover the 
endothelium and to restore local vascular function.18 
The present study further provides evidence for an endothelium-induced suppression of 
overall ECM production in pericytes. This finding partially contrasts with the study of 
Stratman et al., in which basement membrane ECM expression was investigated in single-
cultured and co-cultured human umbilical vein ECs and bovine pericytes in a collagen 
Chapter 3 
80 
 
matrix.51 Similar to our findings, they observed a defined downregulation of FN1 in pericytes 
cultured in the presence of ECs, yet a variety of other ECM molecules, including COL4A1 
and COL4A2, demonstrated increased transcription levels in co-cultured pericytes. These 
apparent inconsistencies in transcriptional response are likely the result of differences in 
experimental approach, however, since we found that Glyceraldehyde-3-Phosphate 
Dehydrogenase, used by Stratman et al. as reference gene, was differentially expressed in 
co-cultured pericytes, it is difficult to draw definite conclusions. The findings on ECM 
expression do however appear to be in line with the many studies demonstrating that, upon 
organ injury, pericytes detach and migrate from the endothelium and differentiate into ECM-
producing cells.5, 14, 21, 52 The observed suppression of ECM production in co-cultured 
pericytes, however, went paradoxically along with enhanced TGFβ signaling. This enhanced 
TGFβ signaling itself is not unexpected, as several studies demonstrated that direct contact 
of pericytes with ECs triggers the activation of latent TGFβ, thereby inducing a swift 
activation of TGFβ-mediated signaling.53 The paradox lies in the fact that TGFβ is well 
known for its role in transforming pericytes into ECM-producing fibroblasts.54 These findings 
thus illustrate that, even in the presence of activated TGFβ signaling, ECM production by 
pericytes is suppressed when in contact with endothelium, implying that either the actual 
level of TGFβ determines healthy or pathological pericyte differentiation, or that a thus far 
unknown endothelial-derived cue must be counteracting TGFβ-induced differentiation of 
pericytes into fibrotic cells. 
Beside secreted signaling molecules, such as VEGFA and PDGFβ, ECs and pericytes also 
interact in a more direct physical manner. At distinct places, the basement membrane 
separating the two cell types is interrupted, allowing the formation of direct contacts called 
peg and socket contacts.8 These contacts are highly enriched in gap- and adherens 
junctions CX43 and CDH2, respectively.9 In the present study, the expression of these 
molecules was suppressed in pericytes to assess if, and which, transcriptional adaptations 
in pericytes upon co-culture with ECs were regulated via these direct contacts. 
Unexpectedly, transcriptional comparison of co-cultured pericytes treated with NT siRNA 
and co-cultured pericytes with suppressed CX43 or CDH2 expression did not reveal 
significant differences. Hirschi et al. demonstrated that CX43 deficient mesenchymal cells 
lost their ability to activate latent TGFβ, and as a result were unable to differentiate into 
mature mural cells.25 This is in contrast to our study where we did not observe any effect on 
TGFβ-mediated transcription in pericytes with suppressed CX43 expression. Our results 
suggest that endothelium-induced pericyte differentiation is not mediated by key gap- and 
adherens junctions CX43 and CDH2. 
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In conclusion, the present study provides important evidence for pericyte differentiation upon 
interaction with ECs, by showing endothelium-induced pericyte maturation and proliferation, 
and suppression of ECM expression. However, functional gap- and adherens junctions do 
not appear to be involved in this process.  
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Supplemental data 
 
 
Supplemental Figure 1: Endothelial PDGFβ, and pericyte HB-EGF and FGF2, are upregulated in 
co-cultured cells and were, like VEGFA, downregulated by siRNA. (A) QPCR results showing 
expression levels of HB-EGF, FGF2, and PDGFβ relative to RPLP0 and POLR2L in mono- and co-
cultured pericytes and co-cultured ECs. N=3, * P<0.05 compared to pericytes in monoculture and ECs 
in co-culture, # P<0.05 compared to pericytes in mono- and co-culture, ‡ P<0.05 compared to ECs in co-
culture, † P<0.05 compared to pericytes in co-culture. (C) QPCR results showing expression levels of 
HB-EGF, FGF2 and VEGFA in pericytes, as well as (D) PDGFβ in ECs relative to RPLP0 and POLR2L. 
N=3-4, * P<0.05 compared to siNT-treated control.  
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Supplemental Figure 2: PLXNA2 and ACTR3 are upregulated in co-cultured pericytes and were 
downregulated by siRNA. (A) QPCR results showing expression levels of PLXNA2 and ACTR3 
relative to RPLP0 and POLR2L in mono- and co-cultured pericytes. N=3, * P<0.05 compared to 
pericytes in monoculture. (B) QPCR results showing expression levels of PLXNA2 and ACTR3 relative 
to RPLP0 and POLR2L in siRNA treated pericytes. N=3-4, * P<0.05 compared to siNT-treated control. 
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Abstract 
The combination of cardiac and renal disease driven by metabolic risk factors, referred to as 
cardiorenal metabolic syndrome (CRMS), is increasingly recognized as a critical 
pathological entity. The contribution of (micro)vascular injury to CRMS is considered to be 
substantial. However, mechanistic studies are hampered by lack of in vivo models that 
mimic the natural onset of the disease. Here, we evaluated the coronary and renal 
microvasculature during CRMS development in obese diabetic Zucker fatty/Spontaneously 
hypertensive heart failure F1 hybrid (ZSF1) rats. Echocardiographic, urine, and blood 
evaluations were conducted in 3 groups (Wistar-Kyoto, lean ZSF1, and obese ZSF1) at 20 
and 25 weeks of age. Immunohistological evaluation of renal and cardiac tissues was 
conducted at both time points. At 20 and 25 weeks, obese ZSF1 rats showed higher body 
weight, significant left ventricular hypertrophy, and impaired diastolic function compared with 
all other groups. Indices of systolic function did not differ between groups. Obese ZSF1 rats 
developed hyperproliferative vascular foci in the subendocardium, which lacked 
microvascular organization and were predilection sites of inflammation and fibrosis. In the 
kidney, obese ZSF1 animals showed regression of the peritubular and glomerular 
microvasculature, accompanied by tubulointerstitial damage, glomerulosclerosis, and 
proteinuria. The obese ZSF1 rat strain is a suitable in vivo model for CRMS, sharing 
characteristics with the human syndrome during the earliest onset of disease. In these rats, 
CRMS induces microvascular fibrotic responses in heart and kidneys, associated with 
functional impairment of both organs. 
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Introduction 
Cardiorenal syndrome (CRS) represents the interdependent relation between the heart and 
kidneys during disease onset and progression. This important link between cardiac and 
renal pathophysiology is demonstrated by the high prevalence of chronic kidney disease 
(CKD) in patients with heart failure and vice versa, whereas dysfunction in both organs is 
strongly associated with increased morbidity and mortality.1 Recent findings have also 
highlighted the connection between CRS and metabolic risk factors: metabolic syndrome is 
a multitude of risk factors that includes high blood pressure, hyperglycemia, obesity, and 
dyslipidemia from which at least 3 occur together, thereby functioning as a synergistic 
complex that drastically increases the risk of cardiovascular disease.2 This syndrome is 
growing ever more prevalent, affecting  approximately 20% of adults in the aging Western 
population.3 A significant amount of evidence clearly shows a strong relation between 
metabolic syndrome and onset and progression of cardiovascular disease.4, 5 In regard to 
renal disease, a clear association between metabolic syndrome and renal dysfunction has 
also been described.4, 6 Thus, metabolic risk factors seem to be the driving force behind 
cardiovascular and CKD disease, and hence CRS. Similarly, the association between all 
individual components of metabolic syndrome and CRS development is now well 
established and is increasingly recognized as a separate disease-entity termed cardiorenal 
metabolic syndrome (CRMS).1, 6, 7 At present, rodent CRS models typically involve renal 
ablation and coronary ligation, either alone or in combination to directly induce diastolic and 
systolic dysfunction.8 An in vivo model that uses metabolic triggers may be more relevant for 
studies that focus on onset and early progression of CRS. Here we propose the obese 
diabetic Zucker fatty/Spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat strain as 
a model for CRMS.9 Recently, we have reported that obese ZSF1 rats develop heart failure 
with preserved ejection fraction (HFpEF) between weeks 10 and 20 of natural aging.9 The 
ZSF1 strain also autonomously develops renal disease, making it suitable for studying CKD 
in relation to metabolic triggers.10, 11 HFpEF development in obese ZSF1 rats was 
characterized by progressive left ventricle (LV) diastolic dysfunction, concentric LV 
remodeling, and hypertrophy.12 This was preceded by insulin resistance, glycosuria, and 
proteinuria.9 This phenotype is consistent with CRMS in humans, which is defined by the 
presence of metabolic syndrome in addition to insulin resistance, microalbuminurina, and 
reduced renal function.13 Therefore, these data indicate that the obese ZSF1 strain may be 
used as an in vivo model of CRS early progression against a well-defined background of 
metabolic injury, thus providing a model to study CRMS. Obese ZSF1 rats also experienced 
increased vascular stiffness and lack of NO response, consistent with endothelial 
dysfunction.14 Persistent nitrosative/oxidative stress and inflammation have been observed 
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in the coronary microvascular bed of patients with HFpEF.15, 16 Vascular oxidative stress 
leading to endothelial dysfunction and inflammation has been proposed as one of the key 
pathways in HFpEF and CRS17-20, and it is strongly linked to metabolic risk factors.19, 21 
However, details of the cardiac and renal microvasculature response in CRMS remain to be 
investigated. Consequently, we studied the microvascular changes in the heart and kidney 
during progression of HFpEF and renal dysfunction in obese ZSF1 rats. 
 
 
Methods 
Ethics 
All animal studies were carried out in accordance with the Council of Europe Convention 
(Directive [2010/63/EU]) for the protection of vertebrate animals used for experimental and 
other scientific purposes with the approval of the National and Local Animal Care Committee 
of Faculty of Medicine of Porto. Animal experiments were performed according to ARRIVE 
(Animal Research: Reporting of In Vivo Experiments) guidelines. 
 
Animal Model 
Nine-week-old male Wistar Kyoto (WKY, n=12), ZSF1 Lean (ZSF1 Ln, n=10), and ZSF1 
Obese rats (ZSF1 Ob, n=12) were obtained from Charles River (Barcelona, Spain) and 
housed in a light, temperature, and humidity controlled environment after a 12-hour light–
dark cycle with free access to water and standard diet (Purina diet no. 5008). Phenotypic 
evaluation was conducted after 1 week of acclimatization, consisting of metabolic and 
echocardiographic studies. Weight gain was monitored every third day. In weeks 18 and 24, 
phenotypic evaluation was repeated. Cardiac hemodynamic measurements followed by 
euthanasia were performed at 20th and 25th week. Heart and kidneys were excised, 
weighed, fixed in formaldehyde, and embedded in paraffin for further analysis. 
 
Echocardiography Evaluation 
Rats were anesthetized by inhalation of sevoflurane (8 and 2.5%–3% for induction and 
maintenance, respectively; Penlon Sigma Delta), mechanically ventilated while homeostasis 
was maintained by anesthetic monitoring. After applying echocardiography gel, a linear 
15MHz probe (Sequoia 15L8W) was positioned on the thorax. Systolic and diastolic wall 
thickness and cavity dimensions were recorded in M-mode and 2-dimensional (2D) 
echocardiography, at the level just above the papillary muscles in the parasternal short-axis 
view. The long-axis diastolic dimensions of the LV and transverse aortic root diameter were 
recorded by 2D and M-mode echocardiography, respectively, in the parasternal long-axis 
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view. Aortic flow velocity was recorded by pulsed-wave Doppler above the aortic valve. 
Mitral flow velocity tracings were obtained with pulsed-wave Doppler above the mitral 
leaflets, peak systolic tissue velocity, and e′ were measured with tissue Doppler at the 
medial mitral annulus and lateral mitral annulus, respectively, and left atrial dimensions were 
measured at their maximum, by 2D echocardiography in the 4-chamber view. Acquisitions 
were conducted while suspending mechanical ventilation and recordings were averaged 
from 3 consecutive heartbeats (Siemens Acuson Sequoia C512). LV mass and volumes 
were calculated by the 2D area-length method and M-mode. For evaluation of diastolic 
function, peak velocity of early (E), and late (A) mitral inflow and the ratio of E over e′ were 
measured as an indicator of LV filling pressure. Myocardial performance index was retrieved 
from the mitral flow pattern. Volumes and masses were indexed for body surface area as 
defined by 9.1*body weight (BW)2/3. 
 
Measurement of biochemical variables 
Plasma samples were treated with chloroform to remove lipids which interfere with plasma 
analysis. Chloroform and plasma (1:1) were centrifuged at 1000 x g for 30 minutes. 
Supernatant was transferred to a new tube and centrifuged at 10000 x g for 45 minutes. 
Supernatant was transferred to a new tube and used for creatinine and urea analysis. 
Plasma and urine creatinine were enzymatically measured (DiaSys PAP FS; DiaSys 
Diagnostic Systems, Holzheim, Germany). Plasma urea was enzymatically measured 
(DiaSys Urea CT FS; DiaSys Diagnostic Systmes, Holzheim, Germany). Total protein 
excretion was measured using Bradford method (BioRad Laboratories, Veenendaal, 
Netherlands). Thiobarbituric Acid Reactive Substances (TBARS) as indicators for the level 
of systemic oxidative stress were measured colorimetrically (Cayman Chemical, Ann Arbor, 
MI).  
 
Hemodynamic evaluation 
Animals were sedated with 100 μg.kg-1 and 5 mg.kg-1 intraperitoneal fentanyl and 
midazolam, respectively), followed by anesthesia (8 and 2.5–3% sevoflurane for induction 
and maintenance, respectively; Penlon Sigma Delta), endotracheal intubation, and 
mechanical ventilation (TOPO, Kent scientific). Fluid replacement with warm Ringer’s lactate 
at 32 mL.kg-1.h-1 (NE-1000, New Era Pump Systems) was administered through a 
peripheral dorsal foot vein catheter (24G) and animals were maintained at 38°C on a heating 
pad. A flowmeter probe was transiently placed in the ascending aorta for cardiac output 
(CO) calibration (2.5PS, Transonic). A pressure-volume catheter (SPR-847 Millar 
Instruments) was inserted in the LV apex and placed along the LV long axis. Silk threads 
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were placed around the inferior vena cava to enable transient occlusions. Parallel 
conductance was determined by 40µL 10% hypertonic saline injection and slope factor α 
was derived by simultaneous measurement of CO by a flowmeter placed around ascending 
aorta (TS420, Transonic). After a stabilization period of 30 minutes, recordings were 
obtained at suspended end-expiration. Transient 5-7 cycle occlusions of the inferior vena 
cava occlusions were performed to obtain load independent indexes of LV chamber stiffness 
by fitting an exponential function to the end-diastolic pressure-volume relationship (EDPVR) 
as previously described.9  Single beat occlusions of the ascending aorta were performed to 
assess diastolic response to isovolumic afterload as reported.22 Three separate acquisitions 
were obtained and averaged in each animal. Data with arrhythmia, heart rate changes 
higher than 2% or evidence of incomplete afterload elevations were excluded. Resting 
periods were allowed between each intervention. Signals were continuously acquired 
(MPVS 300, Millar Instruments), recorded at 1000Hz (ML880 PowerLab 16/30, 
ADinstruments), and analyzed (PVAN 3.5, Millar Instruments). To account for large 
differences in body weight between groups, volumes were indexed for body surface area as 
estimated by 9.1*body weight in grams¾. Upon completion of experiments, blood (4mL) 
wascollected for volume calibration (910–1048, Millar instruments) and storage. Finally the 
anesthetized animals were euthanized by exsanguination. Right ventricle (RV), LV and 
interventricular septum (IVS) were weighed after dissection, and tibia length (TL) was 
measured. Samples were snap-frozen and stored at -80ºC or processed for histology. 
Weights were normalized to TL.  
 
Renal and cardiac immunohistochemistry 
Three to five µm sections were sliced from formaldehyde-fixed, paraffin-embedded kidneys 
and hearts. For the analysis of the kidneys, tubulointerstitial (TI) damage and 
glomerulosclerosis (GS) were scored on Periodic-acid Schiff (PAS) stained sections in a 
blinded manner. TI damage was scored on a scale of 1-5 in at least 10 different non-
overlapping fields per animal. Scored variables include the amount of peritubular 
inflammatory infiltrate, interstitial fibrosis, tubular atrophy and tubular dilatation. GS was 
scored on at least 30 separate glomeruli by quadrants, on a scale of 0 to 4, with 0 meaning 
no quadrant affected and 4 meaning that the whole glomerulus was affected. Scored 
variables for GS were matrix expansion, sclerosis, adhesion of Bowman’s capsule and 
dilation. For both TI and GS a total damage score was calculated. Peritubular and 
glomerular endothelium was stained with a primary antibody for JG12 (mouse anti-JG12, 
BMS1104, 1:200, Bender Medsystems GmbH, Vienne, Austria). Deparaffinized sections 
were subjected to heat-induced antigen retrieval by incubation with citrate/HCl buffer (pH 
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6.0) at 100°C for 20 minutes. As a secondary antibody brightvision-HRP (ImmunoLogic, 
Duiven, Netherlands) was used. Positive cells were visualized with Vector Nova Red (Vector 
Laboratories, Burlingame, CA) and counterstained with hematoxylin. Sections were scanned 
using an Aperio ScanScope XT (Aperio Technologies, Vista, CA) and analyzed using Adobe 
Photoshop (Adobe Systems, San Jose, CA) and ImageJ software. Ten tubular fields and 30 
glomeruli were selected and the percentage of JG12+ area was calculated, to correct JG12+ 
area for glomerular size. For the analysis of the heart, deparaffinized cardiac sections were 
subjected to heatinduced antigen retrieval with antigen retriever 2100 (Aptum Biologics Ltd, 
UK) with citrate/HCl buffer (pH 6.0) for 20 minutes. After a brief wash with PBS, sections 
were blocked with superblock (Life Technologies, Netherlands) for 1 hour before overnight 
incubation at 4˚C with the following primary antibodies; rabbit anti-NG2 (1:100, Abcam 
ab5320), rabbit anti-PDGFRβ (1:100, Abcam ab32570), biotin labelled anti-Lectin (1:200, 
Sigma-Aldrich L-3759), mouse anti-JG12 (1:100, eBioscience BMS1104), rabbit anti-Ki67 
(1:100, Thermo Scientific RM-9106), goat anti-Collagen IV (1:50, Millipore AB769), rabbit 
antiFibronectin (1:100, Sigma Aldrich F3648), mouse anti-CD68 (1:100, Abcam ab31630), 
and mouse anti-CD3 (1:100, Dako M7254). Appropriate secondary antibodies (Invitrogen, 
Netherlands) were used for visualization under fluorescent microscope. Nuclei were 
counterstained with DAPI (1 µg/ml, Sigma-Aldrich). Images were taken by Olympus BX53 
microscope. The numbers of NG2+ or PDGFRβ+ foci were counted for the whole heart 
section by microscope examination. For quantification of Lectin staining, pictures from the 
left ventricle were randomly obtained from lectin stained heart sections (4 in the 
endocardium, 4 near the epicardium). Images were analysed using ImageJ (v1.49) by 
quantification of the percentage of the lectin+ area per image area. 
 
Immunofluorescence cell staining 
Human umbilical vein endothelial cells (HUVECs), pericytes and vascular smooth muscle 
cells (VSMCs) were seeded on sterile glass cover slips and cultured in EGM-2 (Lonza), 
DMEM (Gibco, #41965), and SmGM-2 (Lonza) medium respectively for four days at 37˚C. 
Cells were first washed with PBS and then fixed with cold methanol for 10 minutes. Cells 
were blocked with Super blot (ScyTek Laboratories #AAA125) for 1 hour at room 
temperature. After that, cells were incubated with rabbit anti-NG2 (1:100, Abcam ab5320) or 
rabbit anti-PDGFRβ (1:100, Abcam ab32570) antibodies overnight at 4˚C. After washing 
with PBS, this was followed by incubation with Alex Flour 488-conjugated goat anti rabbit 
antibody for 1 hour at room temperature. Nuclei were counterstained with DAPI. Images 
were taken with the same setting by Olympus BX53 microscope with 20x objective. 
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QPCR analysis 
Total RNA of HUVECs, pericytes, VSMCs and fibroblasts was isolated using RNAeasy kit 
(Qiagen) and treated with DNAse to remove genomic DNA contamination. cDNA was 
generated using iScript cDNA synthesis kit (Bio-Rad) according to manufacturer's 
instructions. Quantitative PCR was performed on the BioRad CFX96 RT system using 
SYBR Green, and mRNA expression levels were normalized to the housekeeping gene B-
actin. The PCR primers used are listed in table 1. 
 
Table 1: Primer sequences used for (q)PCR. 
 
 
Statistics 
Groups were compared by 2-way ANOVA for repeated measurements, followed by Student–
Newman–Keuls post hoc test using SigmaPlot 12.3 (Systat Software Inc, San Jose, CA). 
Data are presented as mean±SD. P<0.05 was considered significant. Alternatively, 1-way 
ANOVA Kruskal–Wallis test was used, followed by Dunn multiple comparison test.  
 
Results 
HFpEF Progression in obese ZSF1 rats 
Obese ZSF1 rats had LV hypertrophy, as shown by increased echocardiographic indices of 
LV mass and LV posterior wall thickness at end diastole versus WKY and lean ZSF1 rats at 
25 weeks of age, and increased LV+IVS weight/tibial length compared to WKY and lean 
ZSF1 rats at 20 and 25 weeks of age (Tables 2 and 3). Echocardiographic data showed 
preserved systolic function in all groups as assessed by ejection fraction, fractional 
shortening, and cardiac index at 20 or 25 weeks of age (Table 3). In contrast, obese ZSF1 
rats presented with increased ratio of E to early diastolic tissue Doppler mitral annulus 
velocity (e′), significantly increased E/e′/end-diastolic volume ratios, and increased left atrial 
area (Table 3), indicative of impaired diastolic function. Hemodynamic evaluation showed 
significant increase in Tau, end-diastolic pressure, and end-diastolic pressure volume 
relationship β1 in obese ZSF1 rats at 25 weeks of age compared with WKY and lean ZSF1 
rats at 20 and 25 weeks (Supplemental Table 1). Furthermore, right ventricular weight/tibial 
length and lung weight/tibial length were increased in obese ZSF1 rats at 25 weeks 
Gene Sense primer sequence Antisense primer sequence 
COL4A1 ACGGGGGAAAACATAAGACC TGGCGCACTTCTAAACTCCT 
COL4A2 TTATGCACTGCCTAAAGAGGAGC CCCTTAACTCCGTAGAAACCAAG 
Β-actin TCCCTGGAGAAGAGCTACGA AGCACTGTGTTGGCGTACAG 
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body weight (g) 360 ± 31 410 ± 26 595 ± 31* 368 ± 24 469 ± 23†‡ 633 ± 36*†
TL (mm) 39.4 ± 0.8 41.9 ± 0.9§ 40.1 ± 1.3 38.8 ± 0.5 40.9 ± 0.8§ 39.2 ± 1.0
LV+IVS weight/TL (mg/mm) 30.1 ± 3.9 28.2 ± 1.0 36.4 ± 2.5* 32.6 ± 4.0 35.0 ± 3.3† 37.4 ± 2.2‡
RV weight/TL (mg/mm) 3.4 ± 1.1 2.7 ± 0.4 4.1 ± 0.6# 3.1 ± 0.8 3.6 ± 0.5 4.8 ± 1.2*
lung weight/TL (mg/mm) 34.9 ± 5.3 40.6 ± 7.8 55.1 ± 5.2* 45.4 ± 6.1† 48.8 ± 3.3† 64.7 ± 3.0*†
WKY 20wks ZSF1 ln 20wks ZSF1 ob 20wks WKY 25wks ZSF1 ln 25wks ZSF1 ob 25wks
compared to WKY and lean ZSF1 rats at 20 and 25 weeks of age (Table 2). Systolic, 
diastolic, and mean blood pressure levels were increased in the obese ZSF1 rats at 25 
weeks compared to WKY and lean ZSF1 rats (Supplemental Table 2). 
  
Table 2: Morphometrics of WKY, lean and obese ZSF1 Rats   
 
 
 
 
Two-way ANOVA with Student–Newman–Keuls post hoc test. n=5-6 animals per group. Values are mean±SD. IVS 
indicates interventricular septum; LV, left ventricle; RV, right ventricle; TL, tibial length; and WKY, Wistar Kyoto. *P<0.05 
vs. WKY and ZSF1 Ln 20 or 25; †P<0.05 vs. week 20; ‡P<0.05 vs. WKY 20 or 25; §P<0.05 vs. WKY and ZSF1 Ob 20 or 
25; #P<0.05 vs. ZSF1 Ln.  
 
Table 3: Echocardiographic data for WKY, lean and obese ZSF1 rats  
 
Two-way ANOVA with Student–Newman–Keuls post hoc test. n=2 to 4 animals per group at 20 weeks; n=5 to 6 animals 
per group at 25 weeks. Values are mean±SD. CI indicates cardiac index; dLVPW, left ventricular posterior wall 
measured in diastole; E/A, ratio between peak E and A waves of pulsed-wave Doppler mitral flow velocity; EDVI, end-
diastolic volume indexed for body surface area; E/e′, ratio between peak E-wave velocity of pulsed-wave Doppler mitral 
flow and peak e′-wave velocity of tissue Doppler at the lateral mitral annulus; EF, ejection fraction; EVD; end-diastolic 
volume; FS, fractional shortening; HR, heart rate; LAA, left atrial area; MPI, myocardial performance or Tei index; S, 
peak systolic tissue Doppler velocity at the mitral annulus; and WKY, Wistar Kyoto. *P<0.05 vs week 20; †P<0.05 vs 
WKY 20 or 25; ‡P<0.05 vs WKY and ZSF1 Ln 20 or 25.  
Heart rate (bpm) 299 ± 18 337 ± 5 309 ± 24 298 ± 55 301 ± 33 282 ± 24
dLVPW (mm) 1.40 ± 0.00 1.45 ± 0.07 1.47 ± 0.11 1.11± 0.05* 1.25 ± 0.15*† 1.46 ± 0.11‡
LV mass (mg) 483 ± 93 628 ± 14 797 ± 35† 386 ± 81 604 ± 142† 976 ± 201*‡
FS (%) 35.4 ± 3.7 41.2 ± 4.4 37.9 ± 1.8 36.2 ± 7.4 34.8 ± 6.1 35.4 ± 5.3
EF (%) 70.8 ± 4.8 77.3 ± 4.7 73.3 ± 2.1 71.0 ± 9.0 69.2 ± 7.9 69.7 ± 6.6
S (mm/s) 45 ± 3 59 ± 6† 58 ± 4† 48 ± 7 54 ± 4 52 ± 4
CI (µl/min/cm 2) 212 ± 30 187 ± 50 215 ± 19 172 ± 32 178 ± 11 220 ± 40
MPI (Tei) 0.60 ± 0.01 0.59 ± 0.01 0.62 ± 0.02 0.64 ± 0.03 0.62 ± 0.05 0.60 ± 0.04
E/A 1.79 ± 0.42 1.40 ± 0.08 1.33 ± 0.15† 1.68 ± 0.24 1.56 ± 0.13 1.30 ± 0.19‡
E/e' 12.7 ± 0.05 11.9 ± 2.3 16.7 ± 0.9‡ 12.2 ± 1.6 11.9 ± 2.1 14.3 ± 1.4*
E/e'/EDV (log 2) 22.9 ± 4.7 13.2 ± 1.6 11.4 ± 0.6† 21.4 ± 9.9 12.5 ± 5.0† 9.0 ± 2.5†
LAA (mm 2) 2.48 ± 0.08 2.81 ± 0.30 3.51 ± 0.06‡ 2.25 ± 0.14 2.70 ± 0.30† 3.71 ± 0.13‡
EDVI (µl/cm2) 1.30 ± 0.17 1.87 ± 0.17 2.35 ± 0.22 1.37 ± 0.41 1.87 ± 0.46 2.45 ± 0.49
WKY 20wks ZSF1 ln 20wks ZSF1 ob 20wks WKY 25wks ZSF1 ln 25wks ZSF1 ob 25wks
Chapter 4 
98 
 
Obese ZSF1 rats develop multiple subendocardial microstructures enriched in ECs 
Hematoxylin/eosin examination of heart cross-sections revealed no major differences in 
tissue morphology between WKY and lean ZSF1 rats at 20 or 25 weeks of age. However, 
multiple areas with high cell density were observed at subendocardial locations of obese 
ZSF1 rats at both time points, which were absent in WKY and lean ZSF1 rats (Figure 1A-B). 
High magnification assessment identified these ZSF1 Ob-specific areas as irregular star-
shaped foci composed of >50 mononuclear cells, located in the interstitial space between 
the cardiomyocytes (Figure 1C-G). Erythrocytes were detected in the extravascular space 
(Figure 1D and 1F), or in the lumen of capillary-like arrangements (Figure 1D, 1F and 1H), 
suggesting that these foci may contain vascular cells. 
Lectin+ ECs were organized in a well-structured capillary network in both WKY and lean 
ZSF1 rats at 20 and 25 weeks of age (Figure 2A-B). Similarly, a well-organized capillary 
network was observed in obese ZSF1 rats at both 20 and 25 weeks of age in the areas 
outside the foci (Figure 2A-B). Quantification of lectin staining showed a significant increase 
in capillary area in obese ZSF1 rats at 20 weeks of age compared with WKY and lean ZSF1 
rats (9.3±1.0 versus 4.7±1.1 and 5.8±1.0, respectively; P<0.01), whereas at 25 weeks, 
capillary areas normalized between groups, mainly because of the increase in WKY and 
lean ZSF1 rats (Figure 2C). The subendocardial foci in obese ZSF1 rats also stained 
positive for lectin, indicating that most of the accumulated cells were endothelial cells (Figure 
2D-E). In contrast to the coherent lectin+ capillary structures that were found outside the 
foci, the bulk of lectin+ ECs inside these foci showed a distinct lack of vascular morphology 
with only limited luminal and monolayer organization (Figure 2D-E, inserts). 
 
Subendocardial foci are enriched in NG2+ and PDGFRβ+ pericytes 
Pericytes are vascular mural cells that are typically found in the capillary bed. They are vital 
for microvascular survival and regulation of blood flow.23 Immunostaining experiments using 
cultured human vascular cells demonstrate that NG2 and PDGFRβ are suitable markers for 
mural cells, predominantly pericytes, being minimally expressed by endothelial cells 
(Supplemental Figure 1A). Immunostaining for NG2 identified vascular pericytes located in 
the subendocardial foci, further validating their vascular identity. In WKY and lean ZSF1 rats, 
NG2+ pericytes were detected at their characteristic peri-EC localization, as shown by lectin 
double staining (Figure 3A). In contrast, in obese ZSF1 rats, the number of NG2+ pericytes 
was markedly increased in the regions outside the foci (Figure 3A). In the subendocardial 
foci, NG2+ pericytes were also observed in close distance to lectin+ ECs (Figure 3A-B). 
Although some coverage of vascular structures could be recognized, the majority of the  
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Figure 1: High cell 
density subendo-
cardial foci develop 
specifically in the 
left ventricles of 
obese ZSF1 rats, 
but not in lean 
ZSF1 rats and WKY 
rats. Representative 
hematoxylin /eosin-
stained LV cross-
sections obese ZSF1 
rats and WKY rats at 
25 weeks of age. (A) 
Low magnification 
micrograph of the 
whole heart section 
of obese ZSF1 rats. 
(AI-AII) Higher 
magnification 
micrographs, high 
cell density 
subendocardial foci 
marked by black 
circles. (B) Low 
magnification figure 
of heart section of 
WKY. (BI-BII) Higher 
magnification figures 
showing the absence 
of high cell density subendocardial foci. (C) High magnification figure showing typical morphology at the 
LV subendocardial location in WKY rats. (D) High magnification detail. Erythrocytes in the capillary bed 
are indicated by arrowhead. (E-G), High magnification examples showing foci morphology in obese 
ZSF1 rats. (F-H) High magnification details with erythrocytes indicated by arrowheads. 
 
NG2+ pericytes formed atypical multilayered clusters mixed with lectin+ ECs (Figure 3B). To 
further validate the vascular content of the foci in obese ZSF1 rats, pericytes were stained 
with a second vascular mural cell marker, PDGFRβ, in combination with a second EC 
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Figure 2: Subendocardial foci in obese ZSF1 rats are enriched with lectin+ EC. Representative LV 
cross-sections from WKY, lean and obese ZSF1 rats at (A) 20 and (B) 25 weeks of age, stained for 
lectin+ endothelium (red signal). Cell nuclei are stained with DAPI (blue signal). (C) Quantification of 
lectin+ endothelial area (%) in WKY, lean and obese ZSF1 rats at 20 and 25 weeks of age. Mean±SD, 
**P<0.01. High magnification detail panels showing the microcapillary structures in obese ZSF1 rats (D) 
outside and (E) inside the subendocardial foci. Arrow indicates vascular structures with open lumen. 
 
marker, JG12. PDGFRβ+ pericytes were detected in WKY and lean ZSF1 rats at peri-EC 
localization (Figure 3C). In the obese ZSF1 rats, PDGFRβ+ pericytes accumulated in the 
foci and were atypically organized with limited perivascular coverage (Figure 3C-D). In the 
capillary network directly surrounding these foci, an increase in PDGFRβ+ pericytes was 
observed when compared with the capillary network in WKY and lean ZSF1 rats (Figure 3E-
F). The number of vascular foci increased by 9- and 20-fold in obese ZSF1 rats versus WKY 
rats and by 4- and 27-fold compared with lean ZSF1 rats, at 20 and 25 weeks, respectively, 
when quantified using the NG2+ signal (P<0.001; Figure 3G). Similarly, quantification of foci 
using the PDGFRβ+ signal showed increases of 7- and 25-fold in obese ZSF1 rats versus 
WKY and of 4- and 29-fold in obese versus lean ZSF1 rats at 20 and 25 weeks, respectively 
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(P<0.001; Figure 3G, right graph). Based on both the NG2 and the PDGFRβ method of 
quantification, the number of foci also increased in obese ZSF1 rats over time (P<0.001; 
Figure 3G). Combined, these data identify the subendocardial structures as vascular cells 
enriched foci that specifically develop in obese ZSF1 rats. 
 
Increased proliferation, fibrosis and AGTR1 expression in vascular foci of obese ZSF1 rats 
The large number of vascular cells in the foci point toward increased endothelial cell 
proliferation. We used a combination of lectin and Ki67 staining to assess the number of 
proliferating endothelial cells. In the foci of obese ZSF1 rats, lectin+ ECs were enriched in 
nuclear Ki67 signals when compared with the surrounding tissue that displayed a regular 
organization of microvascular network (Figure 4A and 4C). These results were verified using 
a second JG12/Ki67 staining combination, which demonstrated a similar preferential signal 
of Ki67 in JG12+ ECs located in the foci (Figure 4B and 4D). 
Fibrogenic activity in these foci was investigated by histological PAS examination, a staining 
method that is often used to detect extracellular deposition of (vascular) basal membrane 
glycoproteins. Extracellular fibril-like Periodic acid-Schiff+ structures were detected in 
between vascular cells located in the foci, pointing toward active glycoprotein deposition 
(cross-section of WKY rats compared with obese ZSF1 foci at 25 weeks; Figure 5A–5F). 
Double staining for lectin+ ECs and fibronectin showed limited deposition of these early 
fibrosis-associated extra cellular matrix components in the regular capillary network of WKY 
and lean ZSF1 rats (Figure 5G). In contrast, fibronectin deposition was increased in the 
subendocardial foci of obese ZSF1 rats, and in the vascular network surrounding these foci 
(Figure 5G and 5H). Double staining for PDGFRβ+ pericytes and collagen IV, a vascular 
basal membrane component predominantly produced by vascular cells, showed robust 
collagen IV deposition in the regular capillary network of WKY and lean ZSF1 rats (Figure 
5I). Similarly, collagen IV was detected in the PDGFRβ+ foci and direct surrounding 
capillaries of obese ZSF1 rats (Figure 5I and 5J).  
Activation of the renin–angiotensin–aldosterone system (RAAS) may contribute to CRMS 
and HFpEF development in the obese ZSF1 animals. Immunostaining for AGTR1, the 
angiotensin II receptor most associated with cardiac hypertrophy, VSMC hyperproliferation, 
and vascular constriction, showed increased expression of AGTR1 by cardiomyocytes and 
interstitial perivascular cells in obese ZSF1 rats versus WKY and lean ZSF1 control rats in 
areas outside the vascular foci (Figure 5K and 5L). AGTR1 was highly expressed by both 
lectin+ ECs and perivascular cells in the obese ZSF1-specific vascular foci (Figure 5M).  
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Figure 3: Subendocardial foci in obese ZSF1 rats are enriched with NG2+ and PDGFRβ+ 
pericytes. (A) Representative LV cross-sections of WKY and obese ZSF1 rats at 25 weeks of age, 
stained for NG2+ pericytes (green signal) and lectin+ endothelium (red signal). (B) High magnification 
detail showing disorganized clusters of lectin+ ECs and NG2+ pericytes in the subendocardial foci of 
obese ZSF1 rats. Arrows indicate lectin+ vascular structures with open lumens. (C) Representative LV 
cross-sections of WKY and obese ZSF1 rats at 25 weeks of age, stained for JG12+ endothelium (green  
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◄ signal), and PDGFRβ+ pericytes (red signal). Cell nuclei are stained with DAPI (blue signal). High 
magnification detail panels showing (D) clusters of disorganized JG12+ ECs and PDGFRβ+ pericytes in 
subendocardial foci of obese ZSF1 rats, (E) typical organization of the microcapillary bed at the 
subendocardial location of WKY rats, (F) increase of PDGFRβ+ pericyte coverage of the JG12+ 
microcapillary bed directly surrounding the subendocardial foci of obese ZSF1 rats. (G) Quantification of 
the number of subendocardial foci per heart cross-section, determined by NG2 and PDGFRβ+ staining 
in WKY, lean and obese ZSF1 rats at 20 and 25 weeks of age. Mean±SD. *P<0.05, **P<0.01. 
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Vascular foci of obese ZSF1 rats are enriched for circulating immune cells 
To assess whether inflammatory cells contribute to the fibrogenic process, double staining 
for lectin+ ECs and CD3+ T cells was conducted. Perivascular CD3+ T cells were absent in 
the microvascular bed of WKY and lean ZSF1 rats (Figure 6A). In contrast, perivascular 
CD3+ T cells were detected in limited numbers in obese ZSF1 rats in the vascular foci, 
whereas the remaining capillary network showed no CD3+ T-cell recruitment. Similarly, 
double staining for lectin+ ECs and ED1+ macrophages showed an absence of perivascular 
macrophages in capillary networks of WKY and lean ZSF1 rats, whereas in obese ZSF1 
rats, ED1+ macrophages accumulated in the subendocardial foci, indicating active 
recruitment of circulating immune cells at these sites (Figure 6B). 
 
 
Figure 4: Subendocardial foci in obese ZSF1 rats are sites of increased endothelial cell 
proliferation. Representative images of subendocardial foci of obese ZSF1 rats at 25 weeks of age, 
stained for (A) lectin+ endothelium (red signal) and Ki67 cell proliferation marker (green signal), and (B) 
JG12+ endothelium (green signal), and Ki67 (red signal). Cell nuclei are stained with DAPI (blue signal). 
High magnification detail panels showing (C) lectin-Ki67 staining and (D) JG12-Ki67 staining. 
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Figure 5: Onset of fibrosis at the subendocardial foci of obese ZSF1 rats. Representative PAS–
stained LV cross-sections of WKY and obese ZSF1 rats at 25 weeks of age. (A) Extra cellular matrix 
(ECM) glycoprotein deposition in the interstitial space between cardiomyocytes in WKY. (B-D) 
Accumulation of ECM glycoprotein in subendocardial foci of obese ZSF1 rats. (E-F) High magnification 
detail showing PAS signal distribution in subendocardial foci of obese ZSF1 rats. (G) Representative LV 
cross-sections of WKY and obese ZSF1 rats at 25 weeks of age, stained for ECM fibronectin (green 
signal) and lectin+ endothelium (red signal) at low magnification (left panel in each row) and at high 
magnification (remaining panels). (H) Representative example of overlap between fibronectin and 
lectin+ endothelial distribution in subendocardial foci of obese ZSF1 rats at low (top) and high 
magnification (bottom). (I) Cross-sections of the LVs of WKY and obese ZSF1 rats at 25 weeks, stained 
for vascular basal membrane collagen IV (green signal) and PDGFRß+ pericytes/mural cells (red signal) 
at low magnification (left panel in each row) and at high magnification (remaining panels). (J) 
Representative example of overlap between fibronectin and lectin+ endothelial distribution in 
subendocardial foci of obese ZSF1 rats at low (top) and high magnification (bottom). Increased 
expression of AGTR1 by cardiomyocytes and subendothelial foci of obese ZSF1 rats. (K) 
Representative LV stainings of WKY, lean and obese ZSF1 rats at 20 weeks of age, double stained for 
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◄ lectin+ endothelium (red signal), and AGTR1+ cells (green signal). Cell nuclei are stained with DAPI 
(blue signal). (L) Quantified results depicting the AGTR1+ areas in WKY, lean and obese ZSF1 rats at 
20 weeks of age. Mean±SD. *P<0.05. (M) Representative example of overlap between AGTR1 (green 
signal) and lectin+ endothelial (red signal) distribution in subendocardial foci of obese ZSF1 rats. Cell 
nuclei are stained with DAPI (blue signal). 
 
Figure 6: Recruitment 
of circulatory immune 
cells at subendocardial 
foci of obese ZSF1 
rats. Representative LV 
stainings of WKY and 
obese ZSF1 rats at 25 
weeks of age, double 
stained for (A) lectin+ 
endothelium (red signal) 
and CD3+ T cells (green 
signal), and (B) lectin+ 
endothelium (red signal) 
and ED1+ macrophages 
(green signal) at low 
magnification (left panel 
in each row) and at 
higher magnification 
(remaining panels). Cell 
nuclei are stained with 
DAPI (blue signal). 
 
 
Decline of renal function in obese ZSF1 rats 
Compared with WKY rats, plasma creatinine was not elevated in lean and obese ZSF1 rats 
at 20 and 25 weeks, whereas plasma urea levels were only slightly increased at 20 weeks. 
At 20 and 25 weeks, a 9- and 38-fold increase in protein/creatinine ratio was observed, 
respectively, in obese ZSF1 rats compared with WKY rats (P<0.001; Table 4). Similarly, at 
20 and 25 weeks, a 6- and 37-fold increase in protein/creatinine ratio was observed in obese 
ZSF1 rats compared with lean ZSF1 rats (P<0.001; Table 4). Oxidative stress, measured by 
TBARS, was increased in obese ZSF1 rats compared with WKY and  lean ZSF1 rats at both 
time points (P<0.001; Table 4). No differences in protein/creatinine and TBARS/creatinine 
ratio were observed between WKY and lean ZSF1 rats.  
Distinct cardiac- and renal microvascular responses characterize HFpEF progression in obese ZSF1 rats 
107 
 
Plasma
   Creatinine (μmol/L) 36.1 ± 1.9 28.3 ± 8.9 21.1 ± 5.5* 34.2 ± 8.7 36.0 ± 8.5 22.4 ± 7.6†
   Urea (mmol/L) 4.1 ± 0.2 5.3 ± 0.7* 6.3 ± 1.0* 7.3 ± 1.1‡ 6.7 ± 0.5‡ 5.9 ± 0.7*
Urine
   Protein/creatinine ratio 119 ± 17 181 ± 9 1086 ± 871† 126 ± 8 130 ± 5 4774 ± 239†
   TBARS/creatinine ratio 4.1 ± 0.2 3.8 ± 0.6 19.3 ± 15.1† 3.0 ± 0.1 2.3 ± 0.1 49.7 ± 8.5†
ZSF1 ob 25wksWKY 20wks ZSF1 ln 20wks ZSF1 ob 20wks WKY 25wks ZSF1 ln 25wks
Tabel 4: Biochemical variables for WKY, lean and obese ZSF1 rats 
 
 
 
 
 
 
 
Two-way ANOVA with Student–Newman–Keuls post hoc test. Plasma sample size; n=3 to 6 animals per group at 20 
weeks. n=5 to 6 animals per group at 25 weeks. Urine plasma size; n=2 to 4 animals per group at 20 weeks. n=4 
animals per group at 25 weeks. Values are mean±SD. TBARS indicates thiobarbituric acid reactive substance; and 
WKY, Wistar Kyoto. ‡P<0.05 vs week 20; *P<0.05 vs WKY 20 or 25; †P<0.05 vs WKY and ZSF1 Ln 20 or 25. 
 
Degradation of renal endothelium and progressive glomerulosclerosis in obese ZSF1 rats 
The highest chronic TI damage and glomerulosclerosis scores were measured in obese 
ZSF1 rats compared with WKY and lean ZSF1 rats at 20 and 25 weeks of age (Figure 7A 
and 7B). Compared with WKY rats, glomerulosclerosis was increased in lean ZSF1 rats 
(11±5 versus 23±5 and 13±5 versus 24±5, P<0.05). With age glomerulosclerosis increased 
in obese ZSF1 rats (39±10 versus 53±14, P<0.01). Peritubular and glomerular endothelium 
were visualized on JG12-stained slides (Figure 8A). Compared with WKY and lean ZSF1 
rats, the percentage of peritubular and glomerular endothelium decreased in obese ZSF1 
rats (Figure 8B and 8C). 
 
 
Discussion 
The main findings of this study are (1) the obese ZSF1 rat strain is a suitable in vivo model 
for CRMS, sharing characteristics with the human syndrome during the earliest onset of 
disease, (2) in obese ZSF1 rats, CRMS induces microvascular fibrotic responses in heart 
and kidneys, associated with functional impairment of both organs. 
 
Humans with metabolic derangements such as obesity, hypertension, hyperglycemia, and 
dyslipidemia—all recognized as important risk factors for CKD and cardiovascular disease24, 
25—often present with preclinical diastolic dysfunction26, diastolic heart failure, or HFpEF.27, 
28 In current and previous reports, we could validate that the obese ZSF1 rats share these 
characteristics with patients with metabolic syndrome2: obese ZSF1 rats are obese (65% 
and 45% increase compared with WKY and lean ZSF1 rats, respectively, Table  
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Figure 7: Increase in TI damage and glomerulosclerosis in the kidneys of obese ZSF1 rats 
compared with lean ZSF1 rats and WKY rats. TI damage (A) and glomerulosclerosis (B) scores for 
WKY, lean and obese ZSF1 rats at 20 and 25 weeks of age. Mean±SD. *P<0.05, **P<0.01, ***P<0.001. 
 
 
 
Figure 8: Rarefaction of the peritubular and glomerular vasculature in obese ZSF1 rats. (A) 
Representative images of JG12-stained renal sections from lean ZSF1 and obese ZSF1 rats. Quantified 
results depicting the JG12+ endothelial area (%) in the (B) peritubular and (C) glomerular vasculature 
determined in WKY, lean and obese ZSF1 rats at 20 and 25 weeks of age. Mean±SD. *P<0.05, 
**P<0.01, ***P<0.001. 
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1), hypertensive (46% and 19% increase in mean blood pressure compared with WKY and 
lean ZSF1 rats, Supplemental Table 2), and show elevated fasting plasma glucose levels 
(65% and 45% increase compared with WKY and lean ZSF1 rats, respectively)9, whereas 
other studies have reported hypertriglyceridemia (increase of >25-fold) and 
hypercholesterolemia (increase of >5-fold) in obese versus lean ZSF1 rats.10, 29 
Furthermore, CRMS in humans is defined by the presence of metabolic syndrome in 
addition to insulin resistance, microalbuminurina, and reduced renal function.13 Current and 
previous findings demonstrate that obese ZSF1 rats develop proteinuria from 10 weeks 
onwards, whereas early signs of HFpEF were detected from 14 weeks onwards.9 Similarly at 
10 weeks, increased oral glucose tolerance and insulin resistance, glycosuria and significant 
weight gain can be detected.9 These observations indicate that the presentation of metabolic 
risk factors accompanies the onset of renal dysfunction (signified by proteinuria) and 
precedes HFpEF development in obese ZSF1 rats, which is consistent with a 
pathophysiological course of CRMS in obese ZSF1 rats, in which metabolic and renal 
complications induce cardiac dysfunction.18 On the basis of these combined data, we 
therefore propose obese ZSF1 rats as a small animal model for metabolic syndrome–
induced CRS (and thus CRMS), in which the combined metabolic risk factors act together to 
trigger early onset and progression of CKD and HF, creating the downward spiral of disease 
progression that is so typical for patients with chronic CRS.10 
 
CRMS was first suggested as a disease entity in 2004.30 Already in this first publication, a 
relation with endothelial dysfunction was proposed.30 Endothelial injury is implicated in 
CRS20, whereas in HFpEF patients, vascular changes represented by endothelial 
dysfunction have been reported.31 A direct link between heart failure, vascular activation, 
metabolic comorbidities, and CKD was presented by Shestakova et al., who demonstrated a 
correlation between endothelial dysfunction and the hallmarks of HF in CRS patients with 
type 1 diabetes mellitus.19 In line with these studies, our data show changes in the coronary 
microvascular bed of obese ZSF1 rats: endothelial and mural cells form atypical vascular 
patches of cells, with remarkable increases in proliferation rate. Not only do these structures 
lack functional organization, they also seem to act as origin sites of fibrosis, for we could 
demonstrate enriched deposition of fibrosis-associated extra cellular matrix components 
such as fibronectin and collagen type IV in these vascular foci. 
 
In CRS rat models that use subtotal nephrectomy in combination with coronary ligation to 
initiate ischemic heart disease, a decrease in LV microvascular density was reported to be 
associated with systolic dysfunction.32, 33 Other clinical and experimental studies provide 
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evidence that coronary microvascular rarefaction in diastolic and hypertrophic heart failure 
promotes tissue hypoxia, cell death, and fibrosis, all contributing to the progression from 
compensated hypertrophy to contractile dysfunction.34, 35 In adults, vascular proliferation is 
part of the compensatory and repair response to local hypoxia and tissue damage in which 
endothelial cells proliferate and migrate into the ischemic injury site during macrophage 
influx and phagocytosis of necrotic tissue. As repair proceeds, dead tissue is replaced by 
granulation tissue, characterized by the deposition of a provisional matrix enriched in 
glycoproteins and fibronectin.36, 37 The vascular foci that developed in obese ZSF1 rats 
resembled this process of scar formation with excessive endothelial cell proliferation, 
fibronectin deposition, and local recruitment of macrophages. 
 
Vascular cells in the foci contribute to the formation of granulation matrix, demonstrated by 
deposition of the typical vascular basal membrane component collagen type IV. Collagen 
type IV is predominantly produced by pericytes and not by fibroblasts, as shown by 
quantitative polymerase chain reaction using in vitro human primary vascular cell types 
(Supplemental Figure 1B). 
 
Extensive myocardial fibrosis is one of the hallmarks of CRMS. Previously, we reported that 
at 20 weeks, cardiac hypertrophy was increased in obese ZSF1 rats versus WKY and lean 
ZSF1 rats, but overall levels of myocardial fibrosis remained comparable between groups.9 
In contrast, glomerulosclerosis score in the kidneys (Figure 8B) was significantly increased 
in obese ZSF1 rats versus WKY and lean ZSF1 rats. Thus, the effect of metabolic risk 
factors on kidney fibrosis seems to precede the effects on fibrosis in the myocardium in the 
obese ZSF1 rats. In this study, we could demonstrate that onset of fibrosis is present in the 
subendocardial vascular foci at 20 and 25 weeks in obese ZSF1 rats. This was 
accompanied by vascular inflammation, yet another hallmark of CRMS. 
 
On the basis of our observations to date, we hypothesize that the hyperproliferative vascular 
reaction in the heart of obese ZSF1 rats is part of a destructive response that leads to 
replacement of functional vascular structures by fibrotic tissue with semi and nonfunctional 
microvascular clusters, which may ultimately deteriorate into large fibrotic areas that are 
completely devoid of vascular support, in line with the previously reported vascular 
rarefaction phenotype. Additional studies are planned to further elucidate this highly dynamic 
process and to validate if microvascular hyperproliferation of pre-existing vessels indeed 
precedes fibrogenesis and vascular rarefaction in CRMS. 
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Potential impact of current findings on the field of CRMS research 
Chronic CRS type 2, which is initiated by chronic cardiac dysfunction (such as congestive 
HF), and type 4, initiated by chronic renal dysfunction (resulting in LV hypertrophy and 
diastolic HF), are currently under-recognized syndromes in the cardiovascular research 
community in comparison with acute CRS types. This is largely because of the lack of a 
suitable animal model to mimic the human condition. However, the population of patients 
with chronic types of CRS is substantial: in adult patients with congestive HF, it has been 
reported that 31% of NYHA III and 39% of NYHA IV patients had renal dysfunction.38 Recent 
findings presented in the PREVEND study also showed that early onset of renal dysfunction, 
indicated by albuminuria, is a strong predictor for new onset of HFpEF, but not HFrEF.39 
Others have also demonstrated that the prevalence of LV hypertrophy is significantly 
increased in patients with CKD from mild renal impairment onwards.40 These findings are 
consistent with the concept that the synergy between renal and cardiac dysfunction is a 
driving factor in the early disease onset of HFpEF. An improved understanding of the 
disease mechanism of, in particular, chronic CRS would greatly aid in the development of 
new diagnostic and treatment options that are specifically targeted to this large subgroup of 
cardiac and renal patients. 
 
The obese ZSF1 strain presents a suitable model to investigate the contribution of different 
disease pathways to CRMS, as the disease course resembles the onset phase of chronic 
CRS within the first 10 to 25 weeks of the animals’ lifespan. In particular, studies that 
investigate the relationship between metabolic risk factors and endothelial dysfunction could 
shed further light on the contribution of vascular injury to HF in chronic CRMS. 
 
Limitations of this study 
The obese ZSF1 model described in this article is not suitable for studying type 1 and type 3 
CRS because these forms require acute cardiac and renal failure to adequately mimic the 
human conditions, and may involve different disease mechanisms compared with the 
chronic forms (see review of disease pathogeneses of CRS subtypes).18 A more suitable 
model for acute CRS would be surgical induction methods for myocardial infarction such as 
coronary ligation, and subtotal nephrectomy for severe renal dysfunction. Previous studies 
have indicated that a dual injury model to heart and kidneys is needed to produce a more 
robust acceleration of renal failure and heart failure with reduced ejection fraction that are 
typical for acute CRS.41, 42 However, the causal relationship between metabolic risk factors 
and chronic CRS can be better studied in the ZSF1 model, as this would best imitate the 
natural course of the disease in patients with chronic CRS. The addition of obese ZSF1 rats 
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to our arsenal of animal models for CRS will greatly expand our means to adequately study 
mechanisms in the earliest phases of disease. 
 
In addition to the proposed mechanism of vascular fibrosis–mediated CRMS, other disease 
mechanisms could trigger CRS, including low-cardiac output leading to impaired renal 
perfusion, which vice versa leads to kidney-mediated RAAS and sympathetic activation. 
Initial renal dysfunction could also induce chronic CRS via RAAS and sympathetic 
activation, in addition to Na+ and H2O overload, hypertension, accumulation of uremic toxins 
and calcium and phosphate abnormalities that all contribute to cardiovascular complications. 
Furthermore, renal impairment and subsequent dysregulation of erythropoietin contributes to 
anemia, which further aggravate hypoxia in both organs.18 In this study, we have not 
specifically assessed the contribution of these mechanisms to CRS development in the 
obese ZSF1 model. However, cardiac output represented by the indexed cardiac output 
(cardiac index, in Table 3) is similar between the 3 groups at both time points assessed. In 
addition, obese ZSF1 rats are indeed hypertensive, and expression of AGTR1, the main 
receptor for RAAS-mediated effects on the cardiovascular system, was increased in LV 
sections of the obese ZSF1 group, particularly at the vascular foci. Further systematic 
evaluation will help identify for which specific pathological mechanisms of chronic CRS, the 
ZSF1 strain is a suitable research model. 
 
In conclusion, this study demonstrates that the obese ZSF1 rat is a suitable in vivo model for 
CRMS, sharing many characteristics with the human CRS during the earliest onset of the 
disease, as triggered and mediated by metabolic risk factors. Further studies in the classic 
pathways of CRMS using this ZSF1 model will enhance our understanding of the 
contribution of microvascular and metabolic changes during the onset of CRMS. 
  
Distinct cardiac- and renal microvascular responses characterize HFpEF progression in obese ZSF1 rats 
113 
 
References 
1. Forman, DE, Butler, J, Wang, Y, Abraham, WT, O'Connor, CM, Gottlieb, SS, Loh, E, Massie, BM, 
Rich, MW, Stevenson, LW, Young, JB, Krumholz, HM: Incidence, predictors at admission, 
and impact of worsening renal function among patients hospitalized with heart failure. J Am 
Coll Cardiol, 43: 61-67, 2004. 
2. Grundy, SM, Brewer, HB, Jr., Cleeman, JI, Smith, SC, Jr., Lenfant, C, American Heart, A, National 
Heart, L, Blood, I: Definition of metabolic syndrome: Report of the National Heart, Lung, and 
Blood Institute/American Heart Association conference on scientific issues related to 
definition. Circulation, 109: 433-438, 2004. 
3. Raimundo, M, Lopes, JA: Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a 
dynamic and life-threatening triad. Cardiol Res Pract, 2011: 747861, 2011. 
4. Galassi, A, Reynolds, K, He, J: Metabolic syndrome and risk of cardiovascular disease: a meta-
analysis. Am J Med, 119: 812-819, 2006. 
5. Gami, AS, Witt, BJ, Howard, DE, Erwin, PJ, Gami, LA, Somers, VK, Montori, VM: Metabolic 
syndrome and risk of incident cardiovascular events and death: a systematic review and 
meta-analysis of longitudinal studies. J Am Coll Cardiol, 49: 403-414, 2007. 
6. Kurella, M, Lo, JC, Chertow, GM: Metabolic syndrome and the risk for chronic kidney disease among 
nondiabetic adults. J Am Soc Nephrol, 16: 2134-2140, 2005. 
7. Whaley-Connell, A, Pavey, BS, McCullough, PA, Saab, G, Li, S, McFarlane, SI, Chen, SC, Vassalotti, 
JA, Collins, AJ, Bakris, G, Sowers, JR, Investigators, K: Dysglycemia predicts cardiovascular 
and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich), 
12: 51-58, 2010. 
8. Bongartz, LG, Braam, B, Gaillard, CA, Cramer, MJ, Goldschmeding, R, Verhaar, MC, Doevendans, 
PA, Joles, JA: Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol 
Renal Physiol, 303: F1253-1263, 2012. 
9. Hamdani, N, Franssen, C, Lourenco, A, Falcao-Pires, I, Fontoura, D, Leite, S, Plettig, L, Lopez, B, 
Ottenheijm, CA, Becher, PM, Gonzalez, A, Tschope, C, Diez, J, Linke, WA, Leite-Moreira, AF, 
Paulus, WJ: Myocardial titin hypophosphorylation importantly contributes to heart failure with 
preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail, 6: 1239-1249, 2013. 
10. Bilan, VP, Salah, EM, Bastacky, S, Jones, HB, Mayers, RM, Zinker, B, Poucher, SM, Tofovic, SP: 
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese 
ZSF1 rats. J Endocrinol, 210: 293-308, 2011. 
11. Griffin, KA, Abu-Naser, M, Abu-Amarah, I, Picken, M, Williamson, GA, Bidani, AK: Dynamic blood 
pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. Am J Physiol 
Renal Physiol, 293: F1605-1613, 2007. 
12. Leite, S, Oliveira-Pinto, J, Tavares-Silva, M, Abdellatif, M, Fontoura, D, Falcao-Pires, I, Leite-
Moreira, AF, Lourenco, AP: Echocardiography and invasive hemodynamics during stress 
testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. 
Am J Physiol Heart Circ Physiol, 308: H1556-1563, 2015. 
13. Sowers, JR, Whaley-Connell, A, Hayden, MR: The Role of Overweight and Obesity in the 
Cardiorenal Syndrome. Cardiorenal Med, 1: 5-12, 2011. 
14. André, PL, Inês, F-P, Rui, C, Dulce, F, Daniela, M, Nazha, H, Walter, P, Adelino, FL-M: Abstract 
17471: The Obese Zsf1 Rat as a New Model of Heart Failure with Preserved Ejection 
Fraction Accompanying the Metabolic Syndrome. Circulation, 126: A17471-A17471, 2012. 
15. Westermann, D, Lindner, D, Kasner, M, Zietsch, C, Savvatis, K, Escher, F, von Schlippenbach, J, 
Skurk, C, Steendijk, P, Riad, A, Poller, W, Schultheiss, HP, Tschope, C: Cardiac inflammation 
contributes to changes in the extracellular matrix in patients with heart failure and normal 
ejection fraction. Circ Heart Fail, 4: 44-52, 2011. 
16. van Heerebeek, L, Hamdani, N, Falcao-Pires, I, Leite-Moreira, AF, Begieneman, MP, Bronzwaer, 
JG, van der Velden, J, Stienen, GJ, Laarman, GJ, Somsen, A, Verheugt, FW, Niessen, HW, 
Paulus, WJ: Low myocardial protein kinase G activity in heart failure with preserved ejection 
fraction. Circulation, 126: 830-839, 2012. 
17. Paulus, WJ, Tschope, C: A novel paradigm for heart failure with preserved ejection fraction: 
comorbidities drive myocardial dysfunction and remodeling through coronary microvascular 
endothelial inflammation. J Am Coll Cardiol, 62: 263-271, 2013. 
18. Ronco, C, Haapio, M, House, AA, Anavekar, N, Bellomo, R: Cardiorenal syndrome. J Am Coll 
Cardiol, 52: 1527-1539, 2008. 
19. Shestakova, MV, Jarek-Martynowa, IR, Ivanishina, NS, Kuharenko, SS, Yadrihinskaya, MN, 
Aleksandrov, AA, Dedov, II: Role of endothelial dysfunction in the development of cardiorenal 
Chapter 4 
114 
 
syndrome in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract, 68 Suppl1: S65-
72, 2005. 
20. Hatamizadeh, P, Fonarow, GC, Budoff, MJ, Darabian, S, Kovesdy, CP, Kalantar-Zadeh, K: 
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat 
Rev Nephrol, 9: 99-111, 2013. 
21. Karnib, HH, Ziyadeh, FN: The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract, 
89: 201-208, 2010. 
22. Leite-Moreira, AF, Correia-Pinto, J: Load as an acute determinant of end-diastolic pressure-volume 
relation. Am J Physiol Heart Circ Physiol, 280: H51-59, 2001. 
23. van Dijk, CG, Nieuweboer, FE, Pei, JY, Xu, YJ, Burgisser, P, van Mulligen, E, el Azzouzi, H, 
Duncker, DJ, Verhaar, MC, Cheng, C: The complex mural cell: pericyte function in health and 
disease. Int J Cardiol, 190: 75-89, 2015. 
24. Hall, JE, Crook, ED, Jones, DW, Wofford, MR, Dubbert, PM: Mechanisms of obesity-associated 
cardiovascular and renal disease. Am J Med Sci, 324: 127-137, 2002. 
25. Cohen, JB, Cohen, DL: Cardiovascular and renal effects of weight reduction in obesity and the 
metabolic syndrome. Curr Hypertens Rep, 17: 34, 2015. 
26. Correa de Sa, DD, Hodge, DO, Slusser, JP, Redfield, MM, Simari, RD, Burnett, JC, Chen, HH: 
Progression of preclinical diastolic dysfunction to the development of symptoms. Heart, 96: 
528-532, 2010. 
27. Afshinnia, F, Spitalewitz, S, Chou, SY, Gunsburg, DZ, Chadow, HL: Left ventricular geometry and 
renal function in hypertensive patients with diastolic heart failure. Am J Kidney Dis, 49: 227-
236, 2007. 
28. Ahmed, A, Rich, MW, Sanders, PW, Perry, GJ, Bakris, GL, Zile, MR, Love, TE, Aban, IB, Shlipak, 
MG: Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a 
propensity matched study. Am J Cardiol, 99: 393-398, 2007. 
29. Tofovic, SP, Kusaka, H, Kost, CK, Jr., Bastacky, S: Renal function and structure in diabetic, 
hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail, 22: 387-406, 2000. 
30. El-Atat, FA, Stas, SN, McFarlane, SI, Sowers, JR: The relationship between hyperinsulinemia, 
hypertension and progressive renal disease. J Am Soc Nephrol, 15: 2816-2827, 2004. 
31. Akiyama, E, Sugiyama, S, Matsuzawa, Y, Konishi, M, Suzuki, H, Nozaki, T, Ohba, K, Matsubara, J, 
Maeda, H, Horibata, Y, Sakamoto, K, Sugamura, K, Yamamuro, M, Sumida, H, Kaikita, K, 
Iwashita, S, Matsui, K, Kimura, K, Umemura, S, Ogawa, H: Incremental prognostic 
significance of peripheral endothelial dysfunction in patients with heart failure with normal left 
ventricular ejection fraction. J Am Coll Cardiol, 60: 1778-1786, 2012. 
32. Windt, WA, Henning, RH, Kluppel, AC, Xu, Y, de Zeeuw, D, van Dokkum, RP: Myocardial infarction 
does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant, 23: 
3103-3110, 2008. 
33. Dikow, R, Schmidt, U, Kihm, LP, Schaier, M, Schwenger, V, Gross, ML, Katus, HA, Zeier, M, Hardt, 
SE: Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol, 
32: 13-22, 2010. 
34. Mohammed, SF, Hussain, S, Mirzoyev, SA, Edwards, WD, Maleszewski, JJ, Redfield, MM: 
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved 
ejection fraction. Circulation, 131: 550-559, 2015. 
35. Oka, T, Akazawa, H, Naito, AT, Komuro, I: Angiogenesis and cardiac hypertrophy: maintenance of 
cardiac function and causative roles in heart failure. Circ Res, 114: 565-571, 2014. 
36. Frangogiannis, NG, Smith, CW, Entman, ML: The inflammatory response in myocardial infarction. 
Cardiovasc Res, 53: 31-47, 2002. 
37. Virag, JI, Murry, CE: Myofibroblast and endothelial cell proliferation during murine myocardial infarct 
repair. Am J Pathol, 163: 2433-2440, 2003. 
38. McAlister, FA, Ezekowitz, J, Tonelli, M, Armstrong, PW: Renal insufficiency and heart failure: 
prognostic and therapeutic implications from a prospective cohort study. Circulation, 109: 
1004-1009, 2004. 
39. Brouwers, FP, de Boer, RA, van der Harst, P, Voors, AA, Gansevoort, RT, Bakker, SJ, Hillege, HL, 
van Veldhuisen, DJ, van Gilst, WH: Incidence and epidemiology of new onset heart failure 
with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up 
of PREVEND. Eur Heart J, 34: 1424-1431, 2013. 
40. Greaves, K, Chen, R, Ge, L, Wei, M, Tong, B, Cai, N, Senior, R, Hemingway, H: Mild to moderate 
renal impairment is associated with increased left ventricular mass. Int J Cardiol, 124: 384-
386, 2008. 
41. van Dokkum, RP, Eijkelkamp, WB, Kluppel, AC, Henning, RH, van Goor, H, Citgez, M, Windt, WA, 
van Veldhuisen, DJ, de Graeff, PA, de Zeeuw, D: Myocardial infarction enhances progressive 
Distinct cardiac- and renal microvascular responses characterize HFpEF progression in obese ZSF1 rats 
115 
 
renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol, 15: 
3103-3110, 2004. 
42. Bongartz, LG, Joles, JA, Verhaar, MC, Cramer, MJ, Goldschmeding, R, Tilburgs, C, Gaillard, CA, 
Doevendans, PA, Braam, B: Subtotal nephrectomy plus coronary ligation leads to more 
pronounced damage in both organs than either nephrectomy or coronary ligation. Am J 
Physiol Heart Circ Physiol, 302: H845-854, 2012. 
 
  
Chapter 4 
116 
 
Supplemental data 
 
Supplemental Figure 1: NG2, PDGFRß, and COL4 expression in human vascular cell types. (A) 
Representative immunofluorescent staining of mural cells derived from human origin (pericytes and 
VSMCs) and HUVECs. NG2 (red), PDGFRß (green), and nuclei (blue). 20X magnification. (B) QPCR 
analysis of COL4a1 and COL4a2 expression levels in human derived vascular cells and fibroblasts. 
n=3, Mean±SD. ***P<0.001 versus all. 
 
Supplemental Tables can be downloaded from: 
http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.115.0
02760/-/DC1 
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Abstract 
Obesity and hypertension are prevalent comorbidities in heart failure with preserved ejection 
fraction. It has been proposed that they act synergistically in development of heart failure. To 
clarify if and how this putative interaction contributes to development of diastolic dysfunction, 
lean and obese ZSF1 rats were treated with placebo, or deoxycorticosterone acetate 
implants plus 6% salt (DS) to induce sever hypertension. In addition to echocardiographic, 
metabolic, and hemodynamic analyses, immunohistochemistry and RNAseq were 
performed on left ventricles. Obesity lowered cardiac output and led to elevated E/e’ ratios. 
DS did not affect cardiac output and minimally elevated E/e’ ratios. Diastolic derangements 
in placebo-treated obese rats developed in absence of inflammation and fibrosis, yet in 
presence of oxidative stress and hypertrophic remodeling. In contrast, hypertension 
triggered apoptosis, inflammation, and fibrosis, with limited synergy of the comorbidities 
observed for inflammation and fibrosis. Transcriptional data suggested that these 
comorbidities exerted opposite effects on mitochondrial function. In placebo-treated obese 
rats, genes involved in fatty acid metabolism were upregulated, whereas DS induced a 
downregulation of genes involved in oxidative phosphorylation. Overall, limited interaction 
was observed between these comorbidities in development of diastolic dysfunction. 
Importantly, differences in comorbidity-induced cardiac remodeling emphasize the necessity 
for thorough phenotypical characterization. 
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Introduction 
The chronic and progressive condition, in which the heart is unable to maintain cardiac 
output commensurate with the body’s requirements, is referred to as heart failure (HF). 
Based on ejection fraction, HF can be divided into HF with reduced ejection fraction 
(HFrEF), marked by the inability to adequately contract during systole, and HF with 
preserved ejection fraction (HFpEF). HFpEF is associated with impaired cardiac relaxation 
and increased passive cardiac stiffness, resulting in elevated end-diastolic pressure and 
impaired left ventricle (LV) filling.1 HFpEF accounts for over 50% of all HF cases in Europe 
and the United States of America, yet currently no effective treatment is available for this 
specific form of HF.1  
This lack of evidence-based treatment options might find its origin in the complex, 
multifactorial disease etiology of HFpEF. Development and progression of HFpEF is 
associated with a high prevalence of non-cardiac comorbidities and in previous studies it 
was proposed that these comorbidities could provoke a state of chronic systemic 
inflammation, leading to coronary microvascular dysfunction, oxidative stress, enhanced 
cardiomyocyte stiffness and myocardial fibrosis.2 Obesity and hypertension are both highly 
prevalent (84% and 60-80%, respectively) among HFpEF patients.3, 4 It has been 
demonstrated that both comorbidities can individually contribute to development of diastolic 
dysfunction in rodent models. For example, deoxycorticosterone acetate- and salt-induced 
hypertensive rats developed perivascular fibrosis, and concentric cardiac hypertrophy 
accompanied by diastolic dysfunction in addition to hypertension.5, 6 Similarly, in leptin-
deficient murine obesity models, ob/ob mice were shown to develop concentric cardiac 
remodeling with increased cardiomyocyte size and diastolic dysfunction7, 8, secondary to 
obesity and type 2 diabetes.9 Importantly, it is estimated that at least 75% of the incidence of 
hypertension in the human population is related to obesity10, and both comorbidities thus 
often present together. The current consensus is that metabolic- and hypertensive disease, 
like other HFpEF-associated comorbidities, contribute to the systemic state of inflammation2, 
and as such, potentially act synergistically in development and progression of diastolic 
dysfunction. However, direct evidence for such a synergistic relation is lacking. More insight 
in the putative synergistic effects might not only provide a better understanding of the 
pathogenesis of HFpEF itself, but could also lead to novel insights in the poor performance 
of antihypertensive drug treatment alone in reducing morbidity or mortality in subsets of 
(obese) patients with HFpEF.11 
Here we tested the hypothesis that metabolic- and hypertensive disease act synergistically 
in development and/or progression of HFpEF. For this purpose, male lean and obese ZSF1 
rats, of which the latter were previously shown to develop diastolic dysfunction between 
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week 10 and 20 of natural aging12, 13, were studied from 12 weeks of age. Both lean and 
obese rats were treated with deoxycorticosterone acetate implants plus high salt diet (DS) or 
placebo from 19 to 26 weeks of age to induce severe hypertension. DS treatment was 
limited to this period to prevent progression to HFrEF. In addition to echocardiographic, 
metabolic, and hemodynamic analyses, immunohistochemistry and RNAseq on LV apex 
tissue was performed, which enabled us to dissect which pathophysiological and 
transcriptional adaptations were associated with obesity and its associated biochemical 
aberrations, and which with DS-induced hypertension. 
 
 
Methods 
Ethics 
All animal studies were approved by the Animal Ethics Committee of the University of 
Utrecht (CCD: AVD115002016462) and were in accordance with the Dutch Codes of 
Practice for the Care and Use of Animals for Scientific Purposes. Animal experiments were 
performed according to ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
guidelines. 
 
Animal Model 
Nine-week old male lean (n=13) and obese (n=13) ZSF1 rats were obtained from Charles 
River (Kingston, MA) and housed in a temperature- and humidity-controlled environment 
with a 12-hour light/dark cycle. Rats had access to water and standard chow (CRM-E; 
Special Diet Services, Witham, Essex, UK) ad libitum. Starting at 12 weeks until 26 weeks of 
age, systolic blood pressure (SBP) measurements via tail-cuff plethysmography were done 
every two weeks. At 12 weeks and every two weeks from 18 to 26 weeks of age 
echocardiography was performed, whereas body weight was measured every week. At 19 
weeks of age, lean and obese rats were randomized and either implanted with a 
deoxycorticosterone acetate pellet (35mg in lean, 50mg in obese; Innovative Research of 
America, Sarasota, Florida, USA) and fed a high salt diet (6% NaCl) or with a placebo pellet 
and fed a normal salt diet. At week 26, after the last measurements, the rats were 
terminated via exsanguination under deep anesthesia and organs were harvested and 
weighed (Figure 1A). 
 
Echocardiography Evaluation 
Rats were anesthetized with isoflurane (3.5-4% for induction and 2-2.5% for maintenance). 
Transthoracic echocardiography was performed with a digital ultrasound machine (model 
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Sonos 5500, Philips Research, Eindhoven, The Netherlands) and a 15-MHz linear array 
transducer (Hewlett Packard, Palo Alto, CA). The LV long-axis dimensions were recorded by 
2D-echocardiography. Two-dimensional B-mode cine loops were recorded in the parasternal 
long-axis and the midpapillary short-axis views. Mitral flow velocity tracings were obtained 
with pulsed-wave Doppler above the mitral leaflets. Tissue Doppler Imaging (TDI) was used 
to obtain early (e’) diastolic velocity at the medial mitral annulus. The recordings were 
averaged from 3 consecutive heartbeats.  
 
Plasma measurements 
Blood samples of 0.5 ml were drawn from the tail vein into EDTA anticoagulant-coated 
tubes, while the rats were under anesthesia. Plasma was extracted by centrifugation at 1500 
x g for 15 min at 4°C and used for determination of plasma glucose, cholesterol and 
triglycerides (DiaSys Diagnostic Systems GmbH, Cholesterol FS, Triglycerides FS, Glucose 
GOD FS, Waterbury, Connecticut, USA). 
 
Metabolic cage studies and TBARS measurements 
Rats were housed individually in metabolic cages with access to food and water for 24 hours 
to collect urine. In urine samples, thiobarbituric acid-reactive substances (TBARS; TBARS 
assay kit, Cayman Chemical, Ann Arbor, Michigan, USA) were measured according to 
manufacturer’s instructions. 
 
Immunohistochemistry 
Deparaffinized cardiac sections were subjected to 3% hydrogen peroxide in PBS for 30 min, 
followed by heat-induced antigen retrieval in citrate/HCl buffer (pH 6.0) for 15 min. To 
visualize capillaries, sections were first blocked in avidin and biotin blocking solution 
(Abcam, Cambridge, UK). Section were then incubated overnight at 4°C with biotin labelled 
anti-Lectin from Bandeiraea simplicifolia (1:200, Sigma, St. Louis, Missouri, USA), after 
which HRP-bound streptavidin (1:500, Bio-Rad, Veenendaal, the Netherlands) was added to 
the samples for 60 min. Finally, 3,3′-diaminobenzidine solution was applied to the sections 
twice, 6 min each. To visualize early apoptosis, sections were incubated for 60 min at room 
temperature (RT) with a primary antibody against active Caspase 3 (1:200, BD Biosciences, 
San Jose, California, USA), followed by 30 min incubation at RT with BrightVision PolyGoat-
HRP-anti-Rabbit IgG (Immunologic BV, Duiven, the Netherlands). To visualize innate 
inflammation, sections were incubated for 60 min at RT with a primary antibody against 
CD68 (1:500, Abcam), followed by 30 min incubation at RT with Poly-Rabbit-anti-Mouse 
(Abcam) and 30 min incubation at RT with BrightVision PolyGoat-HRP-anti-Rabbit IgG. To 
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visualize adaptive immunity, sections were first blocked in avidin and biotin blocking 
solution. Thereafter, sections were incubated for 60 min at RT with a primary antibody 
against CD3 (1:200, Abcam), followed by 30 min incubation at RT with BrightVision 
PolyGoat-HRP-anti-Rabbit IgG. For all immunostainings (with the exception of lectin), finally 
NovaRed buffer was applied to the sections for 10 min, and a counterstaining was 
performed via a brief dip in hematoxylin. Late apoptosis was fluorescently visualized in 
deparaffinized cardiac sections, which were incubated 30 min at 37°C in a 20µg/mL 
proteinase K solution in 10mM Tris/HCL buffer (pH 8.0). After a brief wash, TUNEL labeling 
solution (Sigma) was applied according to manufacturer’s instruction for 60 min at 37°C. 
Nuclei were counterstained with DAPI. For all immunostainings, four non-overlapping fields 
in the sub-endocardium were imaged and analyzed in a blinded fashion. 
 
Gomori staining 
Gomori staining was performed using the Reticulum Stain Kit (Diagnostic Biosystems, 
Pleasanton, California, USA) according to manufacturer’s instructions. Slides were 
counterstained for 3 min using Nuclear Fast Red, and imaged. Cross-sectional areas of 
cardiomyocytes with clearly visible nuclei, and height to width ratios not exceeding 1:2, were 
measured in 4 non-overlapping fields in a blinded fashion using Clemex software. 
 
Picrosirius red staining  
Deparaffinized cardiac sections were stained with Picro Sirius red (Sigma) for 25 min, 
differentiated in 0.2 HCl and rinsed with aquadest, followed by dehydration. Twenty non-
overlapping fields were imaged using a polarizing filter, followed by analysis in a blinded 
fashion using Adobe Photoshop and ImageJ software as described.14 
 
Identification of gene expression 
RNA sequencing was done as described.15 Briefly, RNA was isolated from the cardiac apex 
using the RNeasy isolation kit (Qiagen, Hilden, Germany). NEXTflex Poly(A) Beads 
(PerkinElmer Applied Genomics, Waltham, Massachusetts, USA) were used to isolate 
polyadenylated mRNA, from which sequencing libraries were made using the Rapid 
Directional RNA-seq kit (NEXTflex). Libraries were sequenced using the Nextseq500 
platform (Illumina, San Diego, California, USA), producing single end reads of 75bp. Reads 
were aligned to the rat reference genome. Picard’s AddOrReplaceReadGroups (v1.98) was 
used to add read groups to the BAM files, which were sorted with Sambamba v0.4.5 and 
transcript abundances were quantified with HTSeq-count version 0.6.1p1 using the union 
mode. Subsequently, RPKMs were calculated with edgeR’s RPKM function. Differentially 
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expressed genes in the transcriptome data were identified using the DESeq2 package with 
standard settings.16 
 
Quantitative PCR analysis 
Cardiac apex RNA was reverse transcribed into cDNA using iScript cDNA synthesis kit 
(Bioline, London, UK). Gene expression was assessed by qPCR using SensiFast SYBR & 
Fluorecein kit (Bioline) and primers as listed in Supplemental Table 1. Expression levels are 
relative to the averaged expression of housekeeping genes RPLP0, POLR2A, B2M, and 
YWHAZ. 
 
Pathway analysis 
RNAseq results were further analyzed using Ingenuity Pathway Analysis (IPA, Qiagen). IPA 
was used to identify both differences in pathway dynamics, and upstream regulators (growth 
factors and transcriptional regulators) of differentially expressed genes. P-values were 
calculated based on a right-tailed Fisher Exact Test, calculated by IPA. 
 
Statistics 
Data are presented as means ± SEM. Groups were compared by 2-way ANOVA or 2-way 
ANOVA for repeated measures, followed by Tukey post hoc test when appropriate. 
Statistical significance was accepted when P<0.05. 
 
 
Results 
ZSF1 rats develop diastolic dysfunction with a minimal effect of DS-induced hypertension 
Male ZSF1 rats, heterozygous (lean) or homozygous (obese) for leptin receptor mutation, 
were studied from 12 to 26 weeks of age. Both lean and obese rats were treated with DS or 
placebo from 19 to 26 weeks of age and echocardiographic, metabolic, and hemodynamic 
analyses were performed every two weeks (Figure 1A). ZSF1 rats with leptin receptor 
deficiency had significant weight gain (Table 1). This weight gain was accompanied by 
elevated blood cholesterol and triglycerides, with no distinction between placebo- and DS-
treated obese rats. An increase in blood glucose levels was observed in obese rats, which 
appeared to be attenuated by DS treatment. Systolic blood pressure was increased in both 
lean and obese DS-treated rats, with a synergistic elevation in DS-treated obese rats (Figure 
1B).Obesity, in both placebo- and DS-treated rats, caused a minor reduction in ejection 
fraction (EF), yet in all conditions EF was preserved (>50%; Figure 1C).17 Heart rate was 
reduced in both placebo- and DS-treated obese rats, and cardiac output (CO) tended to 
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Figure 1: DS treatment leads to increased SBP and an intense cardiac transcriptional adaptation, 
whereas obesity triggers diastolic dysfunction (A) Graphical workflow, showing that male lean and 
obese ZSF1 rats were studied from 13 to 26 weeks of age. Both lean and obese rats were treated with 
DS or placebo from 19 to 26 weeks of age to trigger severe hypertension. Echocardiographic, 
metabolic, and hemodynamic analyses were done every two weeks, till sacrifice at the age of 26 weeks. 
Longitudinal plots of (B) systolic blood pressure (mmHg), (C) ejection fraction (%), and (D) E/e’ ratio. 
n=6-7, * obese vs. lean, § obese+DS vs. lean+DS, ‡ lean+DS vs. lean, † obese+DS vs. obese P<0.05. 
(E) Principal component analysis of expression profiles in cardiac tissue. Symbols denoting subgroups 
panels B-E are shown in panel B. (F-I) Graphic display of differential gene expression in which log2FC 
is plotted against the mean of normalized counts. Red dots represent the differentially expressed genes 
(FDR<0.1), gray dots represent non-differentially expressed genes. 
 
be lower in obese vs. lean (p=0.08) and in obese+DS vs. lean+DS (p=0.07). When corrected 
for body mass (cardiac index), placebo- and DS-treated obese rats appeared unable to 
match cardiac output to body mass. Obesity and DS-induced hypertension both tended to 
increase LV weight (LVW) and total heart weight (HW), but a significant increase was only 
observed in presence of both comorbidities. Illustrative for diastolic dysfunction, the ratio 
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Table 1: Parameters in lean and obese ZSF1 rats at 26 weeks of age  
 
Values are means ± SEM, followed by main effect- (effect obesity / effect DS) and interaction p-values, 
as determined by 2-way ANOVA. SBP = systolic blood pressure, TL = tibia length, SV = stroke volume, 
CO = cardiac output, CI = cardiac index, LVW = left ventricle weight, HW = heart weight, RV = right 
ventricle. * obese vs. lean, § obese+DS vs. lean+DS, ‡ lean+DS vs. lean, † obese+DS vs. obese 
P<0.05. 
 
between peak velocity of early mitral inflow and early diastolic mitral annulus velocity (E/e′) 
was increased in obese rats (Figure 1D). Surprisingly, both for the reduced cardiac index 
and the increased E/e’ ratios, no interaction among the comorbidities was observed. In 
contrast to the functional findings, which were principally affected by obesity, RNAseq 
revealed that DS-induced hypertension caused the most predominant transcriptional 
variance (Figure 1E). In cardiac tissue of placebo-treated obese versus placebo-treated lean 
rats, and DS-treated obese versus DS-treated lean rats, a total of 410 and 146 genes were 
differentially expressed (FDR <0.1), respectively (Figure 1F-G, Supplemental Table 2-3). 
However, in DS-treated lean rats versus placebo-treated lean rats, and DS-treated obese 
rats versus placebo-treated obese rats, a total of 1258 and 1504 genes were differentially 
expressed (FDR<0.1), respectively (Figure 1H-I, Supplemental Table 4-5). 
 
Obesity and DS-induced hypertension trigger adverse mitochondrial responses 
Analyses of transcription profiles with Ingenuity Pathway Analysis (IPA) indicated that both 
risk factors had substantial, yet opposite effects on genes involved in mitochondrial function. 
In placebo-treated rats, enzymes involved in fatty acid metabolism and oxidative 
phosphorylation were upregulated in obese versus lean rats (Figure 2A-B). In contrast, both 
lean and obese DS-treated rats had an overall downregulation versus placebo-treated rats 
  
Obesity        DS Interaction
Tibia length (mm) 40.8 ± 0.5 40.0 ± 0.4 38.1 ± 0.4* 39.1 ± 0.6 <0.05 0.93 0.05
Body weight (g) 443 ± 9 417 ± 10 584 ± 13* 607 ± 10§ <0.05 0.91 <0.05
Cholesterol (mM) 2.2 ± 0.1 2.1 ± 0.1 8.2 ± 0.8* 9.1 ± 0.7§ <0.05 0.46 0.34
Triglycerides (mM) 1.5 ± 0.2 1.1 ± 0.2 23.8 ± 4.0* 20.5 ± 2.5§ <0.05 0.44 0.53
Glucose (mM) 9.9 ± 0.5 9.1 ± 0.5 22.5 ± 2.6* 14.0 ± 1.6† <0.05 <0.05 <0.05
SBP (mmHg) 153 ± 3 179 ± 4‡ 150 ± 1 213 ± 5†§ <0.05 <0.05 <0.05
Heart rate (bpm) 381 ± 9 362 ± 8 308 ± 9* 292 ± 6§ <0.05 <0.05 0.81
SV (μl) 212 ± 19 217 ± 23 178 ± 19 187 ± 19 0.13 0.71 0.90
CO (ml/min) 81 ± 7 79 ± 8 55 ± 6 55 ± 5 <0.05 0.87 0.92
CI (ml/min/100g) 18.2 ± 1.6 18.7 ± 1.7 9.5 ± 1.2* 9.0 ± 0.9§ <0.05 0.99 0.73
EF (%) 73 ± 2 70 ± 3 65 ± 1* 59 ± 2†§ <0.05 <0.05 0.48
E/e’ 15.9 ± 0.9 17.5 ± 0.6 20.5 ± 0.6* 22.9 ± 0.7†§ <0.05 <0.05 0.55
LVW (mg) 909 ± 27 1139 ± 64 1172 ± 66 1490 ± 116†§ <0.05 <0.05 0.58
HW (LV+RV; mg) 1338 ± 32 1459 ± 48 1474 ± 41 1684 ± 50†§ <0.05 <0.05 0.32
Obese+DS
(n=7)
p-valuesLean
(n=6)
Lean+DS
(n=7)
Obese
(n=6)
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Figure 2: Pathway analysis revealed opposing mitochondrial responses to obesity and DS-
induced hypertension. (A) Graphical visualization of 3 most affected pathways according to Ingenuity 
Pathway Analysis (orange and blue represent pathway activation and repression, respectively, grey 
represents no direction available). (B) Schematic presentation of RNAseq data for differentially 
expressed genes involved in FAO, (C) KLF15-induced transcription, (D) and oxidative phosphorylation. 
Shown is a color-based representation of the reads per kilobase million, relative to the average 
expression in the lean group, for each individual rat (orange and blue represent increased and 
decreased expression, relatively). (E) QPCR analysis of oxidative stress marker CAT. N=5-7, * P<0.05. 
(F) Analysis of urinary TBARS excretion as marker of systemic oxidative stress. N=6-7, * P<0.05. 
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of genes involved in oxidative phosphorylation, a phenomenon often observed in 
mitochondrial dysfunction (Figure 2A and D).18, 19 IPA predicted that the transcriptional 
regulator Krüppel Like Factor 15 (KLF15), which has been described as a key regulator 
inducing mitochondrial fatty acid substrate usage20, was the most active upstream regulator 
in placebo-treated obese versus lean rats (overlap p=2.66E-13/Z-score=2.95). Interestingly, 
it was among the most suppressed regulators in DS-treated rats (overlap p=5.37E-14/Z-
score=-3.97 and overlap p=7.73E-17/Z-score=-3.70 in lean+DS vs. lean and obese+DS vs. 
obese, respectively; Figure 2C, Supplemental Table 6-8). qPCR analysis of established 
KLF15 targets Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex 
Subunit Beta (HADHB), Acyl-CoA Dehydrogenase Medium Chain (ACADM), and 2,4 
Dienoyl-CoA reductase (DECR1), substantiated this observation (Supplemental Figure 1).  
RNAseq data also widely supported the DS-induced downregulation of genes coding for 
enzymes in oxidative phosphorylation, equally affecting the different complexes of the 
electron transport chain (Figure 2D). Remarkably, DS-induced downregulation of genes 
involved in oxidative phosphorylation was not accompanied by elevated transcription of 
oxidative stress responsive factor Catalase (CAT), whereas the increased transcription of 
fatty acid oxidation (FAO) genes in placebo-treated obese rats on the other hand was 
associated with elevated CAT expression (Figure 2E). Systemic oxidative stress, as 
measured by urinary excretion of thiobarbituric acid reactive substances (TBARS), followed 
a similar pattern, showing an elevation in placebo-treated obese rats (Figure 2F). The 
adaptations in transcription of mitochondrial genes raised the question whether this led to 
programmed cell death. Histological analysis of activated Caspase 3, a marker of early 
apoptosis, indicated no significant changes in sub-endocardial apoptosis (Supplemental 
Figure 2A and 2C), although the apoptotic effect of DS-induced hypertension showed a 
trend (p=0.05; Supplemental Table 9). A similar pattern was observed after labeling cells for 
late apoptosis, using Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling 
(TUNEL). Individually no differences were observed, although overall DS-induced 
hypertension stimulated apoptosis (Supplemental Figure 2B and 2D, Supplemental Table 9). 
Noteworthy, the apoptotic cells were predominantly found in patchy regions (Supplemental 
Figure 2E).  
 
Cardiomyocyte hypertrophy is mostly associated with the presence of obesity 
To get a better insight in myocardial hypertrophy in response to the comorbidities, the cross-
sectional area of individual cardiomyocytes was studied. Presence of both comorbidities led 
to significant cardiomyocyte hypertrophy (Figure 3A-B). In contrast to the HW and LVW, 
which were affected by both DS-induced hypertension and obesity individually, obesity was  
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Figure 3: Immunohistochemistry and transcription analysis revealed DS- and obesity-induced 
cardiomyocyte hypertrophy. (A) Typical examples and (B) quantification of histological staining for 
cardiac hypertrophy (Gomori). N=4-6, * P<0.05. (C) QPCR analysis of cardiac transcription of 
hypertrophy markers MYH6, MYH7, and NPPA, (D) regulators of cytoplasmic Ca2+ levels SERCA2A, 
PLN, and ATP1A2, and (E) transcriptional target of Ca2+-induced NFAT activation RCAN1. N=5-7, * 
P<0.05. 
 
associated with an elevated cellular cross-sectional area, but no contribution of DS-induced 
hypertension was observed (Supplemental Table 9).  
Transcription of Myosin Heavy Chain α (MYH6) and β (MYH7), defined markers for 
myocardial hypertrophy21, resembled this predominant obesity-induced effect on cardiac 
remodeling. Obesity triggered a downregulation of MYH6, and an upregulation MYH7 
(Figure 3C). DS-induced hypertension also reduced the expression of MYH6, though the 
effect size was more than a two-fold lower than that of obesity and appeared additive, not 
synergistic (Supplemental Table 9). Atrial natriuretic peptide (NPPA) on the other hand, like 
MYH6 and MYH7 a well-described hypertrophy marker, was upregulated solely in DS-
treated rats. Transcriptional analysis demonstrated that expression of sarco/endoplasmic  
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reticulum Ca2+-ATPase (SERCA2A) and phospholamban (PLN), both involved in calcium 
reuptake by the sarcoplasmic reticulum during diastole, was affected as well. SERCA2A 
expression was lowered by both comorbidities, whereas PLN appeared to be principally 
affected by DS-induced hypertension (Figure 3D). In line with SERCA2A, transcription of 
ATPase, Na+/K+ transporting alpha 2 (ATP1A2), was significantly lower in response to 
obesity and DS treatment. Of note, both for SERCA2A and ATP1A2, there was no 
interaction of the comorbidities (Figure 3D, Supplemental Table 9). Remarkably, Regulator 
of Calcineurin 1 (RCAN1), which is a direct Ca2+-dependent transcriptional target of Nuclear 
Factor of Activated T-cells (NFAT), was solely upregulated in placebo-treated obese rats, 
whereas the opposite response was induced by DS (Figure 3E). 
 
DS-induced hypertension and obesity in ZSF1 rats do not affect LV microvascular density 
To evaluate whether DS-induced hypertension and obesity affect capillary density, a lectin 
staining was applied on LV cross sections. Surprisingly, no differences were observed in any 
of the conditions (Figure 4A-B). The absence of microvascular adaptations was 
substantiated by transcription levels of well-known affecters of microvascular stability 
Angiopoietin 1 and 2 (ANGPT1 and 2, respectively), and hypoxia associated factor Vascular 
endothelial Growth Factor A (VEGFA). transcription of vascular destabilizing factors 
ANGPT2 and VEGFA was not affected by the comorbidities (Figure 4C). Interestingly, 
 
 
Figure 4: Immunohistochemistry and transcription analysis gave no indication for hypertension 
or obesity-induced LV microvascular changes. (A) Typical examples and (B) quantification of LV 
microvasculature (Lectin). N=4-6, * P<0.05. (C) QPCR analysis of cardiac transcription of factors 
involved in vascular remodeling ANGPT1, ANGPT2, and VEGFA. N=5-7, * P<0.05.  
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transcription of ANGPT1, which promotes vascular stability, was increased in placebo-
treated obese rats, but not in DS-treated obese rats versus their respective lean 
counterparts. 
 
DS-induced LV macrophage influx is aggravated by obesity 
To assess the impact of DS-induced hypertension and obesity on the cardiac inflammatory 
state, presence of CD3+ T-cells and CD68+ macrophages was evaluated. The number of 
CD3+ T-cells, representing adaptive immunity, was low and not affected by obesity or DS-
induced hypertension (Figure 5A and 5C, Supplemental Table 9). In contrast, presence of 
CD68+ macrophages, representing innate immunity, was markedly increased by DS-
induced hypertension (Figure 5B and 5D, Supplemental Table 9). Obesity alone had no 
 
Figure 5: DS-induced LV macrophage influx is aggravated by obesity. (A) Typical examples of 
immunological staining for LV T cell (CD3) and (B) macrophage (CD68) presence. Positively labeled 
cells are depicted with an arrowhead. (C) Quantification of immunological staining for LV T cell (CD3) 
and (D) macrophage (CD68) presence. N=4-7, * P<0.05. (E) Magnified visualization of immunological 
CD68 labeling in DS-treated obese rats, illustrative for the observed DS-induced increase in apoptosis 
seen in regions with high cellular density. 
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effect, but in combination with DS-induced hypertension it significantly increased 
macrophage presence, showing a synergistic trend (interaction p=0.09). In line with the 
observed DS-induced apoptosis, macrophage presence was mostly seen in patchy clusters 
(Figure 5E). 
 
DS-induced hypertension and obesity synergistically trigger TGFβ-induced LV fibrosis 
To evaluate the impact of the comorbidities on the development and progression of fibrosis, 
collagen deposition was measured. Picro Sirius Red positivity in the placebo-treated obese 
ZSF1 rats was not different from the placebo-treated lean rats. In contrast, DS-induced 
hypertension triggered a profound fibrotic response. The DS-induced fibrosis appeared to be 
aggravated by obesity, although no significant interaction was observed (interaction p=0.31; 
Figure 6A-B, Supplemental Table 9). These findings were substantiated by qPCR validation 
of Collagen 1α1 (COL1A1), Collagen 3α1 (COL3A1), and Fibronectin (FN1) expression. 
Obesity alone had no effect, whereas DS-induced hypertension enhanced their transcription. 
This DS-induced upregulation was aggravated in the presence of obesity (Figure 6C) and 
significant synergy was observed for COL3A1 and FN1 (Supplemental Table 9). Based on 
the overall transcription profiles, IPA predicted high activity of Transforming Growth Factor 
(TGF) β1 (overlap p=2.81E-11/Z-score=4.01 and overlap p=2.95E-31/Z-score=6.24 in 
lean+DS vs. lean and obese+DS vs. obese, respectively) and TGFβ2 (overlap p=2.14E-4/Z-
score=1.75 and overlap p=1.82E-6/Z-score=2.51 in lean+DS vs. lean and obese+DS vs. 
obese, respectively) signaling in the hearts of DS-treated versus placebo-treated rats 
(Supplemental Table 10-11). This predicted activation was accompanied by transcriptional 
upregulation of TGFβ1 and TGFβ2 (Figure 6D) upon DS-induced hypertension. Moreover, in 
addition to COL1A1, COL1A3 and FN1, various TGFβ target genes, including Periostin 
(POSTN) and Osteopontin 1 (SPP1) were upregulated (Figure 6E), of which the latter has 
recently been demonstrated to have predictive value for clinical outcome in HFpEF.22 
 
 
Discussion 
In line with previous reports12, 13, ZSF1 rats with a homozygous leptin receptor mutation in 
our current study presented with metabolic derangements, including elevated body weight, 
hypercholesteremia, hyperglycemia, and hypertriglyceridemia. As anticipated, DS treatment 
triggered severe hypertension in both lean and obese ZSF1 rats, and the combination of 
these factors enabled us to study if and how obesity and hypertension interact in the 
development of diastolic dysfunction at a functional, histological, and transcriptional level. 
From this study we could conclude that (1) obesity-associated derangements had the most 
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Figure 6: Synergistic effects of obesity and DS on LV TGFβ signaling and fibrosis. (A) Typical 
examples and (B) quantification of histological staining for cardiac collagen deposition (Picrosirius Red). 
N=6-7, * P<0.05. (C) QPCR analysis of cardiac transcription of extracellular matrix components 
COL1A1, COL3A1, and FN1, (D) activators of TGFβ signaling TGFβ1 and TGFβ2, and (E) 
transcriptional targets of TGFβ signaling POSTN and SPP1. N=5-7, * P<0.05. 
 
predominant effect on development of diastolic dysfunction, with no synergy observed 
between obesity and DS-induced hypertension; (2) obesity also predominantly affected LV 
hypertrophic remodeling, which was associated with increased fetal gene expression and 
Ca2+-mediated transcription; (3) capillary rarefaction was absent in all conditions, whereas 
inflammation and fibrosis occurred in response to DS-induced hypertension, with partial 
synergy observed if in combination with obesity; and that (4) obesity stimulated enhanced 
expression of genes involved in FAO, whereas DS treatment led to an overall 
downregulation of genes involved in oxidative phosphorylation, implying that the 
comorbidities triggered adverse mitochondrial responses. These findings do not support our 
initial hypothesis and illustrate important phenotypical differences in comorbidity-induced 
Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of HFpEF 
135 
 
cardiac adaptation. Moreover, these observations emphasize the need for thorough and 
individualized phenotypical characterization of HFpEF patients.23 
 
Diastolic dysfunction, or more specifically, impaired active relaxation and reduced LV 
passive compliance leading to increased LV diastolic pressures, is a phenotypical hallmark 
of HFpEF.24, 25 A well-defined echocardiographic parameter to define presence of diastolic 
dysfunction is the E/e’ ratio17, which was significantly elevated in both placebo- and DS-
treated obese rats, compared with their lean counterparts. Similarly, obesity was strongly 
associated with a lower CO. Interestingly, DS-induced hypertension had no effect on CO 
and only a minor effect on E/e’ ratio. Surprisingly, no functional interaction was observed 
between the comorbidities. These findings, indicating a relative mild contribution of 
hypertension on development and progression of diastolic dysfunction, and suggesting a 
more pronounced causal relation with metabolic derangements, could explain why 
antihypertensive treatment thus far has not established a major survival benefit in HFpEF 
patients.11 
 
The lower CO in obese rats was principally the result of a lower heart rate, which is 
consistent with diabetes-induced lowering of resting heart rates26, while – surprisingly – 
stroke volume was maintained even when both obesity and DS were present. Stroke volume 
was likely maintained as a result of the bradycardia-induced increase in diastolic filling time, 
thereby compensating for the impaired relaxation and the presence of concentric 
hypertrophy. The latter phenomenon has clinically been associated with an increased risk of 
morbidity and mortality in HFpEF patients.27 In the ZSF1 rats, total HW and LVW reached 
statistical significance only when both comorbidities were present, although variance was 
individually affected both by obesity and DS. Remarkably, variance in cardiomyocyte cross-
sectional area was solely affected by obesity, suggesting that the effect of DS treatment on 
HW might at least in part be secondary to a cellular hypertrophy-independent process, such 
as fibrosis. Transcriptional analysis supported this predominant obesity-induced myocardial 
maladaptation, which generally occurs in the presence of reinitiated fetal gene expression 
and elevated Ca2+-induced transcription21, 28. In that regard, a clear obesity-driven switch 
from MYH6 to MYH7 was noticed, as well as elevated transcription of RCAN1, a defined 
target gene of the Ca2+-responsive transcription factor NFAT.29 The RNAseq data also 
underscored the notion that diastolic dysfunction-associated hypertrophy can develop in 
absence of severe cardiac afterload. In the ZSF1 rats, blood pressure- and wall stretch-
responsive factor NPPA30, was exclusively upregulated in DS-treated rats, whereas in 
placebo-treated obese rats with an apparent absence of elevated wall stretch, hypertrophy 
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developed. Since NPPA has been demonstrated to inhibit NFAT activation28, this DS-
induced upregulation of NPPA could explain why RCAN1 was not upregulated in DS-treated 
rats, even though crucial Ca2+-handling genes (ATP1A2, SERCA2A, and PLN) were 
dysregulated upon DS-induced hypertension. Noteworthy, in none of the hypertrophy-related 
parameters, positive interaction was observed between hypertension and obesity. 
 
In addition to cardiomyocyte hypertrophy, it has been proposed that HFpEF-associated 
comorbidities can induce systemic inflammation, leading to endothelial inflammation and 
oxidative stress, favoring monocyte extravasation, fibrosis, and microvascular rarefaction.2 
Fibrosis is suspected to result from monocyte-induced TGFβ secretion, and to actively 
contribute to LV stiffening31, whereas a reduction in capillary density may impair oxygen 
delivery, limiting systolic and diastolic reserve function32, yet could also lower NO availability 
which contributes to passive stiffness and LV hypertrophy via impaired Protein Kinase G 
activation.2 In LV sections from HFpEF patients, indeed fibrosis and a lower capillary density 
were observed32, but in line with our previous study13, no capillary rarefaction was observed 
in any of the ZSF1 rats. From the current study it cannot be excluded that loss of capillaries 
develops at a later stage of the disease, although these data do suggest that it is not a 
prerequisite for the development of diastolic dysfunction. Interestingly, even in the absence 
of capillary rarefaction, a clear inflammatory and fibrotic response was observed. In contrast 
to the obesity-driven diastolic dysfunction and cardiomyocyte hypertrophy, inflammation and 
fibrosis predominantly occurred in DS-induced hypertensive rats. It has previously been 
shown that resident cardiac macrophages can respond to hypertension by activation of pro-
inflammatory signaling33, due to exposure to altered mechanical forces.34 Additionally, DS-
induced activation of mineralocorticoid receptors could also trigger cardiac inflammation and 
fibrosis, independent of hypertension30, 35, implying that multiple mechanisms could 
orchestrate the observed response in the hypertensive rats. In placebo-treated obese rats, 
no inflammatory or fibrotic responses were observed, suggesting that the increased urinary 
TBARS excretion in these rats was presumably not derived from vascular and neutrophilic 
NADPH-induced oxidative stress.36 Interestingly, obesity did significantly aggravate DS-
induced macrophage presence and triggered upregulation of many extracellular matrix 
components with a TGFβ signature37, 38, suggesting putative interaction with DS-induced 
hypertension for this particular aspect of LV adaptation. As obesity and DS-treatment also 
showed mild interaction in elevation of the systolic blood pressure, it cannot be excluded 
that the observed increase in inflammation and fibrosis is purely hypertension-driven. These 
data, however, do illustrate marked comorbidity-dependent phenotypical differences driving 
development of diastolic dysfunction.  
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The broad range of our analysis enabled us to dissect how functional differences in cardiac 
response to obesity-associated aberrations and DS-induced hypertension were reflected by 
the distinct transcription profiles. By comparing the transcriptome of placebo-treated obese 
rats with that of placebo-treated lean rats, the most abundant response came from elevated 
expression of genes encoding enzymes involved in FAO. Although cardiac hypertrophy is 
associated with decreased FAO and increased glucose metabolism39, this finding was not 
completely unexpected considering the diabetic background of these rats.40 Nonetheless, 
increased FAO is also evident in HFpEF patients41, and due to the lower oxygen efficiency 
compared with glucose metabolism42, this could result in a lower ATP bioavailability, which 
can contribute to hampered energy-consuming diastolic relaxation.43 The increased FAO, 
which may partly occur in peroxisomes44, might also be causally related to the observed 
elevation of oxidative stress. Since peroxisomes lack a respiratory chain, electrons from 
FADH2 are transferred directly to O2, generating H2O2 and heat.44 In line with previous 
studies45, obesity appeared to induce peroxisomal FAO,  as illustrated by higher expression 
of peroxisomal-specific Acyl-Coenzyme A Oxidase 1 (ACOX1) and Acyl-CoA 
Dehydrogenase Very Long Chain (ACADVL). The upregulation of CAT in placebo-treated 
obese rats, which is predominantly involved in peroxisomal H2O2 conversion44, substantiates 
the putative peroxisomal source of oxidative stress. Strikingly, when transcription profiles of 
DS-treated rats were compared with that of placebo-treated rats, an overall downregulation 
of factors involved in oxidative phosphorylation was observed, negatively modulating both 
fatty acid- and glucose oxidation. Others have shown that downregulation of only a minimal 
number of genes involved in oxidative phosphorylation could induce mitochondrial 
dysfunction.18, 19 Mitochondrial dysfunction is causally related to myocardial cell-death46, 47, 
which might explain the effect of DS on sub-endocardial TUNEL labeling. The relation 
between hypertension and mitochondrial dysfunction is well described.48, 49 However, the 
present findings illustrate the adverse effects of two HFpEF comorbidities on energy 
homeostasis, indicating that in obese rats the mechanisms involved in metabolic 
derangements, with a putative role in development of diastolic dysfunction, are dependent 
on the presence or absence of hypertension. These observations emphasize the need for 
thorough phenotypical characterization of HFpEF patients.23  
 
In summary, the present study shows, to our knowledge for the first time, how obesity and 
hypertension contribute to the development of diastolic dysfunction. Our data show that 
intrinsic metabolic derangements in ZSF1 rats have the most evident effect on development 
of diastolic dysfunction. However, from a mitochondrial-, fibrotic-, and inflammatory point of 
view, the presence of severe hypertension appears to have a major impact on disease 
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progression. When considering therapeutic interventions, it thus would seem extremely 
important to anticipate potential pathophysiological differences among HFpEF patients that 
were thus far grouped together based on the common denominator “preserved EF”. For 
instance, aiming for a switch from fatty acids towards more oxygen-efficient glucose 
metabolism, as was previously suggested in HFpEF50, might provide an opening with 
promising therapeutic potential in obese patients, but may well be far less effective when 
applied to HFpEF patients with hypertension-induced mitochondrial dysfunction.   
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Supplemental data 
 
Supplemental Figure 1: Transcription of KLF15 target genes. (A) QPCR results showing expression 
levels of KLF15 targets DECR1, (B) ACADM, and (C) HADHB. N=5-7, * P<0.05.  
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Supplemental Figure 2: Analysis of apoptosis by immunostaining. (A) Typical examples of 
histological analysis of LV early apoptosis (activated Caspase3) and (B) late apoptosis (TUNEL). 
Positively labeled cells are depicted with an arrowhead. (C) Quantification of histological staining for LV 
early (activated Caspase3) and (D) late (TUNEL) apoptosis. N=4-7. (E) Magnified visualization of 
immunological TUNEL labeling in DS-treated obese rats, illustrative for the observed DS-induced 
increase in apoptosis seen in regions with high cellular density. 
 
Supplemental Tables can be downloaded from: 
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fjcmm.14542&fil
e=jcmm14542-sup-0001-AppendixS1.docx 
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Abstract 
As genome-wide association efforts, such as CARDIoGRAM and METASTROKE, are 
ongoing to reveal susceptibility loci for their underlying disease: atherosclerotic disease, 
identification of candidate genes explaining the associations of these loci has proven the 
main challenge. Many disease susceptibility loci co-localize with DNA regulatory elements, 
which influence gene expression through chromatin interactions. Therefore, the target genes 
of these regulatory elements can be considered candidate genes. Applying these biological 
principles, we used an alternative approach to annotate susceptibility loci and identify 
candidate genes for human atherosclerotic disease based on circular chromosome 
conformation capture followed by sequencing (4C-seq).In human monocytes and coronary 
endothelial cells we generated 63 chromatin interaction datasets for 37 active DNA 
regulatory elements that co-localize with known susceptibility loci for coronary artery disease 
(CARDIoGRAMplusC4D) and large artery stroke (METASTROKE). By 4C-seq we identified 
a physical 3D interaction with 326 candidate genes expressed in at least one of these cell 
types, of which 294 have not been reported before. We highlight 16 genes based on 
expression quantitative trait loci. Our findings provide additional candidate-gene annotation 
for 37 disease susceptibility loci for human atherosclerotic disease that are of potential 
interest to better understand the complex pathophysiology of cardiovascular diseases. 
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Introduction 
Atherosclerosis is a chronic inflammatory disease of the lipid-rich vascular wall that 
underlies many cardiovascular diseases (CVD).1 A large part of the disease burden of 
atherosclerosis can be traced back to coronary artery disease (CAD) and large artery stroke 
(LAS). Genome-wide association studies (GWAS) have helped to unravel the complex 
genomic background of these 
diseases, currently explaining about 
10% of heritability.2, 3 The current 
approach is to annotate a novel 
susceptibility locus with the gene at 
the nearest genomic position. Some 
alternative strategies also take into 
account gene expression or protein-
protein interactions.4, 5 A recent effort 
employing these bioinformatics-
based approaches resulted in 98 
new candidate genes for CAD.6 In 
the last few years, the evidence that 
variants identified by GWAS also 
contribute to the disease 
pathogenesis by affecting the 
regulatory DNA sequences they 
reside in is growing.7-9 These genetic 
variants may affect the activity of the 
DNA regulatory elements (DRE) 
and, under specific circumstances, 
lead to dysregulation of gene 
expression. This is mediated by long 
range 3D chromatin-chromatin 
interactions where the regulated 
candidate genes can be located up 
to ~1 MB away10-12 – a distance 
much larger than is normally used to 
annotate candidate genes in GWAS. 
These candidate genes can be 
identified by capturing the physical 
Figure 1 Flowchart of identification of candidate 
genes. Susceptibility loci indicates single nucleotide 
polymorphisms (SNPs) associated with risk of disease in 
METASTROKE and CARDIoGRAM. Viewpoint SNPs 
indicates SNPs used as focus point for primer design of 
the 4C experiment. CAD indicates coronary artery 
disease and LAS indicates large artery stroke. 
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chromatin-chromatin interaction between a known disease susceptibility locus and the 
promoter of the gene(s) it presumably regulates.13 Here we systematically apply this 
principle (study design is summarized in Figure 1) to variants identified by large meta-
analyses of GWAS for CAD and LAS; altogether assaying 47 previously 
identifiedsusceptibility loci.2, 3 Atherosclerotic disease starts in the endothelial lining of the 
affected arteries and involves attraction and proliferation of monocytes.14 Therefore, we 
studied  37 loci that co-localize with active DRE in human monocytes and/or in cardiac 
endothelial cells. We used circular chromosome conformation capture sequencing (4C-seq) 
to identify candidate genes based on their physical interaction with one of the active DRE.  
 
 
Methods 
Cell culture 
Primary commercially available human cardiac endothelial cells (CEC) that were isolated by 
enzymatic detachment  (Lonza Clonetics™) were cultured in RPMI-1640 with 10% FCS and 
standard supplements. Cells were harvested for 4C template preparation by trypsinisation at 
60-80% confluence.  
 
Monocyte isolation 
Human peripheral blood was collected from a healthy donor in sodium-heparin tubes. 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated by Ficoll-Paque gradient 
centrifugation. PMBCs were incubated with magnetic CD14+-microbeads (Milteny, order nr. 
130-050-201) according to manufacturer’s manual. Thereafter cells were magnetically 
separated by the AutoMACS™ Separator, the positive fraction (monocytes) was used for 4C 
template preparation. 
  
Circular Chromosome Conformation Capture-Template preparation 
The 4C template was prepared as previously described13. Summarized, 10x106 cells were 
used per cell type (monocytes and CEC). Cells were crosslinked in 2% formaldehyde. After 
chromatin isolation, the chromatin was digested with DpnII (NEB, # R0543L). Digestion was 
stopped through heat inactivation of the restriction enzyme. Samples were diluted and 
ligated by T4 DNA ligase. The second digestion was carried out with CviQI (NEB, #R069S) 
and inactivated by phenol:chloroform extraction. The chromatin was diluted, for the final T4 
ligation and the chromatin was purified. The quality of digestion and ligation was assessed 
on agarose gels. 
 
Additional candidate genes for human atherosclerotic disease identified by annotation based on chromatin organization 
 
149 
 
Viewpoint selection and primer design 
All SNPs from table 1 and 2 and the young-CAD SNP (rs16986953) from the 
CARDIoGRAMplusC4D paper2 (n=47) and the two replicated SNPs (rs2383207 and 
rs2107595) from METASTROKE3 were considered for viewpoint design (Supplemental 
Table 8). When the SNPs within the susceptibility locus were less than 15,000 bp apart (e.g. 
rs12740374, rs602633 and rs599839 in the SORT1 region), only one SNP was selected as 
a viewpoint. Susceptibility loci that overlapped with active DRE were identified through 
FAIRE, the presence of H3K4Me1, H3K4Me3, H3K27Ac, H3K4Me2 or H3K9Ac, EP300 or 
CTCF binding sites or DNase hypersensitivity sites (Supplemental Table 9). DRE falling 
within the susceptibility locus coordinates were considered overlapping with the 
susceptibility locus. The primers were designed as was described previously.13 Primer 
sequences are listed in Supplemental Table 8. In summary, primers were designed in a 
window of 5 kb up- and downstream from the associated SNP. Forward and reverse primers 
were designed at least 300 bp apart. Forward (reading) primers were designed on top of the 
first restriction enzyme site. The reverse (non-reading) primer was designed close to (max 
100bp away from) the second restriction enzyme site. In case no primer pair could be 
designed within the initial window, the window was extended 5 kb up- and downstream 
(n=8). In the case of rs1561198  this did not result in a suitable primer, so a primer pair that 
was 299bp apart was selected for this viewpoint.  
 
Circular Chromosome Conformation Capture- Sequencing library preparation 
4C-sequencing library preparation was performed as described previously13, with minor 
adaptations in order to make the protocol compatible with the large number of viewpoints: 
the PCR of 4C template was performed with 600 ng (monocytes) or 1,6 µg (coronary 
endothelial cells) of 4C template per reaction. 8 to 10 primer pairs were multiplexed in the 
initial PCR reaction (primer sequences are listed in Supplemental Table 8). Primers pairs 
were pooled according to primer efficiency (based on intensity on gel electrophoresis signal 
after PCR on test template). PCR products were purified after an initial PCR reaction of 6 
cycles (reaction volume = 200 µL) and divided among 8-10 PCR reactions containing single 
primer pairs for another 26 cycles (reaction volume = 25 µL). Thereafter, PCR products 
derived from the same cells were pooled in equimolar amounts and a final 6 cycle PCR 
reaction containing 20 ng of pooled PCR product (reaction volume = 100 µL) was performed 
with primers that contained sequencing adaptor sequences. All fragments >700bp were 
removed using size selection on a 1% agarose gel follow by gel extraction of the selected 
products (Qiagen, #28704). Quality measures for the 4C library preparation and sequencing 
can be found in Supplemental Figure 1. 
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Sequencing 
Libraries were sequenced using the HiSeq2500 platform (Illumina), according to the 
manufacturer’s protocol, producing 50 bp single end reads.   
 
Data analysis 
The raw sequencing reads were de-multiplexed based on viewpoint specific primer 
sequences. Reads were then trimmed to 16 bases and mapped to an in silico generated 
library of fragends (fragment ends) neighboring all DpnII sites in human genome 
(NCBI37/hg19), using the custom Perl scripts. No mismatches were allowed during the 
mapping and the reads mapping to only one possible fragend were used for further analysis. 
 
Identification of the interacting genes 
First, we calculated the number of covered fragends within a running window of k fragends 
throughout the whole chromosome where the viewpoint is located. The k was set separately 
for every viewpoint so it contains on average 20 covered fragends in the area around the 
viewpoint (+/- 100kb). Next, we compared the number of covered fragends in each running 
window to the random distribution. The windows with significantly higher number of covered 
fragends compared to random distribution (p<10-8 based on binominal cumulative 
distribution function; R pbinom) were considered as significant 4C-seq signal. The following 
criteria were defined for the identification of the candidate genes; i) the Transcriptional Start 
Site (TSS) co-localizes with a significant 4C-seq signal (P<10-8) within 5 kbp; ii) the 
susceptibility variant or other variant in linkage disequilibrium (LD) co-localizes with a DNA 
regulatory element identified though FAIRE, the presence of H3K4Me1, H3K4Me3, 
H3K27Ac, H3K4Me2 or H3K9Ac, EP300 or CTCF binding sites or DNase hypersensitivity 
sites (Supplemental Table 9) in the cell type from which the 4C-seq signal originated and iii) 
the gene is expressed (RPKM > 0.5) in the assayed cell type. 
 
Identification of gene expression 
For monocyte expression, data from the ENCODE database were used (Supplemental 
Table 10).15 For coronary endothelial cell expression, HMVECs (Lonza) were cultured on 
gelatine coated plates in EGM2-MV (Lonza) supplemented with penicillin and streptomycin. 
Subsequently, HMVECs were cultured for 20 hours in low serum medium (EBM + 0.5% 
FCS), followed by cell lysis and RNA isolation using the RNeasy isolation kit 
(Qiagen). Polyadenylated mRNA was isolated using Poly(A) Beads (NEXTflex). Sequencing 
libraries were made using the Rapid Directional RNA-Seq Kit (NEXTflex) and sequenced on 
Illumina NextSeq500 to produce single-end 75 base long reads (Utrecht Sequencing 
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Facility).  Reads were aligned to the human reference genome GRCh37 using STAR 
version2.4.2a16. Read groups were added to the BAM files with Picard's 
AddOrReplaceReadGroups (v1.98). The BAM files are sorted with Sambamba v0.4.5 and 
transcript abundances are quantified with HTSeq-count version 0.6.1p117 using the union 
mode. Subsequently, reads per kilobase of transcript per million reads sequenced (RPKM's) 
are calculated with edgeR's rpkm() function.18 
 
Pathway analysis 
The interacting genes (with and without expressed CARDIoGRAMplusC4D/METASTROKE 
genes) were analyzed using QIAGEN’s Ingenuity Pathway Analysis (IPA, 2015 winter 
version, QIAGEN Redwood City, www.qiagen.com/ingenuity). We used IPA to identify 
canonical biological pathways within the Ingenuity Knowledge Base to which the interacting 
genes were mapped. Limits were set to only direct relationships that were experimentally 
observed in humans. We performed six rounds of pathway analysis, three in each of the cell 
types: one with only CARDIoGRAMplusC4D/METASTROKE genes that were expressed in 
the cell type, one with the CARDIoGRAMplusC4D/METASTROKE genes supplemented by 
the newly identified genes and one with the novel genes only. 
 
Tracks and plots 
All tracks were accessed from the UCSC browser (hg19) (http://genome.ucsc.edu/). 
Regional plots were generated using LocusZoom version 1.3.19 
 
Gene-based tests 
Data for CAD were downloaded from the CARDIoGRAMplusC4D website 
(http://www.cardiogramplusc4d.org). We obtained summary statistics from GWAS on body 
mass index (BMI), blood lipids including LDL, HDL, total cholesterol and triglycerides, 
systolic and diastolic blood pressure, coronary calcification, fasting glucose, smoking 
behavior, and type 2 diabetes from public online resources and data on intima-media 
thickness and plaque-presence via data request (Supplemental Table 11). We used a 
VErsatile Gene-based Association Study (VEGAS) to calculate gene-based association 
statistics from the summary statistics of each interacting gene for each trait. The details of 
the methods applied by VEGAS have been described elsewhere.20 In short, SNPs are 
mapped to the gene (in and around ±50kb from 5’ and 3’ gene borders), and using the 
GWAS p-value a gene-based test statistic is calculated corrected for the underlying 
population linkage disequilibrium structure. Finally using simulations an empirical gene-
based p-value of association with the phenotype is calculated per gene. VEGAS results 
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were considered multiple testing significant if they were P < 6.97x10-6 (0.05/22 phenotypes x 
326 available genes in VEGAS).   
 
eQTL analysis in STAGE 
Within the STAGE study, patients undergoing coronary artery bypass grafting (CABG) 
surgery were sampled for seven different tissues, namely atherosclerotic arterial wall (AAW), 
internal mammary artery (IMA), liver, skeletal muscle (SM), subcutaneous fat (SF), visceral 
fat (VF), and fasting whole blood (WB) for RNA and DNA isolation.21 Patients that were 
eligible for CABG and had no other severe systemic diseases (e.g. widespread cancer or 
active systemic inflammatory disease) were included. For quality control in genotyping, 
SNPs filtered for minor allele frequency MAF < 5%, Hardy-Weinberg equilibrium (HWE) p-
value < 1x10-6, and call rate of 100%. Imputation was carried out using IMPUTE2 with 1000 
Genomes EUR as the reference.22 Quality control for imputed genotypes used additionally 
an IMPUTE2 INFO score filter < 0.3. After QC a total of 5,473,585 SNPs remained. The 
Ethical committee of the Karolinska Hospital approved the study, and all patients gave 
written informed consent after the nature and possible consequences of the study were 
explained. An expression trait was tested for association with each genotyped and imputed 
SNP using Kruskal-Wallis test and false discovery rate to correct for multiple testing as 
described before. First, all cis-pairs of SNPs within 50kb of the transcription start or end site 
for each gene were identified. Next, cis SNP-gene pairs were tested for association in all 
seven STAGE tissues using kruX.23 The p-value for eQTL inclusion in kruX was set at 0.05. 
Finally, an empirical FDR estimate for each eQTL-gene pair was calculated using ten 
permutations by shuffling patient IDs on genotype data. As a result, the most significant 
eQTL-gene association in each tissue was reported. 
 
eQTL analysis in Haploreg 
Data on eQTL in healthy individuals were extracted from Haploreg version 4.1 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php). The viewpoint SNPs and 
all SNPs in LD (r2 > 0.8) were used as input. From the output, for each interacting gene, the 
most significant eQTL within each tissue was extracted. 
 
eQTL analysis in CTMM circulating cells 
CTMM circulating cells is a Dutch cohort from four different hospitals comprising of 714 
patients undergoing coronary angiography of whom blood was stored. Monocytes were 
isolated by density centrifugation followed by positive magnetic bead isolation (CD14) and 
expression was measured using the Illumina humanHT-12 v3 Gene Expression BeadChip 
Additional candidate genes for human atherosclerotic disease identified by annotation based on chromatin organization 
 
153 
 
Array. After removal of samples with a median intensity of <50, 370 patients were included 
in the analysis. The data were quantile normalized and and log2 transformed using the lumi 
R package.24 Genotyping was performed using a customized Affymetrix Axiom Tx array 
containing 767,203 genetic markers. Community standard quality control was performed, 
filtering out samples with missingness >5%, outlying heterozygosity (± 4SD from the cohort 
mean) or inconsistent sex. Samples of non-European descent or those that were out of 
Hardy-Weinberg equilibrium (p<5x10-5) were removed. In total, 622 were used in the current 
analysis. Untyped variants were imputed using a combined reference panel of the 1000 
Genomes Project25 and Genome of the Netherlands26 totaling more than 90 million genetic 
variants across the genome. We used the software packages SHAPEIT27 for phasing and 
IMPUTE222 for imputation. Prior to cis-eQTL analysis we filtered the imputed genotype data 
from CTMM based on MAF > 0.5%, HWE P > 1x10-6, Info-metric > 0.9, and only focused on 
those variants in LD (r2 >= 0.8) with the CAD associated variants. We then used fastQTL 
(v2.184)28 to perform I-eQTL analyses using a fixed range (based on the 4C interactions) 
around each probeID available on the expression array.  
 
Mouse knockout models 
Murine gene names were mapped to the genes as follows. First, a custom data file was 
downloaded from the HUGO Gene Nomenclature Committee 
(http://www.genenames.org/cgi-bin/download) including the Approved gene name and the 
Mouse Genome Database ID from the Mouse Genome Informatics database and a file 
containing all available phenotypic information for all knockout mice was downloaded from 
MGI (ftp://ftp.informatics.jax.org/pub/reports/index.html#pheno). Next, for all approved gene 
names of genes identified through 4C-seq, the mouse phenotypes were looked up by linking 
the MGI IDs. If no linkage could be made for the MGI ID, this was coded as no available 
mouse model. If a mouse model was available, but no phenotype was found, this was coded 
as no available phenotype. If a mouse model was specifically coded as not showing any 
phenotype upon knockout, this was coded as a gene not resulting in any phenotype. Murine 
cardiovascular phenotypes were defined as a phenotype resulting in any of the following: 
impaired blood coagulation or abnormal platelets, abnormal glucose levels or homeostasis, 
abnormal vascular morphology, vascular remodeling or arterial differentiation, abnormal 
blood pressure, abnormal vasoconstriction, vasodilatation or vascular permeability, 
abnormal stress response of the heart, myocardial infarction, abnormal (circulating) lipid 
levels, abnormal fat morphology or amount, abnormal body weight, abnormal lipid droplet or 
fat cell size, abnormal macrophage response or inflammation, abnormal wound healing, 
arteritis, vasculitis, vascular occlusion or atherosclerosis.  
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Human knockout models 
The interacting genes were extracted from the supplementary tables of the studies of Sulem 
et al. and MacArthur et al..29, 30 For each of the interacting genes, all SNPs and indels 
resulting in human functional knockouts were reported. 
 
Drug targets 
For the lookup of existing drugs that target any of the candidate genes, we used a custom 
built drug pipeline that searches for drug-gene interactions using DGIdb, which merged the 
most known drug-gene interaction databases, such as DrugBank and PharmGKB.31-33 We 
removed redundant results using  STITCH and WHO’s INN.34, 35 We tested 
overrepresentation of drug groups according to ATC codes using Fisher exact tests.36 
 
 
Results 
4C-seq identifies additional candidate genes 
We identified 37 active DNA regulatory elements that co-localize with susceptibility loci for 
CAD or LAS. Twenty-six were active in both monocytes and coronary endothelial cells, 5 
were only active in monocytes and 6 were only active in coronary endothelial cells 
(Supplemental Table 1). To identify the target genes of these active DRE, we generated 63 
4C-seq interaction datasets. We applied the following criteria for the identification of 
candidate genes: I) the transcriptional start site (TSS) co-localizes with a significant 4C-seq 
signal (P<10-8) within 5kb; II) the susceptibility variant or any other variant in LD (r2 ≥0.8) co-
localizes with an active DRE signal in the cell type from with the 4C-seq signal was obtained 
and III) the gene is expressed (RPKM > 0.5) in the studied cell type. With this approach, we 
identified 326 candidate genes (Supplemental Table 1), 77 in human male coronary 
endothelial cells, 84 in human male monocytes and 165 in both cell types (Figure 1). In total, 
we identified 294 candidate genes that were not previously reported by the CAD and LAS 
GWAS (Supplemental Table 1). We replicated 235/242 (97.1%) of the chromatin interactions 
with expressed genes that were identified in male coronary endothelial cells in female 
coronary endothelial cells (Supplemental Table 1). 
 
4C-seq identifies candidate genes in novel pathways 
We performed cell-type specific pathway analysis of the candidate genes identified by 4C-
seq combined with the candidate genes that were previously identified by the GWAS on 
CAD and LAS (Supplemental Table 2). Notably, these analyses revealed the Hypoxia 
signaling in the cardiovascular system pathway in monocytes (P = 0.01) and the NRF-
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mediated oxidative stress response pathway (P = 4.68*10-4 and P = 0.026 in coronary 
endothelial cells and monocytes respectively, Supplemental Table 2). These pathways are 
both involved in the cellular response to oxidative stress. Additionally, the 4C-seq approach 
revealed PTEN (a player in the Hypoxia signaling in the cardiovascular system pathway) as 
a novel candidate gene (Supplemental Table 1). Although this gene was never reported via 
previous GWAS annotation, PTEN (phosphatase and tensin analog) was found to be a likely 
candidate gene based on dose-dependently upregulation by statins through higher 
peroxisome proliferator-activated receptor-gamma (PPAR gamma) activity.37 A mutation of 
PTEN led to inflammatory plaque characteristics in human atherosclerotic plaque and 
increased stability of PTEN was found to ameliorate atherosclerosis.38, 39 Furthermore, 
PTEN shares its upstream transcription regulator ZEB2 with CDKN2A and CDKN2B 
(enrichment P of overlap for ZEB2-regulated genes: 3.02x10-3 in monocytes and 3.06x10-3 in 
coronary endothelial cells). We reveal multiple novel pathways related to cardiovascular 
disease and we now show that PTEN physically interacts with a DRE at rs2246833 in 
monocytes  ( P interaction = 2.36x10-10).  
 
Expression of identified genes is genotype dependent 
DRE exert their function through regulation of gene expression. We explored this 
mechanism by studying expression quantitative trait loci: the GWAS SNPs (or a SNP in LD;  
r2>0.8) that significantly affected the expression of the candidate genes identified by 4C-seq 
in the studied tissues (Table 1). For the candidate genes identified by 4C-seq in coronary 
endothelial cells, we performed lookups within eQTL data of atherosclerotic artery wall and 
internal mammary artery in the STAGE cohort of patients undergoing cardiac bypass 
surgery. We identified two eQTL (FDR<0.1) in atherosclerotic artery wall (rs9818870: MRAS 
and rs2281727: SRR, Supplemental Table 3a). The SRR gene, that has not been reported 
previously, encodes for the serine racemase enzyme that is an endogenous ligand of the 
glycine site of NDMA receptors in the brain. Blockage of this site was found to prevent 
stroke damage.40 Interestingly, a set of twice the number of genes from the same genetic 
locus that were not identified by 4C-seq as a target gene resulted in no significant eQTL in 
STAGE. Using the HaploReg tool, we additionally examined expression in aorta, coronary 
artery and tibial artery tissue and identified another seven eQTL for genes that we identified 
in coronary endothelial cells (Supplemental Table 3b), of which ARL3 and FAM117B were 
not reported before. Both genes are poorly studied in the context of cardiovascular disease. 
Within the VAMP5-VAMP8-GGCX locus we replicate rs1561198, that was previously  
reported to be an eQTL for GGCX in mammary artery by the CARDIoGRAMplusC4D 
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Table 1: Candidate genes identified by 4C-seq in coronary endothelial cells and/or monocytes 
Chr Susceptibility locus 4C-seq viewpoint(s) Interacting genes 
Cell type of identification 
eQTL 
CEC Monocytes 
1 MIA3 rs17464857 AIDA √ √  
   BROX √ √  
   MARC1 
 
√   
   MIA3 √ √  
   TAF1A √ √  
1 SORT1 rs12740374 AMPD2 √ √  
   ATXN7L2 √ √  
   CYB561D1 √ √  
   GNAI3 √ √  
   GNAT2 √   
   GSTM2 √ √  
   GSTM4 √ √  
   PSMA5 √ √  
   PSRC1  √ √ Monocytes 
   SARS √ √  
   SORT1 √ √  
2 APOB rs515135 LDAH √ √  
2 VAMP5-VAMP8-
GGCX 
rs1561198 GGCX  √ √ CEC 
   C2orf68 √ √  
   ELMOD3 √ √  
   MAT2A √ √  
   RETSAT √ √  
   RNF181 √ √  
   TGOLN2 √ √  
   TMEM150A √ √  
   USP39 √ √  
   VAMP5 √ √  
   VAMP8 √ √ Monocytes 
2 WDR12 rs6725887 CARF  √  
   FAM117B  √ √ CEC/ 
Monocytes 
   NBEAL1  √ √ CEC 
   WDR12 √ √  
3 MRAS rs9818870 MRAS  √ √ CEC 
6 ANKS1A rs12205331 C6orf106 √ √  
   RPS10 √ √  
   SNRPC √ √  
   UHRF1BP1 √ √  
6 PHACTR1 rs9369640, rs12526453 MYLIP  √  
   PHACTR1  √ √ CEC 
8 LPL rs264 INTS10 √ √  
8 TRIB1 rs2954029 TRIB1 √ √  
9 CDKN2BAS rs1333049, rs3217992, 
rs2383207 
CDKN2A √   
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* Only genes that have their interacting viewpoint as eQTL or genes with a significant gene-based P value (P < 
6.97x10-6 by gene-based test using VEGAS (corrected for multiple-testing 0.05/22 phenotypes x 326 available 
genes) are depicted. The full list of genes identified by 4C-seq can be found in Supplemental Table 1. 
Susceptibility locus indicates name of the locus as given by CARDIoGRAMplusC4D or METASTROKE; 
viewpoint indicates SNP used as the focus point for the primer design of the 4C experiment; Interacting gene 
represent  genes physically interacting with viewpoint, determined by 4C-seq;  Bolded genes indicate genes that 
have previously been reported by CARDIoGRAMplusC4D or METASTROKE; Chr: chromosome; eQTL: 
expression quantitative trait locus. 
 
investigators in the ASAP study41, as an eQTL for GGCX in aorta and tibial artery. For genes 
identified by 4C-seq in monocytes, we performed cis-eQTL analysis in monocytes from 370 
patients undergoing coronary angiography for coronary artery atherosclerosis in the CTMM 
(Center for Translational Molecular Medicine) Circulating Cells cohort.42 We identified four 
eQTL (FDR<0.1) of which the genes overlap with genes identified by 4C-seq in monocytes 
of these patients (rs12740374: PSRC1, rs1561198: VAMP8, rs2246833: LIPA, rs12413409: 
USMG5, Supplemental Table 3c). Previously, the CARDIoGRAMplusC4D investigators also 
identified rs1561198 as an eQTL for VAMP8 in lymphoblastoid cells and skin in the 
MuTHER study.43 Inclusion of the previously published cardiovascular cohort of Zeller et al. 
revealed five additional genes (Supplemental Table 3d).44 The SNP that revealed the 
   CDKN2B √ √  
10 CYP17A1-CNNM2-
NT5C2 
rs12413409 ARL3  √ √ CEC 
   USMG5 √ √ Monocytes 
10 CNNM2 rs12413409 BORCS7 √ √  
   WBP1L √ √  
10 KIAA1462 rs2505083 KIAA1462  √  CEC 
10 LIPA rs11203042, rs2246833 LIPA  √ √ CEC/ 
Monocytes 
13 COL4A1-COL4A2 rs4773144 COL4A1 √   
   COL4A2 √   
17 RAI1-PEMT-RASD1 rs12936587 PEMT  √ √ Monocytes 
   RASD1 √ √ Monocytes 
17 SMG6 rs2281727 SRR  √ √ CEC 
   SMG6 √ √  
17 UBE2Z rs15563 CALCOCO2 √ √ Monocytes 
   KPNB1  √  
   UBE2Z √ √ Monocytes 
19 LDLR rs1122608 C19orf52  √  
   CARM1  √  
   LDLR  √  
   SMARCA4  √  
   TSPAN16  √  
   YIPF2  √  
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strongest association with gene expression of PSRC1 in monocytes of CTMM (rs7528419) 
is in perfect LD (1.0) with rs12740374 in the SORT1 region. Interestingly, whereas the minor 
allele of the latter SNP is known to increase SORT1 expression in liver, we found no such 
association between rs7528419 and SORT1 expression in monocytes (nominal P = 0.87). In 
addition, we found an association between higher PSRC1 expression in monocytes with a 
more severe atherosclerotic phenotype identified by a higher atherosclerotic burden, 
quantified using the SYNTAX score (P = 0.003). This association with high atherosclerosis 
burden could not solely be explained by LDL levels, the putative mechanism through which 
SORT1 expression affects cardiovascular disease phenotypes (P when corrected for 
circulating LDL levels = 0.01). Expression of PSRC1 in whole blood has previously been 
associated with cardiovascular disease in an Asian population.45 Largely because the 
functional significance of the minor allele of rs12740374 as a transcription factor binding site 
that increases SORT1 expression directly, no further attention has been given to alternative 
candidate genes in the SORT1 region. With our 4C-seq approach in monocytes, we here 
show first evidence that the expression of PSRC1, a candidate gene in the SORT1 locus, is 
genotype-dependent expressed in monocytes and related to the severity of atherosclerosis. 
This example further supports the implication of our additionally identified candidate genes 
in cardiovascular disease. 
 
Additional genetic annotation 
We further explored current genetic knowledge for the candidate genes identified through 
4C-seq (Table 1, Supplemental Table 4-7). First, if the candidate genes are effector genes 
of the DREs within CVD susceptibility loci, one would expect the genes to be enriched for 
(common) variants associated with CVD. Using the VEGAS algorithm, we concatenated 
GWAS p-values of all single-nucleotide polymorphisms (SNPs) in or within 50kb of a gene 
into a p-value for that particular gene. This way, we studied the genes identified by 4C-seq 
in published and unpublished GWAS data studying a total of 22 traits, either surrogate 
markers of atherosclerosis or known risk factors for cardiovascular disease (Supplemental 
Table 4). Of all 326 candidate genes, 33 showed a significant association (P < 0.05/(22x326) 
= 6.97x10-6) with coronary artery disease in the CARDIoGRAMplusC4D GWAS and 149 
were nominally associated with coronary artery disease in the CARDIoGRAMplusC4D 
GWAS (significant enrichment, 149/326: binomial P = 2.9 x 10-102). Additionally, we found 7 
genes that were significantly associated with BMI in GIANT and 29 genes that were 
significantly associated with at least one lipid trait in GLGC. Second, we annotated the 
prioritized interacting genes from our 4C-seq experiment with phenotypic information of 
mouse models within the Mouse Genome Informatics database (MGI, 
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www.informatics.jax.org). We found murine phenotypic information on 144 mouse 
homologues (Supplemental Table 5). Knockout of 67 of them resulted in a phenotype 
related to cardiovascular disease (significant enrichment, 67/144: binomial P = 1.36x10-47), 
such as abnormal blood vessel morphology (Col4a1, Cxcl12, Epor, Shc1, Tcf7l1), altered 
circulating fatty acid levels (Csf2, Kdm3a, Ldlr, Lipa, Pten) and impaired vascular 
contractility (Acta2). Human variants in ACTA2 are associated with early onset stroke and 
MI.46 Knockout of two candidate gene murine homologues affected development of 
atherosclerotic lesions, namely Ldlr (accelerated development of atherosclerosis) and Shc1 
(resistance to diet-induced atherosclerosis). The p66 isoform of human SHC1 is implicated 
in reactive oxygen species generation and its knockdown in endothelial cells of obese mice 
attenuated production of these radicals and of fatty acids oxidation.47 Third, we investigated 
the biological effect of human knockout variation of the candidate genes to study 
druggability. We queried two datasets of available information on SNPs and 
insertion/deletion variants that cause human functional knockouts.29, 30 We found human 
knockouts, caused by nonsense, splice or frameshift variants, for 89 candidate genes 
(Supplemental Table 6). Fourth, using a custom-built drug discovery pipeline, we found 
available compounds to target 50 of the candidate genes (Supplemental Table 7a). These 
drugs showed a relative overrepresentation for usage as immunomodulating agents (P = 
0.012 in coronary endothelial cells, P < 0.001 in monocytes) (Supplemental Table 7b). 
Together, these findings provide further evidence that by using the 4C-seq method we 
identified additional candidate target genes for human atherosclerotic disease. 
 
 
Discussion 
Based on 3D chromatin-chromatin interactions with DNA regulatory elements that co-
localize with previously identified susceptibility loci, we present 294 additional candidate 
genes for CAD and LAS that are of potential interest in the pathophysiology of human 
atherosclerotic disease. This study is the first to systematically study the human chromatin 
interactions of the CARDIoGRAMplusC4D and METASTROKE loci. Many of the additional 
genes have not been implicated in atherosclerosis before. Our approach, from a DNA 
regulatory point of view, complements conventional methods for candidate gene 
identification of GWAS susceptibility, can help further unravel diseases with a complex 
genetic background, and pave the way for cell-type specific drug development. 
 
We have highlighted the 4C candidate genes that we could annotate via additional analyses 
and that therefore have known or foreseeable effects on cardiovascular disease. Based on 
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tissue-specific pathway analyses, we highlighted PTEN that is known to be upregulated by 
statins and to possess effects on atherosclerosis.37-39 Furthermore, based on eQTL studies, 
we identified SRR, the effect of which was previously implicated in stroke40, and USMG5, 
that was previously associated with white matter hyperintensities in the brain.48 Of special 
interest is the finding of an alternative mechanism by which the susceptibility locus that 
contains rs7528419 (SORT1 region) may exert its effect. Using 4C-sequencing we identified 
a physical interaction between an active regulatory element that overlaps rs7528419 and 
PSRC1 in monocytes. Moreover, we found an association between rs7528419 and the 
expression of PSRC1 in monocytes and an association between PSRC1 expression and 
atherosclerosis severity. This association was independent of LDL levels, which is the 
putative mechanism of rs12740374, a SNP in perfect LD (1.0) with rs7528419 that was 
previously found to increase SORT1 expression in liver.    
 
Mapping the SNPs that identify susceptibility loci in GWAS to genes that affect a complex 
disease, such as cardiovascular disease, is a challenging task. By annotating the locus with 
the linearly closest gene, the 3D conformation of chromatin is inadvertently not taken into 
account. Many of the additional candidate genes we report are located outside the GWAS 
susceptibility loci. Using 5C (chromosome conformation capture carbon copy) the 
importance of studying 3D interactions has been highlighted previously; in a sample of 628 
TSS from the ENCODE project only 7% of the over 1000 long-range looping interactions 
were with the nearest gene.11 In a previous effort to identify candidate genes based on DNA 
regulatory mechanisms, 33 enhancers in the 9p21 locus were scrutinized.49 Interestingly, the 
chromatin interaction between the enhancers identified by 3C (chromatin conformation 
capture) was found to be remodeled upon treatment with interferon-γ in HUVECs. In our 4C-
seq experiment, we confirmed the physical chromatin-chromatin interaction between the 
9p21 susceptibility locus and several candidate genes, among which interferons, in human 
coronary endothelial cells and monocytes. However, we found that these genes were not 
actively expressed in these cell types and therefore did not consider them any further.  
 
There are some limitations to this study. First, there is no consensus about the gold 
standard approach to analysis of 4C-seq data. For example, we used a conservative cut-off 
for calling a chromatin-chromatin interaction (P <10-8). Altering this cut-off may result in more 
candidate genes. However, this likely leads to more false-positive results. We therefore 
report a quantitative measure for the p-value of the interaction of the DRE with the proposed 
candidate gene to enable the reader to take these considerations into account when 
interpreting the data. Second, while 4C-sequencing enables us to look at physical 
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interactions, these interactions do not necessarily mean that the expression in the studied 
tissue is in fact regulated by the association locus or even expressed. We therefore decided 
to only report only genes that are actively expressed in the studied tissues. Furthermore, we 
found no eQTL association between the SNP of interest and any of the genes in the vicinity 
of the genes that were identified by 4C-sequencing, indicating that the resolution of the 
technique is sufficient to distinguish between candidate genes and less relevant genes 
within a genomic region. A more accurate cell type-specific mapping of susceptibility loci to 
candidate genes in humans is of paramount importance for the development of specific 
compounds in the pharmaceutical industry. The genes we identified display only partial 
overlap between coronary endothelial cells and monocytes. This finding stresses the 
importance of cell-specific approaches in order to grasp the complex biology of 
atherosclerotic disease. It also highlights the possibility to develop cell-specific compounds 
to target atherosclerotic disease. Our results therefore underline the need to investigate cell 
type-specific 3D chromatin conformation in future functional follow-up of GWAS data. 
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Supplemental data 
 
 
Supplemental Figure 1: Quality of 4C datasets of coronary endothelial cells and monocytes. The 
graphs show the quality measures of the 4C datasets. Y-axes shows the percentage of fragends 
covered around the viewpoint (measure for the complexity of the dataset), x-axes show the percentage 
of reads in cis i.e. the percentage of reads that map to the chromosome of the viewpoint (measure for 
the specificity of the dataset). Each dot represents one viewpoint. 
 
Supplemental Tables can be downloaded from: 
http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.116.001664/-
/DC1 
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Abstract  
Genome wide association studies (GWAS) identified many genetic risk factors for chronic 
kidney disease (CKD). However, linking common variants to genes that are causal for CKD 
etiology remains challenging. By adapting self-transcribing active regulatory region 
sequencing (STARR-seq), we demonstrated the perturbing effect of genetic variation on 
DNA regulatory elements (DRE). Variants in linkage with the CKD-associated SNP 
rs11959928 were shown to affect DRE function, illustrating that genes regulated by DREs 
colocalizing with CKD-associated variation can be dysregulated and therefore be considered 
as CKD candidate genes. To identify target genes of these DREs, we used circular 
chromosome conformation capture (4C) sequencing on glomerular endothelial cells and 
renal tubular epithelial cells. Our 4C analyses revealed interactions of CKD-associated 
susceptibility regions with the transcription start sites of 304 target genes. Overlap with 
multiple databases confirmed that many of these target genes are involved in kidney 
homeostasis. Expression quantitative trait loci analysis revealed that mRNA levels of many 
target genes are genotype dependent. Pathway analyses showed that target genes were 
enriched in processes crucial for renal function, identifying dysregulated geranylgeranyl 
diphosphate biosynthesis as a potential disease mechanism. Our data annotated multiple 
genes to previously reported CKD–associated SNPs and provided first time evidence for 
interaction between these loci and their target genes. This current pipeline provides a novel 
technique for hypothesis generation and complements classic GWAS interpretation. Future 
studies are required to specify the implications of our dataset and to further reveal the 
complex roles that common variants play in complex diseases such as CKD. 
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Introduction 
Chronic kidney disease (CKD) is a condition marked by loss of kidney function, which can 
lead to end stage renal disease and is associated with a dramatic increase in cardiovascular 
disease-related morbidity and mortality.1 Based on the latest report of the Center for Disease 
Control and Prevention (2007-2014), over 15% of the U.S. population is affected by CKD 
and the numbers are expected to rise. CKD incurs substantial rising medical costs in the 
U.S., with similar developments observed globally. Over the last decade, the findings of 
multiple genome wide association studies (GWASs) have established common DNA 
variants as genetic risk factors for CKD.2, 3 However, functional annotation and explanation 
of these loci remains an issue. Currently, the functional annotation of GWAS data is mainly 
conducted by linking susceptibility loci by spatial proximity to the nearest gene.4 For 
example, well-known single nucleotide polymorphisms (SNPs) that are associated with CKD 
include SNPs annotated with ALMS1 and UMOD. ALMS1 is required for medullar collecting 
duct ciliogenesis5, whereas UMOD is involved in the inhibition of calcium oxalate 
crystallization in renal fluids and has an evolutionary role in protection from urinary tract 
infections.6,7 Since these SNPs are located in coding regions of genes with important renal 
protective functions, it is conceivable that the genetic variation marked by these SNPs 
affects both genes, contributing to CKD pathogenesis. For many of the CKD associated 
susceptibility loci that are not directly located in or near protein coding regions, the causal 
contribution to disease etiology is far less straightforward.  
New insights brought by epigenetic research have revealed the prevalence of DNA 
regulatory elements (DREs), such as enhancers and repressors, located in both coding- and 
non-protein-coding DNA regions (Figure 1A).8 These DREs play a crucial role in regulating 
gene expression in a cell specific manner. Enhancer elements regulate transcription of their 
target genes through 3D chromatin interactions with transcriptional start sites (Figure 1B). 
Importantly, DREs can regulate expression levels of gene targets over a distance up to 
thousands of kilobase pairs (kbp)9, far exceeding the current standard distance for GWAS 
annotation. Common genetic variation in DREs could be a causative factor in dysregulation 
of target gene expression, leading to disease or other phenotypes (Figure 1C-D). This was 
demonstrated previously for the SNP rs12913832, which was shown to modulate human 
pigmentation by affecting the enhancer regulation of the OCA2 promoter.10 Systematic 
mapping of the target genes of DREs that overlap with known CKD associated SNPs, could 
greatly improve our understanding of the complex genetics of CKD.  
Here we used self-transcribing active regulatory region sequencing (STARR-seq) to 
evaluate the potential effect of CKD associated genetic variation on transcriptional 
regulation. In a proof of principle approach we cloned putative DREs located on the same 
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Figure 1: Genetic variation 
in DREs could be a 
causative factor in 
dysregulation of distal 
target gene expression. (A) 
Many of the susceptibility loci 
that are not located in protein 
coding regions, overlap with 
DREs such as enhancers and 
repressors. (B) DREs play a 
crucial role in regulating gene 
expression, in a cell specific 
manner, by modulating 3D 
chromatin interactions, and 
increasing spatial proximity of DREs with transcriptional start sites, thereby regulating transcription of 
genes on a non-linear DNA scale. (C) Distal transcriptional activity of DREs  could be compromised (D) 
by genetic variation (represented by colocalization with disease-associated SNP). 
 
linkage disequilibrium (LD) block as the CKD associated SNP rs11959928 from 20 donors in 
STARR-seq reporter plasmids. This approach enabled us to study the effect of all variants 
found on this susceptibility region in the donor pool on enhancer activity in primary human 
renal proximal tubular epithelial cells (HRPTECs), human renal glomerular endothelial cells 
(HRGECs), and the human embryonic kidney cell line HEK293a. The findings of this 
experiment illustrated how regulatory function could be affected by common small variants, 
thereby highlighting the relevance of studying downstream target genes of DREs 
overlapping with disease-associated susceptibility regions to add an additional layer to post 
GWAS analysis. Subsequently, we used circular chromosome conformation capture-
sequencing (4C-seq) to identify putative candidate genes for CKD by examining 3D 
interactions between DREs that colocalize with CKD susceptibility loci and their target 
genes. This allowed us to study long range regulation of target gene promoters by cross-
linking the folded and interacting DRE segments, followed by two restriction-ligation steps of 
the DNA strands and DNA sequencing. As transcriptional regulation is cell-type specific, and 
CKD pathogenesis is associated with reduced glomerular filtration rate as a result of tubulo-
interstitial fibrosis as well as loss of peritubular and glomerular capillaries11-13, we conducted 
the 4C-seq in HRPTECs and HRGECs. Chromatin interactions were studied in these 
primary cells from healthy donors to create an overview of genes interacting with CKD 
susceptibility loci. We conducted a systematic screen of 39 putative regulatory elements that 
colocalize with previously reported susceptibility regions for CKD. This led to the 
A 
B 
C D 
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identification of 304 target genes that are potentially transcriptionally affected by these CKD-
associated SNPs. This study shows for the first time a direct interaction between CKD-
associated common variant regions and the promoter regions of CKD-associated target 
genes. Although additional functional studies are needed to determine the exact mechanism 
of action, in its current form our data presents an extensive overview of potential target 
genes for the previously reported CKD-associated SNPs, providing new gene candidates for 
hypothesis-driven future studies.  
 
 
Methods 
Cell culture 
Primary human renal glomerular endothelial cells (HRGECs; derived from human donor cell 
biobank Sciencell) and human renal proximal tubular epithelial cells (HRPTECs; Sciencell) 
were cultured on fibronectin and gelatin coated plates on ECM medium (supplemented with 
endothelial cell growth kit, and penicillin/streptomycin; Sciencell), and EpiCM medium 
(supplemented with epithelial cell growth kit, and penicillin/streptomycin; Sciencell) 
respectively. Human Embryonic Kidney Cells (HEK293a) were cultured on gelatin coated 
plates on DMEM (Lonza) supplemented with 10% fetal calf serum (Gibco) and 100U/ml 
penicillin/streptomycin (Lonza). All cells were cultured in 5% CO2 at 37 ˚C. The experiments 
with primary cells were conducted with cells at passage 3. 
 
STARR-seq reporter assay 
DNA from 20 individual donors was isolated from whole blood obtained from the Mini Donor 
Service (positive approval from the medical ethics committee of the UMC Utrecht – protocol 
number 07/125) via salt precipitation. Regions (~1200 base pairs in size) containing DNase 
hypersensitivity sites overlapping with candidate variants (minor allele frequency>0.03) 
within the susceptibility locus were PCR amplified (primers in Supplemental Table 1), 
equimolarly pooled and cloned into pSTARR-seq_human vector (Addgene). The library 
complexity was verified by dilution series after transformation and was estimated to contain 
50.000 individual reporter clones. 40 million cells were placed in 1600µl electroporation 
buffer (Bio-Rad) supplemented with 120µg (HEK293a) or 240µg (HRPTECs and HRGECs) 
library, after which electroporation mixture was divided over 16 2mm electroporation 
cuvettes (Bio-Rad), followed by electroporation with a square wave (110V/25ms for 
HEK293a, 125V/20ms for HRPTECs and HRGECs) using Gene Pulser Xcell™ (Bio-Rad). 
After electroporation cells were seeded in normal culture medium for 24h, followed by RNA 
extraction using the RNeasy isolation kit (Qiagen). The polyadenylated fraction of the total 
RNA was isolated using Dynabeads Oligo dT 25 (Thermo Fisher). The reporter specific 
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cDNA was synthesized and amplified according to standard STARR-seq protocols.14 The 
amplified cDNA was subsequently fragmented (Covaris S2 ChIP seq programme (power 
peak 40, duty factor 5 cycle/burst 200)) and cleaned, followed by sequencing library 
preparation using NEXTflex ChIP-Seq library prep kit for Illumina sequencing. The libraries 
were sequenced on Illumina NextSeq500 platform to produce 75bp long single end reads. 
 
4C-seq  
4C template was prepared as previously described.15 In summary, 10 million HRGECs or 
HRPTECs (both primary cells from healthy donors) were fixed in 2% formaldehyde, after 
which cells were lysed. The chromatin of the lysed cells was digested with the 4 base cutter 
DPNII (NEB), followed by ligation in a heavily diluted environment with T4 ligase (Roche). 
The ligated samples were de-crosslinked, followed by a second digestion with the 4 base 
cutter CvIQI (NEB). Next, samples were ligated once more in a diluted environment after 
which the chromatin was purified. The efficiency of each digestion and ligation step was 
validated on agarose gels. Viewpoints were selected based on the CKD susceptibility loci 
found in the GWASs of Y. Okada et al. (2012) and A. Köttgen et al. (2010). If multiple SNPs 
were found in a genomic region spanning less than 20kbp, only the SNP with the lowest P 
value was selected as viewpoint. To study the chromatin interactions of CKD associated 
susceptibility loci with 4C, primers were designed for each viewpoint as described 
previously.15 Briefly, primers were designed within a 5kbp window surrounding the CKD 
associated SNP. Forward primers were designed in the first restriction site and the reversed 
primers were designed close to the second restriction site (<100bp), with a minimum 
distance of 300bp between the forward and the reversed primer. In case no suitable primers 
could be designed based on these specifications, either the window size surrounding the 
SNP was increased to 10kbp or the distance between the forward and reversed primer was 
reduced (Supplemental Table 8). 4C libraries were sequenced using the NextSeq500 
platform (Illumina), producing single end reads of 75bp. The raw sequencing reads were 
then de-multiplexed based on viewpoint specific primer sequences. Reads were trimmed to 
16 bases and mapped to an in silico generated library of fragends (fragment ends) 
neighboring all DpnII sites in human genome (NCBI37/hg19), using the custom Perl 
scripts.16 No mismatches were allowed during the mapping. The reads mapping to only one 
possible fragend were used for further analysis. 
 
Target gene identification 
First, the number of covered fragends within a running window of k fragends throughout the 
whole chromosome was calculated (only the viewpoint’s chromosome was taken into 
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account). The k was set separately for every viewpoint so it contained on average 20 
covered fragends in the area around the viewpoint (+/- 100 kbp). Next, we compared the 
number of covered fragends in each running window to the theoretical random distribution. 
The windows with significantly higher number of covered fragends compared to random 
distribution (p<10-8 based on binominal cumulative distribution function; R pbinom) were 
considered as a significant 4C signal. The following criteria were defined for the identification 
of the candidate genes: (1) The Transcriptional Start Site (TSS) colocalizes with a significant 
4C-seq signal (p<10-8) within 5kbp. (2) The susceptibility variant or other variant in linkage 
disequilibrium (LD) colocalizes with at least one of the published datasets that represent 
candidate regulatory sequences (Supplemental Table 3) in a similar cell type as from which 
the 4C signal was. (3) The candidate gene has been validated to be expressed by mRNA 
datasets. 
 
Identification of gene expression 
HRPTECs expression data was used from publically available datasets (NCBI Gene 
Expression Omnibus accession number GSE12792).17 Expression data from microvascular 
endothelium was generated via RNA extraction from cultured microvascular endothelial cells 
in low serum medium (EBM-2 medium supplemented with 0.5% fetal calf serum) using the 
RNeasy isolation kit. Poly(A) Beads (NEXTflex) were used to isolate polyadenylated mRNA, 
from which sequencing libraries were made using the Rapid Directional RNA-seq kit 
(NEXTflex). Libraries were sequenced using the Nextseq500 platform (Illumina), producing 
single end reads of 75bp. Reads were aligned to the human reference genome GRCh37 
using STAR version 2.4.2a. Picard’s AddOrReplaceReadGroups (v1.98) was used to add 
read groups to the BAM files, which were sorted with Sambamba v0.4.5 and transcript 
abundances were quantified with HTSeq-count version 0.6.1p1 using the union mode. 
Subsequently, RPKMs were calculated with edgeR’s RPKM function. Genes were accepted 
as expressed if probe intensity >6 or log2(RPKM) >-1 in HRPTECs and microvascular 
endothelium, respectively. 
 
Haploblock localization 
Haploview (Broad Institute) was used to download LD plots 500kb up- and downstream from 
CKD associated SNPs (pairwise comparisons of markers <2000kbp apart). From these LD 
plots, haploblocks, containing CKD associated SNPs, were extracted to evaluate target 
gene localization in relation to CKD associated susceptibility region. 
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Genetic annotation with OMIM 
The Online Mendelian Inheritance in Man (OMIM) morbid map database was used to find 
mutant alleles that were associated with CKD. CKD associated traits were mapped based 
on the phenotype category queries ‘renal’, ‘kidney’, and ‘nephro’. The gene set found in 
OMIM was used to identify known CKD associated genes in the list of genes generated via 
the 4C-seq approach. 
 
Genetic annotation with MGI 
The MGI database was used to find monogenic mutant murine alleles that led to CKD 
related traits. A data file containing the ‘approved gene name’ and the ‘mouse genome 
database ID’ was downloaded from the HUGO Gene Nomenclature Committee to identify 
the mutated murine genes in the MGI database that led to CKD related traits. CKD related 
traits were mapped based on the following phenotype categories: Abnormal kidney 
morphology, abnormal kidney angiogenesis, urine abnormalities, blood abnormalities, 
glomerulus abnormalities, renal tubules abnormalities, podocyte abnormalities, kidney cysts, 
abnormal renal filtration, other kidney related traits. The gene set found in MGI was used to 
identify known CKD associated genes in the list of genes generated via the 4C-seq 
approach. 
 
eQTL study in GTEx portal 
The GTEx portal database, containing data on eQTL in 449 genotyped donors with 
expression data in 44 different tissues was used to list genes that significantly correlated in 
their expression with CKD associated SNPs that colocalized with active DREs. Genes found 
via this approach were overlapped with the 4C-seq captured gene list to validate whether 
the 4C-seq approach indeed detected target genes that showed correlations in expression 
levels with the CKD associated SNPs. 
 
Pathway analysis 
Datasets were analyzed using QIAGEN’s IPA. IPA was used to study both enrichment of 
4C-seq identified genes in canonical pathways and upstream regulators of identified 
candidate genes, independently for HRGECs and HRPTECs. P-values were calculated 
based on a right-tailed Fisher Exact Test, calculated by IPA. Expression levels of upstream 
regulators of which target genes were found enriched in the candidate genes identified by 
4C-seq were evaluated in a publically available micro-array dataset which was used to study 
gene expression in CKD in renal biopsy specimens (NCBI Gene Expression Omnibus 
accession number GSE66494).18 
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Results 
STARR-seq demonstrates the effect of genetic variation on  regulation of gene expression 
To illustrate the effect of genetic variation on regulatory activity of DREs as an additional 
layer to GWAS interpretation, the STARR-seq reporter set-up was used to test the influence 
of common genetic variants colocalizing with possible DREs positioned on the haploblock 
marked by the CKD-associated SNP rs11959928. The STARR-seq reporter assay is based 
on a reporter plasmid containing a minimal promoter, followed by an incorporated candidate 
enhancer sequence.14 The activity of each enhancer is reflected by its ability to induce the  
promoter activity leading to RNA transcription of the enhancers sequence (Figure 2A). The 
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◄ Figure 2: STARR-seq analysis illustrates the effect of CKD-associated genetic variation on 
transcriptional regulation. (A) The STARR-seq reporter principle is based on a reporter plasmid 
containing a minimal promotor, followed by a cloned candidate enhancer sequences. The activity of 
each enhancer is reflected by its ability to transcribe themselves. (B) Putative DREs, identified by 
H3K4Me1, H3K27Ac, and DNAse clusters (Human Umbilical Vein Endothelial Cells in blue, Human 
Epidermal Keratinocytes in pink, overlap in purple - adapted from USCS genome browser), located on 
the haploblock marked by CKD-associated SNP rs11959928 (I, II, III) were cloned into the STARR-seq 
plasmid from 20 individual donors. (C) The library of STARR-seq plasmids was transformed in 
HRGECs, HRPTECs and HEK293a, followed by RNA-seq of the produced enhancer RNA strands. 
Shown in replicate is the percentage of the reference allele in the input library, the percentage of the 
reference allele in cellular transcribed RNA, and the delta between the prevalence in the library versus 
transcribed RNA (found in region I). 
 
advantage of this approach over luciferase reporter assays is that STARR-seq allows 
parallel (and thus “high throughput”) assessment of all genomic variation in the enhancer 
regions located on this specific haploblock, as the effect of a variant on enhancer strength is 
reflected by its relative prevalence in transcribed RNA compared to its prevalence in the 
pool of reporter plasmids. Putative DREs located on the haploblock marked by the CKD-
associated SNP rs11959928 (Figure 2B), containing at least three potential regulatory 
regions (I, II, III) as illustrated by H3K4Me1, H3K27Ac, and DNAse clusters in human 
umbilical vein endothelial cells and human epidermal keratinocytes (adapted from USCS 
genome browser), were cloned from 20 individual donors into one combined reporter library 
(Supplemental Table 1). This library was transformed in HRGECs, HRPTECs and HEK293a 
(the latter cell type was used an additional control), followed by sequencing of the produced 
enhancer derived RNA, as well as the library itself, enabling us to compare transcription 
frequency of each variable allele located in the enhancer sequences on the haploblock with 
its original frequency in the library (Supplemental Table 2). Via this approach, one particular 
region containing 5 variants was found to be strongly affected by allele specific activity in all 
three examined cell types (Figure 2C). Four of these variants had a reference allele 
frequency of 45.2-74.8% in the library input, yet virtually only the reference alleles were 
transcribed in all three cell types. The other allele had a wild-type penetrance of 31.8-36.5% 
in the library input, but its frequency was strongly reduced in the transcribed RNA. This 
example illustrates that disease-associated SNPs may not only affects gene coding 
sequences, but might also affect the transcriptional regulation of DRE target genes. 
 
4C-seq leads to discovery of new target genes for CKD-associated SNPs 
Building on the illustrative STARR-seq findings, 39 CKD associated susceptibility loci that 
colocalize with DREs were studied in HRGECs and HRPTECs in order to identify the target 
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genes of putative DREs.2, 3 Activity of these DREs was assessed in renal epithelium and 
fetal renal tissue for HRPTECs and microvascular endothelium for HRGECs based on 
DNase hypersensitivity and H3K4me3 chromatin immunoprecipitation data (Supplemental 
Table 3). Of the 39 studied loci, 6 colocalize only with active DREs in renal epithelium, 5 
colocalize only with active DREs in microvascular endothelium, and 28 loci colocalize with 
active DREs in both renal epithelium and microvascular endothelium. For the discovery of 
target genes of these regulatory elements, the TSSs that interacted with these loci were 
examined in HRPTECs and HRGECs using 4C-seq (Figure 3A-F). 67 chromatin interaction 
 
 
Figure 3: 4C-seq was used to study chromatin interactions leading to the discovery of 304 CKD 
target genes in total. The 3D chromatin conformation of the DREs was studied in detail based on 4C 
template, which was generated by fixing the chromatin structure (A), followed by enzymatic (DPNI) 
digestion of the fixed chromatin (B). The digested chromatin was ligated into circular fragments (C), 
after which the chromatin was de-crosslinked (D). The circular DNA molecules followed another round 
of enzymatic (CvIQI) digestion and ligation, after which the 4C-seq library was prepared with primers 
that target sequences in close proximity of the CKD susceptibility loci (E). This library was sequenced to 
identify genes that were physically interacting with CKD susceptibility loci (F). (G) The 4C analysis was 
performed on 48 viewpoints based on CKD associated SNPs, of which in total 39 colocalized with 
DNase hypersensitivity or H3K04me3 ChIP-seq datasets (33 in HRGECs and 34 in HRPTECs with 
partial overlap of SNPs). Of these 39 studied viewpoints, only 36 (31 in HRGECs and 34 in HRPTECs 
with partial overlap of viewpoints) were interacting with a total of 304 target genes with validated 
expression in the assessed cell types. These 304 genes were subsequently processed for genetic 
annotation to renal failure associated traits in the online mendelian inheritance in man (OMIM) database 
and the mouse genome informatics (MGI) database, in addition to eQTL analysis in the GTEx portal 
database, and pathway analysis using Ingenuity Pathway Analysis (IPA) software. 
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Figure 4: Analysis of 
chromatin interactions 
of CKD susceptibility 
loci using 4C-seq led to 
the discovery of 199 
CKD target genes in 
human renal glomerular 
endothelial cells. (A) 
Chromatin interactions 
were studied in cultured 
HRGECs to define 
endothelial target genes of 
CKD suscep-tibility loci 
that colocalize with active 
regulatory elements. (B) 
Of a total of 33 replicated 
4C datasets, based on 
CKD suscep-tibility loci 
that colocalize with active 
regulatory elements, 30 
interacted with at least one 
target gene that was 
expressed in endothelium, 
which led to the 
identification of 199 CKD 
target genes. Studied 
SNPs are displayed 
ordered on position, 
followed by haploblock 
information and the SNP-
TSS distance in kbps. 
*SNP solely associated 
with serum creatinine 
(estimated glomerular 
filtration rate), **SNP 
solely associated with 
serum urate, ***SNP 
solely associated with 
blood urea nitrogen, nsnon-
synonymous SNP. 
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Figure 5: Analysis of 
chromatin interactions of CKD 
susceptibility loci using 4C-
seq led to the discovery of 229 
CKD target genes in human 
renal proximal tubular 
epithelial cells. Chromatin 
interactions were studied in 
cultured HRPTECs to define 
epithelial target genes of CKD 
susceptibility loci that colocalize 
with active regulatory elements. 
(B) Of a total of 34 4C datasets, 
based on CKD susceptibility loci 
that colocalize with active 
regulatory elements, 34 
interacted with at least one target 
gene that was expressed in 
HRPTECs, which led to the 
identification of 229 CKD target 
genes in total. Studied SNPs are 
displayed ordered on position, 
followed by haploblock 
information and the SNP-TSS 
distance in kbps (B). *SNP solely 
associated with serum creatinine 
(estimated glomerular filtration 
rate), **SNP solely associated 
with serum urate, ***SNP solely 
associated with blood urea 
nitrogen, nsnon-synonymous 
SNP. 
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datasets were generated in twofold, of which only the replicated chromatin interactions were 
considered as candidate genes. These candidate genes were filtered per cell type for  
expression in that specific cell type, using in-house and public expression datasets (Figure 
3G). This led to the discovery of 304 CKD target genes, of which 199 were found in 
HRGECs (Figure 4, Supplemental Table 4) and 229 in HRPTECs (Figure 5, Supplemental 
Table 5). Amongst the 199 target genes interacting in HRGECs and 229 target genes 
interacting in HRPTECs, 124 were identified in both cell types (Figure 3G). These 304 
candidate genes all fulfilled the following three criteria: (1) The TSS of the candidate gene 
colocalizes with a significant 4C-seq signal (P<10-8) within 5kbp. (2) The SNP or any other 
SNP in LD (r>0.8) colocalizes with active regulatory regions. (3) The candidate gene is 
expressed in the cell types of interest (reads per kilobase million reads sequenced (RPKMs) 
>-1 and probe intensity >6 for microvascular endothelium RNA-seq data and HRPTECs 
microarray data, respectively).19 The TSS of the majority of candidate genes found with 4C 
(both expressed and non-expressed), were positioned within 500kbp from the lead SNP 
position (88% in HRGECs, 84% in HRPTECs), but occasionally interacting genes were 
found over 1000kbp from the SNP locus (7 in HRGECs, 23 in HRPTECs) (Supplemental 
Figure 1A-B).  
 
Genetic annotation of candidates in OMIM and MGI demonstrates link with CKD 
We evaluated if the identified candidates were associated with CKD, using the Online 
Mendelian Inheritance in Man (OMIM) and the Mouse Genome Informatics (MGI) database. 
The OMIM database is a catalogue of human genetic disorders that connects rare gene 
variants with phenotype. We established the overlap of our HRPTECs and HRGECs gene 
lists with the genes retrieved from the OMIM Morbid Map by searching for the keywords 
“kidney”, “renal” and “nephro”. Monogenetic defects in 5 CKD candidate genes were directly 
correlated with a renal disease phenotype, of which 2 are completely located on a different 
haploblock than the 4C viewpoint (table 1, green mark). The MGI database contains murine 
phenotypic information of mutant alleles. Analysis revealed that monogenetic silencing of 23 
of the CKD candidate genes in mice, caused direct renal failure related traits, including 
albuminuria (ALMS1, MPV17, SCARB2), abnormal renal filtration rate (SLC14A1), and 
glomerular sclerosis (CCNI, MPV17, VEGFA) (table 2). Of the 23 renal failure traits 
associated target genes found with MGI, 13 are located entirely on a different haploblock 
than the 4C viewpoint (green mark). 
 
eQTL analysis reveals genotype dependent expression of CKD candidate genes 
A candidate gene with an expression level that is significantly correlated with co-occurrence 
of a SNP is likely to be transcriptionally regulated by a DRE affected by the SNP. These loci 
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Table 1: Overlapping genes in 4C-seq retrieved genes and CKD associated genes in OMIM. 
 
 
 
Table 2: Overlapping genes in 4C-seq retrieved genes and CKD associated genes in MGI. 
  
Gene ID Phenotype MIM Number 4C SNP SNP-TSS (kbp) HRGECs HRPTECs
MUC1 Medullary cystic kidney disease 1 158340 rs2049805 32 x x
PKD2 Polycystic kidney disease 2 173910 rs2725220 31 x
SCARB2 Epilepsy, progressive myoclonic 4, with or without renal failure 602257 rs13146355 277 x x
SLC2A9 Hypouricemia 612076 rs3775948 28 x
SLC34A1 Nephrolithiasis/osteoporosis, hypophosphatemic 182309 rs6420094 6 x
Gene completely outside SNP haploblock
Gene completely inside SNP haploblock
SNP haploblock inside gene
Gene ID Phenotype 4C SNP SNP-TSS (kbp) HRGECs HRPTECs
ALMS1 abnormal kidney morphology, urine-, renal tubules-, and other rs13538 255 x x
kidney related abnormalities
ASH1L glomerulus- and other kidney related abnormalities rs2049805 337 x x
CCNI urine-, blood-, glomerulus-, podocyte-, and other kidney related rs13146355 585 x x
abnormalities
CTSS abnormal kidney angiogenesis rs267734 213 x x
DCTN1 blood abnormalities rs13538 734 x
GNAS urine- and other kidney related abnormalities rs6026584 54 x x
GRK6 glomerulus- and other kidney related abnormalities rs6420094 36 x x
IFT172 abnormal kidney morphology, glomerulus abnormalities rs1260326 18 x
MAF abnormal kidney morphology, renal tubules abnormalities rs889472 11 x
MECOM blood abnormalities rs16853722 287 x x
MPV17 abnormal kidney morphology and angiogenesis, urine-, blood-, rs1260326 185 x
glomerulus-, renal tubules-, and other kidney related abnormalities
PKD2 abnormal kidney morphology, kidney cysts, blood-, renal tubules-, rs2725220 31 x
and other kidney related abnormalities
RNF7 abnormal kidney angiogenesis rs347685 350 x x
SCARB2 urine abnormalities rs13146355 277 x x
SHC1 abnormal kidney angiogenesis rs2049805 252 x
SLC14A1 urine- and blood abnormalities, abnormal renal filtration rs7227483 117 x
SLC14A2 urine abnormalities, abnormal renal filtration rs7227483 8 x
SLC2A9 kidney cysts, urine-, blood-, renal tubules-, and other kidney related rs3775948 28 x
abnormalities
SLC4A5 urine abnormalities, abnormal renal filtration rs13538 702 x
SLC7A9 renal tubules abnormalities rs12460876 4 x
SOD2 blood abnormalities rs2279463 554 x
THBD abnormal kidney morphology rs911119 582 x
VEGFA abnormal kidney morphology and angiogenesis, blood-, glomerulus-, rs881858 69 x x
renal tubules-, and podocyte abnormalities
Gene completely outside SNP haploblock
Gene partly in SNP haploblock
Gene completely inside SNP haploblock
SNP haploblock inside gene
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that contribute to variation in gene expression levels, called expression quantitative trait loci 
(eQTL), are identified using GWAS and RNA-seq data of the target organ. To date, no large 
genome wide eQTL data of the human kidney has been published that allows adequate 
analysis of all CKD associated SNPs.20 To evaluate if the expression levels of the CKD 
candidate genes are affected by CKD-associated SNPs, we used the Genotype-Tissue 
Expression (GTEx) database. Although GTEx so far only contains kidney specific 
expression data of 26 genotyped donors, which does not reach the GTEx threshold for 
eQTL analysis (>70), the database does include genotype- and expression-matched data of 
449 donors for which eQTL analysis was conducted in 44 non-renal tissues, which is large 
enough to stratify most of the individual CKD SNPs and wild-type alleles assessed in our 
study. Of the 39 CKD associated susceptibility loci, 25 were annotated in GTEx. These 25 
SNPs were significantly correlated with the expression of 54 genes, of which 48 physically 
interacted with the 4C-seq input loci (data not shown). Of these 48 captured target genes, 
38 were actually expressed in HRPTECs and/or HRGECs and included 10 genes located  
on a completely different haploblock than the CKD-associated SNP (table 3, green mark). 
Thus, although the lack of genotype-kidney expression datasets prohibited us to study these 
eQTLs in renal tissue, this demonstrates the ability of the studied elements to establish a 
SNP dependent expression pattern of captured target genes in the 4C-seq approach. 
Interesting eQTL target genes also picked up by 4C-seq include the solute carriers 
SLC28A2 and SLC30A4 (rs2453533), and in relation to renal fibrosis, the genes encoding 
for the secreted proteases CTSS and CTSK (rs267734) (Figure 6A-B). 
 
Pathway analysis reveals potentially disrupted mechanisms and regulators in CKD 
Besides studying individual loci and interacting genes, we used Ingenuity Pathway Analysis 
(IPA, QIAGEN) to determine the pathways in which the CKD candidate genes are involved 
in. In both HRGECs and HRPTECs the 4C candidate genes were most significantly enriched 
in biosynthesis pathways (Supplemental Table 6 and 7), including the superpathway of 
geranylgeranyl diphosphate biosynthesis (p=4.17E-04, p=7.26E-04), and the trans, trans-
farnesyl diphosphate biosynthesis pathway (p=6.63E-06, p=1.11E-03), respectively (Figure 
7A-B). Interestingly, both molecular pathways are linked to the mevalonate pathway 
(Supplemental Figure 2). 4C-seq identified FDPS and PMVK (rs2049805), and IDI1 and IDI2 
(rs10794720) as candidate genes in relation to the mevalonate pathway in CKD. In addition, 
IPA was used to identify upstream regulators of which the target genes were 
overrepresented amongst the CKD candidate genes. Targets of the transcription factors 
ATF6 (p=2.00E-03, p=4.50E-04) and FOXO4 (p=5.23E-05, p=1.24E-04) were significantly 
enriched in the CKD candidates in both HRGECs and HRPTECs respectively, whereas 
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eQTL Gene ID SNP-TSS (kbp) eQTL in (tissue): HRGECs HRPTECs
rs10794720 IDI2 84 Muscle x
NUDT19 174 Artery, Nerve x
SLC7A9 4 Adipose, Skin, Thyroid, Nerve, Lung x
TDRD12 146 Testis x
SNX17 138 Muscle x x
FNDC4 13 Thyroid x x
NRBP1 79 Adipose, Testis x x
KRTCAP3 66 Adrenal gland x
ALMS1 255 Pancreas x x
TPRKB 96 Artery x x
NAT8 1 Adipose, Thyroid, Skin, Esophagus, Pancreas, Artery, Brain x
THBS3 17 Whole Blood, Thyroid, Esophagus, Colon, Lung, Stomach, Testis, Spleen x x
GBA 16 Esophagus, Nerve, Thyroid x x
MUC1 32 Esophagus x x
FAM189B 30 Thyroid x x
EFNA1 95 Skin x x
HCN3 52 Nerve x
SPATA5L1 53 Nerve, Adipose, Esophagus, Thyroid, Whole Blood, Artery, Muscle, Heart x x
SLC30A4 174 Adipose x
GATM 30 Thyroid, Muscle, Esophagus, Lung, Skin, Whole blood x
SLC28A2 97 Nerve, Thyroid, Adrenal gland, Colon, Ovary x
ANXA9 3 Skin, Testis x x
CTSS 213 Adipose, Skin, Artery, Muscle, Thyroid, Nerve, Esophagus x x
CTSK 171 Whole blood x x
ARNT 102 Whole blood x
rs2725220 PKD2 31 Testis, Esophagus x
rs4744712 FAM122A 40 Artery x
MEN1 114 Testis x
NRXN2 53 Lung, Artery, Esophagus, Nerve, Adipose, Muscle, Skin x
RGS14 33 Skin, Artery, Testis x x
FGFR4 304 Nerve x
SLC34A1 6 Esophagus x
RSBN1L 91 Brain x
TMEM60 11 Artery, Testis x
rs653178 ALDH2 197 Skin x x
rs911119 CST3 6 Testis, Lung, Whole blood, Nerve x x
rs9895661 TBX2 238 Artery x
Gene completely outside SNP haploblock
Gene partly in SNP haploblock
Gene completely inside SNP haploblock
SNP haploblock inside gene
SNP not in defined haploblock
rs504915
rs6420094
rs6465825
rs12460876
rs1260326
rs13538
rs2049805
rs2453533
rs267734
Table 3: Overlapping genes in 4C-seq retrieved genes and eQTL genes derived from GTEx portal. 
 
 
targets of HNF4α were only enriched in HRPTECs (p=3.76E-02). It was previously shown 
that HNF4α was crucial for establishing and maintaining transcriptional enhancer elements 
in the renal proximal tubule and that sub-optimal DNA binding properties amongst others led 
to transcriptional dysregulation of a variety of solute carriers.21 Interestingly, from publically 
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Figure 6: Expression levels of 4C-seq captured genes are correlated with the associated CKD 
SNP. (A) The expression level of solute carriers SLC28A2 and SLC30A4 is lower in the presence of the 
heterozygous (Het) and homozygous alternative (Homo Alt) allele (rs2453533), compared to the 
homozygous reference (Homo Ref) “wildtype” allele, p-value 6.8E-10 and 1.9E-05, respectively 
(adjusted from GTEx portal). (B) Similarly, the expression levels of the secreted proteases CTSS and 
CTSK are lower in the presence of the heterozygous and homozygous alternative allele (rs267734), 
compared to the homozygous reference allele, p-value 1.4E-07 and 0.5E-06, respectively (adjusted 
from GTEx portal). SNP-target gene pair p-values were based on matrix eQTL analysis in linear 
regression mode, as described by the GTEx consortium.22 
 
available micro-array data (NCBI Gene Expression Omnibus accession number 
GSE66494)18 all three transcription factors were found to be significantly upregulated in 
renal biopsies from patients with CKD compared to healthy controls (Figure 7C), suggesting 
these three factors are potentially key regulators in CKD.  
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Figure 7: CKD candidate genes are enriched in pathways of biosynthesis, microangiopathy and 
molecular transport. IPA revealed that CKD candidate genes in both HRGECs (A) and HRPTECs (B) 
were most enriched in biosynthesis pathways, including the superpathway of geranylgeranyl 
diphosphate biosynthesis, and the trans, trans-farnesyl diphosphate biosynthesis pathway. These 
pathways play crucial roles in protein reuptake in HRPTECs. P-values were calculated by a right-tailed 
Fisher Exact Test. (C) Upstream regulators, identified by IPA based on the enrichment of their target 
genes in the 4C-seq derived candidates, were significantly higher expressed in renal biopsy specimens 
from CKD patients (derived from GSE66494). *p<0.05, **p<0.001, p-values were calculated by a non-
parametric t-test. 
 
 
Discussion 
The main findings of the study are: (1) CKD-associated variation can affect transcriptional 
regulation, as demonstrated in a proof of principle approach for rs11959928 using STARR-
seq. (2) CKD-associated loci interact with promoter regions of target genes via 3D chromatin 
folding. By taking this DNA regulatory information into account in GWAS annotation, we 
found many novel CKD candidate genes. (3) Multiple SNP-target genes sets can be 
distinguished. (4) The identified target genes can be linked to CKD in human and murine 
disease databases (OMIM and MGI). (5) eQTL analysis reveals that expression of many 
target genes are genotype dependent. (6) HRGECs and HRPTECs-derived target genes 
share trans, trans-farnesyl diphosphate biosynthesis pathway as a common molecular 
mechanism. Combined, our data annotated multiple new genes to previously reported CKD–
associated SNPs and provided first time evidence for direct interaction between these 
common variant regions and their targets. Future studies are now required to pinpoint causal 
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genetic variant(s) at each locus, allowing a deeper understanding of their associated 
disease mechanisms and their relevance in kidney disease. 
 
Previously reported GWASs for CKD-associated SNPs used classic annotation based on 
spatial proximity principles to identify affected target genes.4 This includes annotation of 
SNPs based on location in coding regions or in close proximity of TSS (taking into account 
that the average promotor is 100-1000bp long), but also taking into consideration that these 
SNPs could be markers for less common variants in gene bodies. Using STARR-seq 
analysis, variants in LD with the CKD-associated SNP rs11959928 were shown to affect 
activity of a DRE in an allele specific manner, emphasizing that not only protein coding 
variants, but also variants located in regulatory regions could be at the basis of development 
or progression of complex diseases. Therefore, we examined the 3D folded state of the 
chromatin by 4C-seq to list genes that interact with DREs in LD with CKD associated SNPs. 
This approach led to the identification of 304 CKD candidate genes of which many are not 
directly located near the associated susceptibility loci. Most enhancers are located several 
hundreds, sometimes even thousands kbp from their target genes.9 In our study, the 
majority of the SNPs are located between 100-500kbp from the target genes’ TSS, 
supporting the idea that the interactions observed in the 4C-seq approach are enhancer-
target gene interactions. The effect of common genetic variants in DNA regulatory elements 
is relatively low23, therefore it is unlikely that the CKD associated SNPs in these elements 
will result in creating new or completely ablating 3D DRE-gene interactions. Rather, 
dysregulation in the expression of a gene profile that is part of the regulation of kidney 
homeostasis in healthy individuals, is more likely the contributing factor in CKD etiology. The 
4C-seq approach helps interpreting genetic variants as a determining factor of the 
expression levels of interacting targets in the pathogenesis of CKD. 
By overlapping our 304 CKD target genes with datasets provided by OMIM and MGI, we 
confirmed their relevance to kidney disease: Analysis with the MGI database showed that 
mice deficient for the CKD candidate genes MPV17, CCNI, ASH1L and SLC4A5 suffer from 
renal failure related traits.24-27 These genes are located 185kbp (rs1260326), 585kbp 
(rs13246355), 337kbp (rs2049805), and 702kbp (rs13538) from the CKD associated SNP 
respectively. In addition, validation of the 4C-seq approach was provided by analysis in the 
OMIM dataset, which demonstrated that multiple target genes were linked to CKD 
associated traits in human. For example, MUC1 and PKD2 were identified by 4C-seq, as a 
result of the interaction of their promoter regions with regulatory domains that colocalize with 
rs2049805 and rs2725220, respectively. MUC1 encodes the protein mucin-1, which is a 
membrane anchored mucoprotein involved in providing a protective barrier against 
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pathogens. A frameshift mutation in MUC1, leading to a novel stop codon, induced medullar 
cystic kidney disease type 1 (MIM: 158340).28 PKD2 encodes the polycystin-2 protein, which 
is involved in renal calcium transport and calcium signaling. Mutations in the gene, leading 
to loss of function, causes the formation of fluid-filled cysts, eventually leading to progressive 
destruction of the renal parenchyma (MIM: 173910)29, but was recently also demonstrated to 
be involved in branching and network formation of lymphatic endothelium which plays a 
crucial role in renal function.30, 31 Such examples illustrate the potential relevance of the 
candidate genes identified by 4C-seq for renal function, and provide clear evidence for the 
functional association between the investigated SNP regions and their corresponding 4C-
seq captured genes in (human) CKD. 
Evidence for the transcription regulatory function of the CKD-associated SNP regions was 
provided by GTEx database analysis. Many of the CKD susceptibility loci were eQTLs, 
showing a significant correlation between SNP genotypes and expression level of linked 
target genes in a variety of tissues. These eQTL target genes include CTSS and CTSK, 
coding for cathepsin S and K respectively, both downregulated in the presence of rs267734. 
Cathepsins are potent proteases and the negative correlation between rs267734 and 
cathepsin S and K expression might be relevant in relation to renal fibrosis, which is critically 
involved in CKD progression. In a bleomycin lung fibrosis model it was shown that cathepsin 
K deficient mice had more severe lung fibrosis than wild-type mice.32 Furthermore, it was 
observed that pharmacological inhibition of cathepsin activity in mice with unilateral ureteral 
obstruction induced renal fibrosis led to a worse outcome33, indicating that reduced 
expression of cathepsin S and K in the presence of rs267734 could contribute to CKD. 
 
Pathway analysis demonstrated enrichment of 4C-seq captured genes in multiple 
biosynthesis pathways involved in the generation of isoprenoid pyrophosphates. 
Interestingly, this enrichment was observed in HRGECs, and HRPTECs, though with 
different identified target genes per cell type. Isoprenoid pyrophosphates are indispensable 
for renal proximal tubular protein reabsorption, as inhibition of 3-hydroxy-3-methylglutaryl 
CoA reductase in de mevalonate pathway leads to reduced prenylation of GTP binding 
proteins involved in receptor mediated endocytosis, eventually resulting in proteinuria.34 
Similarly, altered levels of prenylation of RhoA affects eNOS activity in endothelial cells, 
resulting in imbalance of ROS levels, contributing to the endothelial dysfunction reported in 
CKD onset.35 
 
In our systemic approach, besides the non-coding variants, we also included 2 non-
synonymous SNPs (SNPs in gene coding regions that alter protein sequence: rs1260326 in 
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GCKR and rs13538 in NAT8) were amongst the studied regions. Presumably, the affected 
genes are involved in the associated disease phenotype. Especially reports on NAT8 activity 
in association with kidney disease seem convincing.36-38 However, it was previously 
demonstrated that DREs can also be located in coding regions39, and it remains of interest 
that by 4C-seq we found interactions of this locus with TSS of multiple other genes of which 
the expression levels according to GTEx are significantly associated with the occurrence of 
the variant. The incorporation of regulatory information provides an additional layer in post-
GWAS data to aid in our interpretation of these GWAS datasets, but certainly does not 
replace the candidate genes identified based on spatial proximity such as NAT8. Along the 
same lines, several SNPs associated with a single trait were included. Several SNPs are 
solely associated with serum creatinine (estimated glomerular filtration rate). Although these 
SNPs might be causally associated with CKD, they might also affect creatinine 
production/secretion independent of renal function. Rs91119 is only associated with serum 
cystatin C (estimated glomerular filtration rate), and is located directly within the CST locus. 
Again, this SNP does not necessarily have to be causally associated with CKD, but could 
also be involved in the dynamics of cystatin C production. The same is true for SNPs solely 
associated with serum urate or blood urea nitrogen, although the authors that identified 
SNPs associated with the latter group had corrected for non-renal factors.3 
 
In conclusion, taking the 3D structure of chromatin into account, we have identified 304 
putative CKD candidate genes of DREs that colocalize with CKD susceptibility loci. In this 
hypothesis generation-driven approach, we present a new method of GWAS interpretation 
based on DRE target gene identification by 4C analysis that complements the classic 
methods of candidate gene identification. In addition, incorporation of the adapted STARR-
seq method up or down stream of the 4C pipeline, would further narrow down the 
identification of causal variants in DNA regulatory function, and help us to greatly expand 
our understanding of the role that common low risk variants play in the onset of complex 
diseases such as CKD. 
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Supplemental data 
 
 
Supplemental Figure 1: The majority of genes identified with 4C-seq were positioned up to 500kbp 
from the CKD associated SNP locus. (A) Graph indicates the distance from the SNP to the TSS of the 
target genes found with 4C in HRGECs (X-axis), expressed as the number of target genes (frequency 
on Y-axis) per 100kbp. The majority of target genes was positioned up to 500kbp from the SNP, but 
occasionally candidate genes were found at locations over 1.5mb from the SNP locus. (B) The TSS of 
the majority of candidate genes found with 4C in HRPTECs was positioned up to 500kbp from the SNP 
position, but some candidate genes were found at locations over 1.5mbp from the SNP locus. 
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Supplemental Figure 2: Target genes of DREs colocalizing with CKD-associated SNPs, highlighted in 
red, are enriched in the mevalonate pathway and the trans, trans-farnesyl diphosphate biosynthesis 
pathway (adapted from IPA). 
 
Supplemental Tables can be downloaded from: 
http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2016080875/-/DCSupplemental. 
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General discussion and summary 
 
Cardiovascular diseases are the leading cause of disease burden and deaths globally.1 The 
term cardiovascular disease covers a broad domain of acute and chronic disruptions of 
vascular and cardiac function, which are often interrelated. In contrast to what the term 
suggests, cardiovascular diseases are not tightly framed concerning only the heart and 
vessels. The kidneys for instance are bidirectionally related to cardiovascular homeostasis, 
not only functionally depending on it, but also playing a crucial role in maintaining this 
homeostasis.2 Moreover, considering that every cell in the body depends on oxygen and 
nutrients, whose transport is facilitated by the cardiovascular system, it is not surprising that 
dysregulation of this system can both have a causal-, and a contributing role in organism-
wide pathological conditions, varying from development of exercise intolerance to 
tumorigenesis facilitated by excessive vascular growth. Over the years, a plethora of studies 
has focussed on the many different aspects of cardiovascular- and renal disease, which has 
not only led to better insights into the existence and management of risk factors, but has 
also provided the intellectual basis for successful therapeutic interventions. Unfortunately, 
many mechanisms underlying development and progression of these diseases are still 
poorly understood, and the aim of this thesis was therefore to provide novel insights in the 
molecular regulation of renal and cardiovascular homeostasis. 
 
Endothelial FZD5 signaling and therapeutic potential of its modulation 
Dysregulation of vascular growth is associated with the onset and progression of many 
diseases and restoration of the angiogenic balance might provide an opening with far-
reaching therapeutic potential.3 Over the past decades, a lot of progress has been made in 
unraveling the pathways involved in regulating vascular quiescence and angiogenesis. This 
led to the development of treatment strategies aiming for instance to enhance collateral 
vessel formation in myocardial ischemia4, and to block detrimental angiogenesis as 
observed in atherosclerosis and tumorigenesis.5 Although some of these therapies are now 
implemented in standard treatment protocols, our incomplete knowledge of vascular growth 
often leads to unexpected and undesirable outcomes. Anti-angiogenic therapy in cancer for 
instance, often faces therapeutic resistance due to upregulation of alternative angiogenic 
pathways and selection of tumor cells capable of growing in a low oxygen environment.6, 7 In 
addition to current therapeutic barriers, graft vascularization comes as one of the most 
predominant challenges in regenerative medicine, and the current incomplete knowledge of 
angiogenesis limits progression in this field to avascular applications.8 Overall, these 
shortcomings in current medicine underscore the necessity to further explore the 
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mechanisms involved in regulation of vascular growth and stabilization. In previous studies it 
has been suggested that WNT receptor Frizzled 5 (FZD5) might be an important regulator in 
angiogenesis.9 FZD5 knockout mice have previously been shown to die in utero with severe 
defects in yolk sac and placenta angiogenesis.9 However, the mechanism underlying the 
poor vascular phenotype in absence of this receptor had not been elucidated.  
In chapter 2 we show that WNT5a is able to activate FZD5-mediated phosphorylation of 
Dishevelled in endothelial cells and that siRNA-mediated knockdown of this receptor 
attenuated angiogenesis in an in vitro 3D co-culture model. These findings reveal the direct 
role of endothelial FZD5 in angiogenesis, superimposing the reported defect in chorionic 
branching morphogenesis to which part of the murine FZD5 full body knockout phenotype 
had previously been ascribed.10 Chapter 2 furthermore illustrates that blockade of 
endothelial FZD5 expression induced upregulation of VEGFr1 and Angpt2. Angpt2 by itself 
is known to have a positive effect on neovessel formation, as it antagonizes binding of 
Angpt1 to the endothelial Tie2 receptor, leading to pericyte detachment and destabilization 
of the endothelium, thereby potentiating the actions of pro-angiogenic factors.11, 12 However, 
in the absence of VEGFa, or in the presence of elevated levels of the VEGFa decoy 
receptor VEGFr1, Angpt2-induced destabilization eventually proceeds to vascular 
regression.13, 14 Using various pharmacological- and siRNA-mediated inhibitory experiments, 
we demonstrated that the upregulation of VEGFr1 and Angpt2 did not depend on 
dysregulation of well-described WNT/β-catenin, WNT/Ca2+ and WNT/planar cell polarity 
signaling. Instead, we found that in absence of FZD5, Ca2+-independent Protein Kinase C 
induced Ets1-mediated transcription of these vascular regression-associated factors. In 
parallel with our findings, a genome-wide CRISPR-Cas9 study recently demonstrated that 
FZD5 is a potentially druggable target in specific subtypes of pancreatic tumors.15 Signaling 
via FZD5 in these tumor cells was shown to induce β-catenin-mediated proliferation and 
treatment of these pancreatic adenocarcinoma cells with FZD5 antibodies led to inhibited 
cell growth, both in vitro and in xenograft models in vivo.15 Although these pancreatic 
adenocarcinoma tumors are not excessively vascularized, they were previously shown to 
depend on angiogenesis for growth.16, 17 Our data demonstrate the importance of FZD5 for 
endothelial cells during angiogenesis and future studies should be aimed at elucidating 
whether targeting FZD5 in these pancreatic tumors, beside its inhibitory effect on growth of 
pancreatic adenocarcinoma cells, provides an additional effect on tumor angiogenesis 
without affecting the healthy vasculature. 
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Characterization of endothelium-induced pericyte differentiation 
Pericytes play a major role in capillary stabilization, a function for which they rely on well-
orchestrated and bidirectional cross talk with the endothelium.18 Considering their role in 
maintaining vascular quiescence, pericytes are inseparable from the process of 
neovascularization and in our attempts to get a better appreciation of this process, it is thus 
essential that we do not limit our scope to the endothelium. Moreover, novel insights in 
pericyte function and their interaction with the endothelium could not only have a beneficial 
impact on angiogenic- and regenerative medicine applications, but might also provide a 
better understanding of pathological conditions such as organ fibrosis, in which disturbed 
vascular crosstalk has been suggested to be causally involved in progression towards organ 
failure.19-21  
To get a better appreciation of pericyte function and the effect of interaction with endothelial 
cells hereon, we compared the transcriptome of pericytes cultured in absence, and in direct 
presence of microvascular endothelial cells. In chapter 3 we describe the capillary niche-
dependent differentiation of pericytes. The sonic hedgehog transcription factor Zinc Finger 
Protein GLI1 (GLI1), which was previously described to mark immature pericyte 
progenitors21, was significantly reduced in co-cultured pericytes. In contrast, well-validated 
pericyte markers22, including Chondroitin Sulfate Proteoglycan 4 (NG2), Alpha Smooth 
Muscle Actin 2 (ACTA2), Melanoma Cell Adhesion Molecule (CD146) and Nestin (NES), 
were highly upregulated upon direct interaction with endothelial cells, underscoring the 
importance of direct endothelial interaction for pericyte maturation. Chapter 3 furthermore 
describes how endothelial cells stimulate pericyte proliferation and survival. Although it had 
previously been suggested that this was a VEGFa-dependent phenomenon23, we could not 
confirm this finding in our study. In contrast, both pathway analysis and siRNA-mediated 
interventions demonstrated the significant proliferative contribution of Heparin-binding EGF-
like growth factor (HB-EGF) and fibroblast growth factor 2 (FGF2), which unlike VEGFa 
were upregulated in co-cultured pericytes. In line with our findings, both factors have 
previously been shown to stimulate proliferation in a variety of cell types and our data 
suggest the existence of an endothelial-induced autocrine proliferation signaling axis in 
pericytes.24-26 Similarly, our findings confirmed the importance of the endothelial-derived 
Platelet Derived Growth Factor β. This well-described pericyte mitogen was upregulated in 
co-cultured endothelial cells27, and siRNA-mediated knockdown significantly reduced 
proliferation of pericytes. Moreover, chapter 3 illustrates that in addition to pericyte 
maturation and proliferation, direct interaction with endothelial cells has a major suppressive 
effect on extracellular matrix synthesis, as evidenced by an overall downregulation of 
Fibronectin (FN1), Alpha- and Beta Laminins (LAMAs and LAMBs, respectively), and 
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numerous Collagen isoforms. In previous studies, renal- and cardiac tissue resident 
pericytes were shown to be major contributors to injury-induced fibrosis and their 
detachment from the endothelium was shown to coincide both with capillary rarefaction and 
differentiation towards ECM-producing myofibroblasts.21 Whether injury-induced stimulation, 
or loss of endothelial interaction drove this differentiation is not completely understood, but 
since ablation of these cells substantially ameliorated cardiac- and renal fibrosis21, they 
seem promising targets for future therapeutic interventions. Our findings argue that 
differentiation into a scarring phenotype might at least in part be secondary to loss of direct 
interaction with the endothelium, and that future interventions, aiming for prevention of initial 
pericyte detachment, have the potential to act as a double-edged sword - not only stabilizing 
capillaries and thus preventing capillary rarefaction and local ischemia, but also limiting 
differentiation of pericytes into ECM-producing cells.  
 
ZSF1 rats as animal model of comorbidity-induced diastolic dysfunction 
To facilitate the distribution of oxygen- and nutrients throughout the body, the vascular 
system relies on proper cardiac function. The chronic and progressive condition, in which 
the heart is unable to maintain cardiac output commensurate with the body’s requirements, 
is referred to as heart failure (HF). Based on ejection fraction, HF can be divided into HF 
with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). 
HFrEF is associated with systolic impairments, whereas HFpEF results from diastolic 
dysfunction. Both HFrEF and HFpEF are associated with the presence of multiple systemic 
comorbidities, including chronic kidney disease (CKD) and hypertension.28 In general, 
systemic impairments in HFrEF are largely driven by a primary defect in systolic function.29 
Since these primary defects, such as loss of muscle mass due to a coronary artery 
obstruction, can properly be induced in animal models, the etiology of HFrEF is relatively 
well studied and major therapeutic progress has been made in reducing its mortality over the 
last decades.30 Conversely, the etiology of HFpEF is still poorly understood and common 
successful therapeutics for treatment of HFrEF, such as angiotensin-converting enzyme 
inhibitors and β-blockers, have shown no significant impact on clinical outcomes in HFpEF.31 
Moreover, it remains unclear how the associated comorbidities contribute to the 
development of the different aspects of diastolic dysfunction and identification as well as 
characterization of animal models that develop HFpEF, driven by relevant systemic impair-
ments, could provide novel pathological insights and may lead to therapeutic opportunities. 
In chapter 4 we describe the obese Zucker spontaneously hypertensive fatty (ZSF1) rat 
strain, which has been reported as a suitable in vivo model to study HFpEF development in 
presence of renal- and metabolic derangements.32 At the age of 25 weeks, these rats had 
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substantially increased body weight, showed elevated fasting plasma glucose levels, and a 
decline in renal function as evidenced by severe proteinuria. Renal dysfunction was 
accompanied by glomerular sclerosis and capillary rarefaction, and in addition to the 
metabolic- and renal derangements, the ratio between peak velocity of early mitral inflow 
and early diastolic mitral annulus velocity (E/e’) was significantly elevated, indicative of 
diastolic dysfunction. Moreover, LV mass, left atria and lung weight were increased, typically 
resembling clinical features of HFpEF.33 In chapter 4 we report that progression of diastolic 
dysfunction in obese ZSF1 rats was not accompanied by capillary rarefaction. Instead, 
development of fibrotic patches with highly proliferative and disorganized microvascular 
clusters was observed in the LV subendocardium. In a previous study, cardiac biopsies from 
HFpEF patients were shown to contain clear interstitial fibrosis, yet in contrast to our 
findings, capillary density was reduced.34 Although additional studies are required to further 
elucidate this dynamic process, we hypothesize that the cardiac hyperproliferative vascular 
response in obese ZSF1 rats was part of a maladaptive response that leads to replacement 
of functional vascular structures by fibrotic tissue with semi- and nonfunctional microvascular 
clusters, which may ultimately deteriorate into the previously reported fibrotic areas that are 
devoid of vascular support. In chapter 4 we also illustrate that the fibrotic foci are not only 
enriched in endothelial cells, but also in NG2- and PDGFRβ-positive pericytes. Remarkably, 
these pericytes were atypically organized, showing limited vascular coverage. Double 
staining for PDGFRβ-positive pericytes and Collagen type 4 (COL4), a vascular basement 
membrane component predominantly produced by pericytes, demonstrated a robust COL4 
deposition in the fibrotic foci, indicative for a potential fibrotic contribution of pericytes, which 
has also been described in chapter 3. Future studies are planned in which we aim to get a 
better appreciation of the putative role of pericytes in HFpEF-associated cardiac fibrosis. 
 
Limited synergy between obesity and hypertension in development of diastolic dysfunction 
In previous studies it has been proposed that presence of non-cardiac comorbidities could 
provoke a state of chronic systemic inflammation, leading to coronary microvascular 
dysfunction and myocardial fibrosis.35 Fibrosis is suspected to limit LV relaxation, whereas 
microvascular dysfunction lowers NO availability, which causes impaired myocardial Protein 
Kinase G (PKG) activity, leading to cardiomyocyte hypertrophy and Titin (TTN) 
hypophosphorylation.35 This hypophosphorylation of TTN was also evident in 
cardiomyocytes from obese ZSF1 rats, and was experimentally shown to be a major 
contributor to cardiac stiffness.32 Based on this proposed mechanism, several successful 
pre-clinical studies paved the road for a multitude of large clinical trials aiming to improve 
perspectives of HFpEF patients. For instance, phosphodiesterase-5 inhibitor sildenafil and 
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guanylate cyclase stimulator veriguat were used to stimulate myocardial PKG activity36, 37, 
whereas the mineralocorticoid receptor antagonists spironolactone on the other hand, was 
supposed to limit both endothelial dysfunction and myocardial fibrosis.38 Unfortunately, none 
of the HFpEF-related clinical trials so far led to significant improvement of exercise capacity 
or clinical status. It is currently believed that this lack of success might find its origin in the 
phenotypical diversity among HFpEF patients and personalized therapeutic strategies are 
therefore proposed.39 In order to successfully implement personalized medicine, it is of the 
essence that we get a better appreciation of phenotypical differences among HFpEF 
patients, and how these, for instance, relate to presence of different comorbidities.31  
In chapter 5 we studied the superimposing effect of deoxycorticosterone acetate- and high 
salt diet- (DS) induced hypertension on diastolic dysfunction in lean and obese ZSF1 rats 
discussed in chapter 4. This not only enabled us to dissect which adaptations were 
associated with obesity and its associated biochemical aberrations, and which were 
associated with hypertension, but also to directly study their putative interaction. We found 
that obesity-associated derangements had the most predominant effect on development of 
diastolic dysfunction, lowering of cardiac output, and cardiomyocyte hypertrophy, with only a 
limited additive effect of hypertension. Not only are these findings in line with observations 
from the MONICA registry and the ALL-HAT trial40, 41, which showed a larger contribution of 
obesity to HFpEF development than hypertension, they also illustrate why blood pressure 
lowering drugs alone did not reduce morbidity and mortality in HFpEF patients.42 Other 
findings in chapter 5 further support that, when considering therapeutic interventions, it is 
extremely important to anticipate potential pathophysiological differences among HF patients 
that were thus far grouped based on the common denominator “preserved ejection fraction”. 
For instance, cardiac inflammation and subsequent fibrosis, unlike diastolic dysfunction and 
hypertrophy, were predominantly driven by DS-induced hypertension, with partial synergy 
observed when combined with obesity. Although hypertension-induced fibrosis was 
accompanied by only a mild increase in diastolic dysfunction, it has previously been shown 
to be an independent predictor of morbidity and mortality in HFpEF43, 44, suggesting that 
mineralocorticoid receptor antagonists could in essence have beneficial effects in HFpEF 
patients, provided that they are evaluated and used in relevant patient subsets. Similarly, in 
chapter 5 we also demonstrate that obesity stimulated enhanced expression of genes 
involved in fatty acid oxidation, whereas DS-induced hypertension led to an overall 
downregulation of genes involved in oxidative phosphorylation, implying that the 
comorbidities triggered adverse mitochondrial responses. Aiming for a therapeutic switch 
from fatty acids towards more oxygen-efficient glucose metabolism45, as was previously 
suggested for HFpEF46, might provide a promising opportunity for obese patients, but may 
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well be far less effective when applied to HFpEF patients with hypertension-induced 
mitochondrial dysfunction. In summary, chapter 5 illustrates the limited interaction among 
obesity and hypertension, and implies that, in order to successfully attenuate or reverse 
disease progression, differences in comorbidity-induced cardiac remodeling require 
personalized interventions, according to the differences in HFpEF phenotypes. 
 
Chromatin organisation-based annotation of candidate genes in atherosclerosis and CKD 
Although cardiovascular- and renal disease are heavily influenced by environmental factors, 
genome wide association studies (GWASs) have also identified many common genetic 
variants or single nucleotide polymorphisms (SNPs) that are associated with onset and 
progression of these pathological conditions.47-50 Among the disease-associated variants, 
non-synonymous SNPs (affecting protein sequence) are exceptionally rare and functional 
annotation of most risk loci therefore till date remains an issue. Annotation has thus far 
mainly been conducted by linking risk loci to genes at the nearest genomic position based 
on linear spatial proximity, taking into consideration that disease-associated SNPs could be 
markers for less common non-synonymous variants.51 Unfortunately, this approach has only 
partially been able to explain genetic variation-induced disease development. Recent 
epigenetic studies have revealed that our genetic material is packed with DNA regulatory 
elements (DREs), such as promoters, enhancers and repressors, located in both coding- 
and non-protein-coding DNA regions.52 These DREs play a crucial role in transcriptional 
regulation in a cell type- and circumstance-specific manner and growing evidence suggests 
that variants residing in regulatory sequences, in addition to non-synonymous variants, 
could contribute to pathogenesis.53 Systematic mapping of genes that are transcriptionally 
regulated by DREs that colocalize with disease-associated common variants could greatly 
improve our understanding of the complex genetics involved in cardiovascular- and renal 
disease.  
In chapter 6 and chapter 7 we used circular chromosome conformation capture sequencing 
(4C-seq), which enabled us to identify genes that physically interacted with DREs 
colocalizing with atherosclerosis- and CKD-associated risk loci, respectively. Since 
transcriptional regulation might differ among individual cell-types, 3D chromatin interactions 
in relation to atherosclerotic disease were evaluated in microvascular endothelial cells and 
monocytes. In these cells we found 37 active DREs that colocalized with SNPs associated 
with coronary artery disease and stroke. Both are conditions to which a large part of the 
disease burden of atherosclerosis can be traced back to. These 37 active DREs were shown 
to physically interact with a total of 326 candidate genes, of which 296 had not been 
reported before. In chapter 7, we employed a similar approach to identify candidate genes 
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for SNPs associated with CKD, using renal proximal tubule epithelial cells and glomerular 
endothelial cells. In these cells we studied 36 CKD-associated SNPs that colocalized with 
active DREs. In total, these 36 risk loci interacted with a total of 304 candidate genes.  
The physical interactions identified by 4C-seq, do not per se mean that expression of the 
captured genes is affected by the associated loci. However, evaluation of known expression 
quantitative trait loci (eQTL) substantiated this putative regulatory relation between many 
studied risk loci and the identified candidate genes. In chapter 7 we used the Genotype-
Tissue Expression (GTEx) database. We found that among the studied CKD-associated risk 
loci, 25 were highly correlated with differential expression of 54 different genes. Of these 54 
genes, the promoter regions of 48 genes were captured by 4C-seq, and although the lack of 
kidney-specific expression data from genotyped donors in GTEx did not allow us to study 
these eQTL in renal tissue, it did provide direct evidence for the hypothesized transcriptional 
regulation by the studied risk loci and showed that 4C-seq enabled us to capture relevant 
target genes. In chapter 7 we further substantiated the causal role of common variants in 
transcriptional regulation by applying self-transcribing active regulatory region sequencing 
(STARR-seq).54 In a proof of principle approach, studying the CKD risk locus marked by 
rs11959928, this technique enabled us to pinpoint specific variants that colocalized with 
DREs in this locus and affected transcriptional activity. For coronary artery disease on the 
other hand, eQTL analysis could be performed in monocytes and the vasculature, 
resembling the tissue in which the initial 4C-seq was performed. In line with the findings from 
the CKD study, in chapter 6 we report a variety of atherosclerosis-associated risk loci that 
were shown to affect transcriptional regulation of many genes captured with 4C. Of 
particular interest was the coronary artery disease-associated variant rs12740374. The 
minor T allele of rs12740374 creates a CCAAT/enhancer binding protein (C/EBP) 
transcription factor binding site which was previously demonstrated to elevate liver sortilin 1 
(SORT1) expression.55 Various in vitro and in vivo studies demonstrated that overexpression 
of SORT1 resulted enhanced low-density-lipoprotein (LDL) clearance, whereas SORT1 
deficiency, mimicking the effect of the rs12740374 risk allele, led to impaired LDL 
clearance56, 57. Largely because of this clear effect that appears to explain much of the 
causal relation with atherosclerosis, no further attention has been given to alternative 
candidate genes for this risk locus. Remarkably, SORT1 expression was not affected by 
rs12740374 in monocytes, whereas expression of proline and serine rich coiled-coil 1 
(PSRC1), which was captured by 4C-seq, was genotype-dependent. Interestingly, the 
expression of PSRC1 also correlated with atherosclerosis severity independent of LDL 
levels, the putative mechanism through which dysregulation of SORT1 acts, suggesting that 
in addition to SORT1, PSRC1 could be considered as a promising candidate for future 
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mechanistic studies in atherogenesis. Using various online databases containing human and 
murine phenotypic information on monogenetic mutations, we furthermore found that many 
of the identified candidate genes were strongly associated with different aspects of the 
studied disorders. Phosphatase and tensin analog (PTEN) for instance, of which the 
promoter region interacted with the atherosclerosis-associated LIPA risk locus (rs2246833), 
has previously been correlated with inflammatory plaque characteristics and intimal smooth 
muscle cell proliferation58, whereas increased stability of PTEN on the other hand appears to 
ameliorate atherosclerosis (chapter 6).59 Similarly, Mucin-1 (MUC1) physically interacted 
with the CKD-associated variant rs2049805, which was also shown to be an eQTL for 
MUC1. MUC1 is a membrane-anchored mucoprotein, in which a pre-mature stop codon-
inducing frame shift mutation has previously been demonstrated to result in medullar cystic 
kidney disease type 1 (chapter 7).60 These illustrative examples highlight the indispensable 
nature of both factors, and underscore that genetic variation-induced dysregulation of their 
expression might very well contribute to pathogenesis. Overall, our findings reported in 
chapter 6 and chapter 7 annotated multiple genes to previously reported CKD-associated 
SNPs and provided evidence for interaction between these loci and their target genes. This 
pipeline provides a novel technique for hypothesis generation and complements classic 
GWAS interpretation. Future studies are required to specify the implications of our findings, 
focusing both on the mechanism by which the newly annotated genes might contribute to 
disease, as well as on applying STARR-seq more broadly to specifically identify disease 
causing variants, rather than variants marking risk loci. Moreover, in future studies these 
techniques could also be applied to further dissect the role of genetics in the renocardiac- 
and cardiorenal syndrome. It has for instance been demonstrated that the cardiac 
transcriptome is heavily influenced by CKD-associated circulating factors, such as 
Endothelin 1 and Angiotensin II, as well as accumulating renal toxins.61 This implies that 
these factors have a profound effect on DRE activity in cardiomyocytes, cardiac fibroblast or 
coronary endothelium. Mapping those responsive regulatory elements, followed by STARR-
seq and 4C-seq analysis of colocalizing heart failure-associated risk loci, could contribute to 
our understanding of renal dysfunction-induced heart failure. Similarly, studying CKD-
associated risk loci colocalizing with DREs affected for instance by low oxygen levels, 
mimicking heart failure-induced renal hypoperfusion, might provide a better appreciation of 
the complex interplay between the heart and kidney during disease. 
 
Future perspectives 
The studies presented in this thesis aimed to provide novel insights in the molecular 
regulation of renal and cardiovascular homeostasis. With these proceeding insights, several 
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new questions arose that should be pursued in future studies. Firstly, the in vitro studies on 
the role of endothelial FZD5 signaling, described in chapter 2, illustrate the importance of 
this receptor in vascular growth. The finding that in vivo blockade of this receptor with FZD5 
antibodies also attenuated growth of ring finger protein 43 (RNF43) mutant pancreatic 
tumors15, raised the question whether part of this effect was the result of the inhibition of 
angiogenesis. Simple but effective ways to assess the impact of FZD5 antibodies on tumor 
angiogenesis would be to focus more on the tumor vasculature in response to the FZD5 
antibodies rather than tumor size only, or to implant a non-RNF43 mutant tumor in 
immunodeficient mice instead of the originally used HPAF-II xenografts and evaluate overall 
tumor growth over time, with and without infusion of FZD5 antibodies. Not only would this 
lead us to a more comprehensive understanding of the working mechanism of these FZD5 
antibodies as therapeutic agent against RNF43 mutant tumors, it could also provide valuable 
insights on the potential of FZD5 inhibition in a more general approach to block tumor 
angiogenesis. Secondly, the combined results from chapter 3 and chapter 4, in which we 
illustrate that pericytes need stable interaction with endothelium to suppress a fibrotic 
phenotype, and that subendocardial fibrotic foci in obese ZSF1 rats are enriched in 
atypically organized pericytes, respectively, made us wonder to what extent these pericytes 
are causally related to the development of these fibrotic foci. In future experiments, using a 
single-cell sequencing approach on LV material from lean and obese ZSF1 rats, it might be 
possible to distinguish different subsets of cardiac pericytes, which would enable us to 
evaluate their putative fibrotic nature in obese rats in more detail. This approach would 
furthermore complement our current findings described in chapter 5, providing a better 
appreciation of cell type-specific adaptations involved in development of diastolic 
dysfunction. Finally, in our attempts to get a better appreciation of the effect of CKD-
associated common variants on transcriptional regulation, described in chapter 7, we found 
a particular region marked by the CKD-associated SNP rs11959928, in which five variants 
significantly affected transcription. As these five variants are in high linkage disequilibrium 
with each other, it is possible that not all of them are actively involved in transcriptional 
regulation. Using site-directed mutagenesis, the variants causing transcriptional 
dysregulation identified with STARR-seq should one-by-one be replicated, which would 
enable us to individually assess their impact on transcription. Subsequently, we should 
replicate variants affecting transcription into the genome of human primary renal cells and 
verify which of the candidate genes, that we identified with 4C-seq, are in fact 
transcriptionally regulated by this CKD risk locus. This strategy would allow us to empirically 
select candidate genes for functional follow-up studies, and may lead us to a better 
understanding of disease-associated common variants. 
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Cellen zijn fundamentele biologische eenheden die voor hun functie afhankelijk zijn van 
zuurstof en voedingsstoffen. Met het ontstaan van complexe organismen, opgebouwd uit 
miljoenen cellen, ontwikkelde zich gaandeweg het probleem dat de opname van zuurstof en 
voedingsstoffen niet meer simpelweg uit de omgeving van het organisme plaats kon vinden 
omdat de diffusie afstand daarvoor te groot werd. Om in de behoefte van alle cellen te 
kunnen blijven voorzien zijn complexe organismen, de mens inclusief, uitgerust met een 
cardiovasculair systeem, waarin het hart als pomp fungeert om het voedingsstof- en 
zuurstofdragende bloed via een ongekend stelsel van bloedvaten tot aan de meest inwendig 
gelegen cellen te transporteren. Met deze elementaire rol van het cardiovasculaire systeem 
in het achterhoofd, is het niet moeilijk voor te stellen dat zowel acute als chronische 
verstoringen van hart- en vaatfunctie een enorme impact kunnen hebben op het algehele 
welzijn, en ondanks de grote medische vooruitgang van de afgelopen decennia, dit 
wereldwijd nog steeds een belangrijke oorzaak is van ziekte en sterfte. Deze verstoringen 
van hart- en vaatfunctie, die worden geclusterd onder de noemer hart- en vaatziekten, zijn 
vaak niet op zichzelf staand en gaan veelal gepaard met functionele verstoringen van 
andere organen. De nieren zijn daarvan een sprekend voorbeeld. Niet alleen zijn de nieren 
functioneel afhankelijk van cardiovasculaire homeostase, ze spelen ook een cruciale rol bij 
het handhaven daarvan. In de loop der jaren heeft een groot aantal onderzoeken zich 
gericht op de vele verschillende aspecten van zowel cardiovasculaire, als renale dysfunctie, 
welke niet alleen hebben geleid tot betere inzichten in het bestaan en het beheersen van 
risicofactoren, maar ook de intellectuele basis hebben gelegd voor succesvolle 
therapeutische interventies. Helaas zijn echter nog steeds veel mechanismen die ten 
grondslag liggen aan cardiovasculaire ziekten niet, of slechts ten dele bekend, en het doel 
van dit proefschrift was dan ook om nieuw inzicht te verschaffen in de moleculaire regulatie 
van renale en cardiovasculaire homeostase. 
 
Al tijdens de primaire fase van de embryonale ontwikkeling is het essentieel dat een 
functioneel netwerk van bloedvaten ontwikkeld. De basis hiervoor wordt gelegd door 
vasculogenese, waarbij angioblasten differentiëren in endotheelcellen welke een primair 
tubulair netwerk vormen. Vanuit dit netwerk groeit de vaatboom zowel prenataal als 
postnataal proportioneel mee met het ontwikkelende organisme via angiogenese, een strak 
gecontroleerd proces waarbij endotheelcellen vanuit het bestaande vaatnetwerk delen en 
migreren in de richting van een zuurstofarm gebied. Na volgroeiing van een individu, wordt 
de activiteit van angiogenese beperkt tot nieuwgroei van weefsel, bijvoorbeeld aanmaak van 
nieuwe spieren. Dit kan echter ook in pathologisch verband gebeuren, zoals het geval is bij 
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tumorgroei. De delende cellen van de tumor zijn net als alle andere cellen afhankelijk van 
voedingsstoffen en zuurstof, waarin ze worden voorzien door ingroei van nieuwe vaten. Het 
remmen van angiogenese wordt momenteel gezien als een mogelijke ingang om tumorgroei 
te reduceren. Visa versa, is in sommige gevallen juist aanwas van nieuwe bloedvaten 
gewenst, zoals bijvoorbeeld in het zuurstofarme gebied dat ontstaat na een hartinfarct. Tot 
op heden zijn we echter pas beperkt in staat om angiogenese op een therapeutisch 
verantwoorde wijze in ons voordeel te gebruiken, deels ten gevolge van een nog 
ontwikkelende kennis van de moleculaire signalering cascades die angiogenese reguleren. 
Om hier een beter inzicht in te krijgen is in hoofdstuk 2 de rol van Frizzled 5 (FZD5) in 
angiogenese bestudeerd. Uit eerdere studies is gebleken dat deze receptor onmisbaar is 
voor het ontwikkelen van een functioneel vasculair netwerk, maar de exacte wijze waarop 
FZD5 hieraan bijdraagt was tot op heden niet bekend. Uit onze studie is gebleken dat het 
verlagen van de aanwezigheid van FZD5 in endotheelcellen ervoor zorgde dat de cellen niet 
alleen stopten met delen, maar ook minder in staat waren te migreren, en als gevolg 
daarvan ook geen nieuwe vaatjes meer konden vormen. Tegelijkertijd leidde een lagere 
aanwezigheid van FZD5 tot een verhoogde aanmaak van Vascular Endothelial Growth 
Factor Receptor 1 en Angiopoietin 2, welke respectievelijk zorgen voor een verminderde 
gevoeligheid voor pro-angiogenese signalen uit zuurstofarme gebieden en een vermindering 
van vaatstabilisatie.  
Deze vaatstabilisatie is een belangrijk onderdeel van angiogenese. Enerzijds zorgt het 
ervoor dat nieuw gevormde vaatjes niet direct desintegreren, en anderzijds voorkomt het 
overmatige gevoeligheid voor pro-angiogenese factoren. Deze stabilisatie van 
endotheelcellen komt voor een groot deel op het conto van perivasculaire cellen, genaamd 
pericyten. In de literatuur is al veel geschreven over de wijze waarop deze pericyten het 
endotheel, en daarmee angiogenese beïnvloeden, maar tegelijkertijd is nog relatief weinig 
bekend over de invloed van deze interactie op de pericyten zelf. In hoofdstuk 3 is de 
genexpressie van pericyten vergeleken in aan- en afwezigheid van endotheelcellen. Uit 
deze studie is naar voren gekomen dat interactie met endotheel differentiatie en groei van 
pericyten stimuleert. Tevens lieten pericyten in afwezigheid van endotheelcellen een 
verhoogde aanmaak van fibrotische eiwitten zien. In eerdere onderzoeken is aangetoond 
dat pericyten in bijvoorbeeld de nieren een belangrijke bijdrage leveren aan door schade 
geïnduceerde fibrose. Tot op heden is het onduidelijk of dit het gevolg is van een 
pathologische over-interpretatie van reparatie mechanismen, of dat endotheel dysfunctie en 
de daarbij horende verstoorde endotheel interactie met omliggende cellen een rol van 
betekenis speelt, maar onze data wijzen er in ieder geval op dat endotheel in staat is de 
productie van lidtekenweefsel door pericyten te onderdrukken. 
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Om het transsport van zuurstof en voedingsstoffen door het lichaam te kunnen faciliteren, is 
het vasculaire systeem afhankelijk van een goed werkend hart. Wanneer het hart niet in 
staat is om hierin te kunnen voorzien, spreken we van hartfalen. Hartfalen kan worden 
opgedeeld in falen met verminderde ejectie fractie en falen met behouden ejectie fractie. 
Waar verminderde ejectie fractie vaak het gevolg is van verlies aan pompkracht, 
bijvoorbeeld na onherstelbare schade aan de hartspier ten gevolge van een hartinfarct, is 
falen met behouden ejectie fractie doorgaans het gevolg van verslechterde ontspanning van 
het hart. Dit wordt respectievelijk systole en diastole dysfunctie genoemd. Beide vormen van 
hartfalen zijn geassocieerd met de aanwezigheid van meerdere comorbiditeiten, waaronder 
een verminderde nierfunctie, hypertensie, en obesitas. Over de jaren is er enorme 
vooruitgang geboekt in de behandeling van systolisch hartfalen, maar helaas is er door een 
tot op heden beperkt inzicht in hartfalen met een behouden ejectie fractie op dit moment nog 
geen succesvolle behandel methode voor deze aandoening. Bovendien is het ook nog niet 
geheel duidelijk hoe de verschillende comorbiditeiten bijdragen aan deze aandoening. 
Om een beter inzicht te krijgen in de processen die betrokken zijn bij de ontwikkeling en 
progressie van diastole dysfunctie is de Zucker spontaneously hypertensive (ZSF1) rat 
bestudeerd. ZSF1 ratten met een mutatie in de leptine receptor ontwikkelen obesitas, 
gevolgd door diabetes type 2, verminderde nierfunctie en diastole dysfunctie. In hoofdstuk 
4 zijn de mircovasculaire veranderingen in het hart en de nieren van de ZSF1 ratten met de 
leptine receptor mutatie vergeleken met die van de ratten zonder mutatie. Wat opviel in deze 
dieren was dat ze diastole dysfunctie ontwikkelde, maar dat er in tegenstelling tot wat 
bekend is uit mensen, geen vermindering van capillaire dichtheid of toegenomen fibrose op 
trad in het hart. Wel ontwikkelde zich in de linker ventrikel specifieke kleine fibrotische 
regio’s die werden gekenmerkt door snel delende en slecht georganiseerde vasculaire 
structuren. Binnen deze atypisch georganiseerd clusters werd tevens een verrijking aan 
pericyten gevonden en met de bevindingen uit hoofdstuk 3 in het achterhoofd zijn er 
nieuwe studies gepland om de exacte bijdrage van de pericyten aan de fibrotische regio’s 
verder te onderzoeken. In hoofdstuk 5 is hetzelfde soort rat gebruik om een beter inzicht te 
krijgen op welke manieren verschillende comorbiditeiten bijdragen aan het ontwikkelen van 
hartfalen met behouden ejectie fractie. In deze studie zijn de ratten, bovenop de eerder 
genoemde comorbiditeiten, blootgesteld aan deoxycorticosterone en een hoog zout dieet 
(DZ), wat zorgde voor de ontwikkeling van ernstige hypertensie. Uit deze studie kwam naar 
voren dat er slechts minimale interactie was tussen de metabole factoren en DZ-
geïnduceerde hypertensie. De obese ZSF1 ratten ontwikkelde de sterkste vermindering van 
de diastole functie en het hartminuutvolume, en slechts een minimaal additief effect werd 
gezien in combinatie met DZ-geïnduceerde hypertensie. Wel leidde DZ-geïnduceerde 
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hypertensie, zowel in aan- en afwezigheid van obesitas, tot een sterke toename in fibrose 
en inflammatie, en zorgde het voor mitochondriële dysfunctie en verminderde capaciteit om 
vetzuren te verbranden, waar de placebo-behandelde obese ZSF1 ratten juist meer gebruik 
leken te maken van de verbranding van vetzuren. Al met al laat deze studie zien dat de 
comorbiditeiten die geassocieerd zijn met diastole dysfunctie zorgen voor cruciale 
verschillen in remodelering van het hart, iets wat van cruciaal belang kan zijn bij het 
ontwikkelen en testen van toekomstige medicijnen. 
 
Naast de eerder genoemde comorbiditeiten, zijn aan de hand van zogenaamde ‘genome 
wide association studies’ (GWAS) genetische risicofactoren gevonden die bijdragen aan de 
ontwikkeling van cardiovasculaire en renale aandoeningen. In deze studies wordt het DNA 
van een groot aantal patiënten vergeleken met dat van gezonde mensen, waarna kan 
worden bekeken of genetische varianten, ook wel SNPs genoemd, vaker voorkomen in een 
zieke populatie dan in een gezonde populatie. Deze genetische variatie ligt maar zelden in 
DNA coderend voor eiwitten en om die reden wordt voor functionele annotatie van de 
variatie voornamelijk gekeken naar de meest dichtbij gelegen genen. Helaas heeft deze 
benadering tot nu toe slechts ten dele gezorgd voor opheldering en klinische significantie. 
Epigenetische studies hebben aangetoond dat in ons DNA, naast eiwit coderende regio’s, 
veel zogenaamde regulatie elementen liggen, zoals enhancers en repressors. Deze 
regulatie elementen spelen een belangrijke rol in regulatie van transcriptie. Varianten die in 
deze regulatie elementen liggen zouden kunnen bijdragen aan pathogenese, door 
verstoorde regulatie van genexpressie. Om dit verder te bestuderen voor genetische variatie 
geassocieerd met atherosclerose en chronische nierziekte, is respectievelijk in hoofdstuk 6 
en hoofdstuk 7 gebruik gemaakt van ‘cricular chormosome conformation capture 
sequencing’ (4C-seq) om een beeld te krijgen van genen waarvan de expressie wordt 
gereguleerd door regulatie elementen die overlappen met deze variatie. In totaal zijn voor 
atherosclerose 326 genen gevonden die in de 3D conformatie van chromatine interactie 
hadden met een regulatie elementen die overlapten met atherosclerose geassocieerde 
genetische variatie. Op eenzelfde wijze zijn voor chronische nierziekte 304 kandidaat genen 
gevonden. In hoofdstuk 7 is tevens aan de hand van ‘self-transcribing active regulatory 
region sequencing’ (STARR-seq) fysiek bewijs geleverd voor het effect dat chronische 
nierziekte-geassocieerde genetische variatie, liggend in een regulatie element, kan hebben 
op transcriptie. De beschreven pijplijn in deze studies biedt een nieuwe techniek voor het 
identificeren en prioriteren van kandidaat genen en vormt een aanvulling op de klassieke 
GWAS-interpretatie. Toekomstige studies zijn echter nodig om de implicaties van onze 
bevindingen te specificeren. 
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Dankwoord 
Alhoewel het fysieke schrijven van een proefschrift van tijd tot tijd een wat eenzaam karakter 
kent, heb ik mij altijd gesterkt gevoeld door de steun van mijn collega’s, vrienden en familie. 
Ik zou alle mensen die daarin een bijdrage hebben gehad dan ook hartelijk willen danken. 
 
Te beginnen met mijn promotor, prof. Dirk Duncker. Dirk, ik heb mijn tijd binnen jouw groep 
als een waar genoegen ervaren. Alhoewel jouw fysiologische inslag tegenover mijn 
interesse in basaal moleculair werk initieel slechts op bepaalde punten raakvlakken 
vertoonden, heb jij altijd geprobeerd deze raakvlakken uit te diepen. Jouw punctualiteit, 
evenals je principiële houding omtrent betrokkenheid bij een project waarvan je mede auteur 
bent, zijn eigenschappen waar menig collega een voorbeeld aan kan nemen. De passie en 
gedrevenheid waarmee jij jouw draai aan de wetenschap geeft hebben mij geïnspireerd en 
ik ben je daar dankbaar voor.  
 
Caroline Cheng, een hoop moois in het leven is gebaseerd op vertrouwen. Toen jij mij in 
2012 een positie aanbood om als promovendus aan de slag te gaan, realiseerde ik me dat 
ik daar op basis van mijn genoten opleiding eigenlijk niet voor in aanmerking kwam. Jij nam 
met dat vertrouwen in mij in zekere zin een risico en alleen al om die reden ben ik je zeer 
dankbaar. In de daaropvolgende jaren ontwikkelde ik onder jouw vleugels een zelfstandige 
manier van werken en het vermogen om mijn bevindingen te delen met mijn collega’s en de 
rest van het wetenschappelijk veld. Bovendien kreeg ik van jou alle ruimte om een groot 
wetenschappelijk netwerk op te bouwen, en ook al sloeg de schrik me om het hart toen je 
me ooit “voor de grap” vertelde dat ik mijn bureau in Rotterdam kon opruimen om vanaf dat 
moment weer in Utrecht aan de slag te gaan, heeft de tijd waarin ik daar initieel werkzaam 
was een grote bijdrage geleverd aan dat netwerk. Ik durf te zeggen dat niets van dit alles 
van de grond was gekomen zonder jou, en het vertrouwen dat je me hebt gegeven, en ik zal 
je daar altijd dankbaar voor zijn. 
 
Ook wil ik graag de leden van mijn promotie commissie, prof. Marianne Verhaar, prof. 
Daphne Merkus en prof. Max Kros, hartelijk danken voor de tijd die zij hebben genomen 
voor de beoordeling van dit proefschrift. Marianne, ik zou je daarnaast ook willen bedanken 
voor de mogelijkheid die je me hebt geboden om tijdens mijn promotietraject mijn 
werkzaamheden deels uit te voeren op jouw lab. Daphne, wij lijken elkaar gaandeweg 
steeds vaker tegen te komen en ik heb plezier in de gedachtewisselingen die daarmee 
gepaard gaan. Jouw ruime wetenschappelijk ervaring in combinatie met je toegankelijke 
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persoonlijkheid maken je voor mij tot een waardevolle collega, dus nogmaals, excuses voor 
dat akkefietje met de Alpenhoorn, ik wist niet dat je zo licht sliep. 
 
Mijn paranimfen, Maurits en Ihsane, het is me een eer dat jullie naast mij willen staan tijdens 
mijn promotie en ik ben uiteraard ook dankbaar voor jullie onbaatzuchtige aanbod mij na de 
borrel te repatriëren naar de metropool van de randstad – Oud-Beijerland.  
 
Ihsane, je vertelde mijn vader ooit dat je een man van me had gemaakt. Het behoeft geen 
verdere uitleg dat dit aan mijn kant van de tafel voor wat verbaasde blikken zorgde. Echter, 
wat je mijn vader probeerde te vertellen was dat ik mede door jouw enthousiaste 
begeleiding mijn stage, en daarmee mijn studie, succesvol had afgerond. Ik moet bekennen, 
je enthousiasme werkte inderdaad aanstekelijk, en niet lang na mijn afstuderen werd ik 
officieel je collega. Geruime tijd hebben wij vervolgens samengewerkt in de groep van 
Caroline, waarin jij mij gevraagd en ongevraagd bleef voorzien van advies, een luisterend 
oor en uiteraard koffie. Ik was op mijn beurt ook jouw steun en toeverlaat, zoals bijvoorbeeld 
ten tijde van je CMTM3/4-us-fiasco. Naast onze reguliere werkzaamheden hebben we 
samen ook veel mooie momenten meegemaakt, waaronder memorabele congressen, de 
borrels, onze trip naar New York en het jaarlijkse thorax zaalvoetbal toernooi – wat waren 
wij goed. Dit is een tijd geweest waarin ik jou leerde kennen als een echte vriend, en ik moet 
bekennen dat ik het oprecht jammer vond dat ik het laatste stukje van mijn promotietraject 
zonder je heb moeten doen, alsof ik plotseling verder moest zonder zijwieltjes. Je bent dan 
weliswaar niet degene die een man van me heeft gemaakt, maar de tijd die ik met je heb 
doorgebracht heeft mij in veel opzichten wel een completer mens gemaakt en daar ben je ik 
bijzonder dankbaar voor. Ik wens je het allerbeste in het vervolg van je carrière en ik hoop 
dat onze wegen elkaar ook daarin nog eens gaan kruisen. 
 
Ook de collega’s met wie ik kamer Ee2369 deel wil ik bedanken. Ruben, ik heb ooit het 
groot lexicon van nutteloze feiten gelezen. Dit was vermakelijk, ik kan het iedereen 
aanraden, maar jou niet. Waarom niet? Jij bent van nature een zeer vriendelijke, mobiele 
uitgave. Jij kent je feitjes, van racefietsen tot tuinieren. Van ‘s werelds snelst vallend dier, en 
inmiddels ook van het langzaamst promoverend exemplaar. Bedankt voor je opbouwende 
kritiek op mijn posters en de hulp die je mij gaf bij de interpretatie van echodata. Oana, 
bedankt voor de vele waardevolle tips die je mij gaandeweg toeschoof. Je bent een 
begenadigd wetenschapster en ik heb in de afgelopen jaren een hoop van je mogen leren. 
Als een ware matriarch regeerde jij over onze kamer, al bleek op een terras in Wenen dat jij 
jezelf niet herkende in deze rol. Dat was een wijze les. Het zal de afgelopen jaren niet altijd 
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makkelijk voor je zijn geweest en er zijn vast momenten waarvoor een gebaar van excuus 
op zijn plaats zou zijn geweest. Smakeloze grapjes en ongepaste opmerkingen, je hebt het 
allemaal moeten verduren, maar dan moet je maar zo denken; zo is Jens nu eenmaal en 
daar zullen we allemaal mee moeten leren leven. Jens, je bent een arts. Initieel moest ik 
daarom even aan je wennen omdat dit betekende dat, wanneer je het lab opkwam, al het 
glaswerk moest worden gezekerd en de pipetten moesten worden voorzien van hun 
“beschermhoedjes”. Echter, gaandeweg realiseerde ik me dat deze – aan jouw medische 
achtergrond gerelateerde – klunzigheid ook impliceerde dat je wellicht over bepaalde kennis 
beschikte die ik zelf niet voorradig had, en wat bleek, jij was bereid deze kennis met me te 
delen. Ik heb me hier veelvuldig aan kunnen optrekken en daar ben ik je erg dankbaar voor. 
Ranga, you may consider yourself the most recent acquisition of room Ee2369. It makes you 
feel alive, doesn’t it? You are a gifted young scientist, and I wish you all the best in your PhD 
journey. 
 
Esther en Lau, men zegt wel eens; wijsheid komt met de jaren. Jullie zijn erg wijs. Dat is 
maar goed ook, want daar varen een hoop collega’s van de 23e, waaronder ik zelf, wel bij. 
Lau, zo vaak als ik bij jou aan je bureau heb gestaan om de map met historische protocollen 
van stal te halen is denk ik niet op één hand te tellen. En Esther, geen verzoek was voor jou 
teveel. Had je geen tijd? Dan maakte je tijd. Met jouw initiatieven voor uitjes, ijsjes en ander 
moois zorgde jij tevens voor cohesie tussen de collega’s, een laagje cement dat de hele 
boel bij elkaar hield. Een lab kan niet zonder mensen zoals jullie en ik ben jullie allebei 
enorm dankbaar voor de tijd en energie die jullie in mij, en daarmee ook in mijn proefschrift, 
hebben gestoken. 
    
Jarno, tot kort geleden had ik de fatsoenlijke gewoonte om, alvorens mij naar het volgende 
honk te begeven, iemand wat beter te leren kennen. Zelf noemde je dit ook wel eens 
principes meen ik me te herinneren. Jij, en het twijfelaartje dat we in Orlando deelden, 
hebben mij echter geleerd dat principes op meerdere manieren kunnen worden 
geïnterpreteerd. Bedankt. Martine, het schept een band dat we beide net iets langer dan 
gemiddeld over ons proefschrift hebben gedaan. De gesprekken die wij hierover hebben 
gehad hebben mij geholpen om door te zetten en ik hoop dat dit jou op eenzelfde manier 
verder helpt. Ook mijn overige (oud) collega’s van de afdeling experimentele cardiologie – 
Monique, Liesbeth, Maaike, Marc, Metin, Richard, Kelly, Ilona, Zhongye, Siyu en Annemarie 
– wil ik van harte bedanken. Ieder van jullie heeft op zijn of haar eigen manier een 
substantiële bijdrage geleverd. Onder de oud collega’s wil ik ook nog kort stil staan bij 
Dennie, Vincent en Andre. Jullie hebben een gemene deler die ik altijd erg heb kunnen 
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waarderen; net-over-het-randje humor. Tegelijkertijd hebben jullie alle drie een eigen idee 
over een postdoctorale carrière, een aspect waarover jullie met mij hebben gesproken, 
omdat dit destijds voor mij toekomstmuziek was waar ik maar moeilijk richting aan kon 
geven. Jullie blik daarop heeft mij vastigheid gegeven, waarvoor ik jullie, naast alle 
ongevraagde adviezen en ‘afbouwende’ kritiek, zeer dankbaar ben. 
 
Christian, voor mij blijf jij altijd nummer 1. Stagiaire nummer 1, want chronologisch 
nummeren bleek toch eenvoudiger dan al die namen te onthouden. Desalniettemin was je 
wel een ontzettend goede stagiaire, en de bak met werk die je tijdens je stage hebt verzet 
heeft mij een vliegende start gegeven. Ik heb genoten van de – weinig aan wetenschap 
gerelateerde – gesprekken bij de koffieautomaat, waarbij wij genoten van ons kopje koffie, 
en Ihsane van zijn bakje oestrogeen met suiker. Momenteel zijn we werkzaam op 
verschillende instituten, maar gelukkig hebben we nog een aantal gedeelde projecten wat 
ervoor zorgt dat we nog regelmatig contact met elkaar hebben. Wanneer ik Christian 
bedank, kan ik de overige (oud) collega’s uit Utrecht niet vergeten; Laura, Merle, Isabel en 
Jiayi, bedankt voor jullie bijdragen en het praatje bij de koffie wat ervoor zorgde dat, 
wanneer ik mijn gezicht na lange tijd weer in Utrecht liet zien, ik me toch altijd een beetje 
thuis voelde. 
 
Jaap, ik heb je in mijn tijd bij de Nefrologie in het UMC Utrecht niet alleen leren kennen als 
een vriendelijke man, maar ook als een ongekend kundige man. Die kundigheid ging zo ver, 
dat er in den beginne momenten waren dat ik ermee kon leven als je op vakantie was 
wanneer ik mijn data voor de afdeling moest presenteren. Gaandeweg ben ik je kritische 
blik, evenals je punctualiteit, echter gaan waarderen. Sterker, ik durf te zeggen dat dit van 
groot belang is geweest voor mijn ontwikkeling, omdat je mij leerde op een minstens zo 
kritische manier over mijn bevindingen na te denken. Bedankt, en geniet van je pensioen! 
 
Michal, I’m not really sure how our paths crossed, but somehow we ended up working 
together in many different projects. I’ve always appreciated your patience, which was 
necessary for me to understand fractions of the unearthly complex matter called 
bioinformatics. Many of the projects I’ve been working on over the past years couldn’t have 
succeeded without your help, and for that I’m grateful.  
 
De Studenten die ik na Christian heb mogen begeleiden; Eva, Lisa, Robin, Celia, Farhana, 
Senna en Samraa, jullie hebben veel werk verzet, en op mijn beurt heb ik ook van jullie veel 
kunnen leren. Bedankt voor de inzet, ik wens jullie het beste.  
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Jasper, ik denk dat je maar zelden zo’n onbevredigende samenwerking bent aangegaan 
(zowel op het financiële als op het creatieve vlak). Desondanks ben ik je erg dankbaar voor 
de tijd die je voor me hebt vrijgemaakt en ik ben uitermate tevreden met de cover die je voor 
me hebt ontworpen. 
 
Lieve papa en mama, jullie hebben mij altijd gestimuleerd om het beste uit mezelf te halen. 
Toegegeven, de weg hier naartoe was bij tijd en wijle wat hobbelig, maar jullie stonden altijd 
achter me. Die onvoorwaardelijke steun heeft mij het vertrouwen gegeven door te zetten en 
hebben mij uiteindelijk gebracht waar ik nu ben. Ik kan jullie hier niet genoeg voor bedanken. 
 
Lieve Wendy, ik zou graag met jou en de kinderen willen eindigen. Jij hebt mijn keuze om te 
promoveren vanaf het eerste moment gestimuleerd, ook al betekende dit dat het, met de 
komst van Noortje en Gijs, voor jou moeilijker werd om aan je eigen carrière te werken. De 
zorg voor die twee apenkoppen kwam veelal op jouw bordje, en ondanks die scheve 
verhouding bood je me altijd een warm en liefdevol thuis waarin ik een volwaardig deel van 
het gezin was en alles kon relativeren tot een wereld waarin ik gewoon papa was van twee 
geweldig lieve en gezonde kinderen. Dit is voor mij, en voor het voltooien van mijn 
proefschrift, van onschatbare waarde geweest en ik ben je daar intens dankbaar voor. Ik 
hou van jullie.  
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